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Chapter 1- Introduction 
Proteins: from synthesis to degradation 
Protein folding 
 
Maintaining the proteome to preserve the health of an organism in the face of 
developmental changes, environmental insults, infectious diseases, and rigors of aging 
is a formidable task. The challenge is magnified by the inheritance of mutations that 
render individual proteins subject to misfolding and/or aggregation . Maintenance of 
the eukaryotic protein homeostasis, or proteostasis, requires the orchestration of 
protein synthesis, folding, degradation, and trafficking by highly conserved and deeply 
integrated cellular networks that sometimes synergize and sometimes compete to 
regulate the function of the proteome [Morimoto RI 1998; Balch WE et al. 2008; 
Morimoto RI and Cuervo AM 2009; Powers ET et al. 2009; Jarosz DF et al. 2010; Taipale 
M et al. 2010]. Proteins are macromolecules made up of α- amino acid residues 
connected together by amide bonds. They range in size from approximately 35 to 
more than one thousand amino acid residues and are often composed of more than 
one independently folding domain [Lindquist and Kelly 2011]. Proteins have evolved to 
contain all the information required to adopt their correct architecture within their 
own amino acids sequences [Luheshi LM and Dobson CM 2009]. The biosynthesis of 
proteins occurs on the ribosome, a complex riboprotein nanomachine that translates 
messenger RNA (mRNA) into a polypeptide chain. The linear synthesis of proteins 
performed by the ribosome in the amino to carboxy-terminal direction allows 
individual domains to fold and/or be engaged by proteostasis network components 
(e.g., chaperones) before the entire protein is synthesized [Junker M et al. 2009]. 
Mechansisms such as the unfolded protein response have also evolved in the cell for 
sensing and responding to an excess of misfolded proteins and for targeting them to 
be degraded by proteolytic systems such as the proteosome [Luheshi LM and Dobson 
CM 2009]. Protein folding is the physical process by which a polypeptide chain changes 
its conformation to reach a biologically active threedimensional structure. Folding in 
vivo is in some cases co-translational and it is initiated before the completion of 
protein synthesis, whereas the nascent chain is still attached to the ribosome. Other 
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proteins, however, undergo the major part of their folding in the cytoplasm after 
release from the ribosome, whereas yet others fold in specific compartments, such as 
mitochondria or the endoplasmic reticulum (ER), after trafficking and translocation 
through membranes [Dobson CM 2003]. Native states of proteins almost always 
correspond to the structures that are most thermodynamically stable under 
physiological conditions [Dobson CM et al 2003]. Cyrus Levinthal in 1968 for the first 
time poses the problem of how, and with which mechanism, can a protein fold so 
quickly. If a given protein is to attain its correctly folded configuration by sequentially 
sampling all the possible conformations, it would require a time longer than the age of 
the universe to arrive at its correct native conformation [Levinthal 1969], that is the 
famous “Levinthal paradox”. The energetics of the folding behaviour of a polypeptide 
chain is best described by the energy landscape of an amino acid polymer. The energy 
landscape contains all conformational states accessible to the polypeptide chain 
together with their entropy, free energy and fraction of native contacts. These species 
are heterogeneous, highly dynamic and disordered conformational ensembles whose 
structures are far from the native one (Fig 2). The protein energy landscape is encoded 
in the amino acid sequence and, in the case of natural proteins, is robust and has the 
very special appearance of a rough funnel biased towards the native state. The folding 
funnel view of structure acquisition makes it clear that there are multiple pathways for 
arriving at the folded ensemble, and when the surface is rough, partially folded 
intermediates are populated (confirmed by experiments) that can be prone to 
aggregation and proteolysis [Lindquist and Kelly 2011]. It is proposed that the key 
signature for a protein to fold correctly can be traced back to the pattern of 
hydrophobic and polar (notably charged) residues that favours preferential 
interactions of specific residues as the compactness of the structure progressively 
increases. Once these interactions have established the correct topology of the folding 
protein, the process evolves rapidly and invariably to generate the native compactly 
folded structure [Stefani M 2008]. Ptitsyn suggested that folding could occur in a 
hierarchical process with the initial rapid formation of secondary structures, such as α-
helices or β-sheets [Fersht AR 2008]. At each step, the formation of a new layer of 
structure stabilized the previous one [Fersht AR 2008]. Thus, solving Levinthal’s 
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paradox implies that folding proceeds in a step-wise manner and that several 
intermediates with increasing native-like structure are populated along the folding 
coordinate. In the past two decades major advances have been done in folding 
experiments and possible mechanisms of protein folding have been proposed. 
Presently we know that intermediate states are ubiquitous in protein self-assembly. 
On their way to such states, protein molecules tend to hop between transiently 
populated partially folded states, thus spending most of their traveling time in a few 
metastable minima on their free energy landscapes. This behavior can be attributed to 
the fact that protein self-assembly is generally driven initially by nonspecific forces, 
such as hydrophobic interactions, and then finetuned by more specific interactions, 
such as hydrogen bonding [Vendruscolo and Dobson 2013]. 
Characterisation of intermediates 
 
In the last 30 years, the use of technique like hydrogen exchange pulse labelling 
coupled to NMR [Roder H et al. 1988] and of protein engineering methods 
[Matouschek A and Fersht AR 1991] allowed structural characterization of partially 
folded states. More recently, the development of new instrumentation, such as ultra-
rapid mixing devices [Shastry MC et al. 1998] and temperature jump relaxation 
techniques [Mayor et al. 2003] allowed the measurements of events within dead-time 
of normal stopped flow experiments. Finally, the destabilization of native state has 
allowed to increase the equilibrium population of partially folded states [Religa TL et 
al. 2005]. This has allowed solution NMR methods to be applied to solve the structure 
of folding intermediates of small proteins [Religa TL et al. 2005]. The characterisation 
of partially folded states raised the question as to whether these states are productive 
species en-route to the native state (on pathway intermediates) or kinetic traps that 
slow down the process (off-pathway partially folded conformations [Bai Y 1999; Gianni 
S et al. 2007] (Fig 1). If many proteins were shown to form on-pathway partially folded 
states [Bai Y 1999; Capaldi AP et al. 2002; Travaglini-Allocatelli C et al. 2003; Jemth P et 
al. 2004], recent observation that non-native interactions may be observed for 
productive on-pathway intermediates suggests that partial protein misfolding may be 
an obligatory step preceding native state consolidation [Capaldi AP et al. 2002; Religa 
Chapter 1- Introduction 
| 4 
 
TL et al. 2005]. Moreover, in many cases evidence emerged that parallel pathways can 
lead to the formation of native states [Matagne and Dobson 1998] . This led to the 
description of energy landscapes for protein folding [Dinner et al. 2000; Dobson 2003; 
Vendruscolo M and Dobson CM 2005]. This “new view” uses the idea of an energy 
surface to describe the conformational ensemble accessible during folding. Unfolded 
molecules, structurally different, follow different pathways and populate different 
conformational states characterised by weak interactions [Matagne and Dobson 1998]. 
Faster paths and local minima exist in the landscape, but Brownian motions allow each 
molecule to escape kinetic traps and continue the search for the native state. If the 
trajectories can be numerous, the transition state is unique and all pathways lead to 
the formation of native state as native interactions are the most stable [Dinner et al. 
2000]. Thus, energy landscapes are not in contrast with the concept of folding 
pathway; they are instead able to join different pathways that can be detected with 
different experimental approaches. 
 
 
 
Figure 1 Partially folded states can play different roles in folding. They can be (1) onpathway 
intermediates, (2) off-pathway partially folded states, (3) local minima transiently populated in one of 
many parallel pathways that lead to the formation of the native state (F). U refers to the unfolded state.. 
On the right side, schematic energy landscape for protein folding. The surface is derived from a 
computer simulation of the folding of a highly simplified model of a small protein. The surface ‘funnels’ 
the multitude of denatured conformations to the unique native structure. Modified from [Stefani M 
2008]. 
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Protein misfolding and aggregation 
 
The inability of a protein to adopt, or remain in, its native conformation, often referred 
to as protein misfolding, can be at the basis of some of the most important disorders 
that affect humans [Bellotti and Chiti 2008]. Many diseases, often known as misfolding 
or conformational diseases, ultimately result from the presence in a living system of 
protein molecules with structures that are ‘incorrect’, that differ from those in 
normally functioning organisms. Such diseases include conditions in which a specific 
protein, or protein complex, fails to fold correctly (e.g. cystic fibrosis, Marfan 
syndrome, amyotrophic lateral sclerosis) or is not sufficiently stable to perform its 
normal function (e.g. many forms of cancer) [Stefani and Dobson 2003]. Misfolding is 
influenced by the amino acid composition, and certain mutations are known to 
accelerate the process. Moreover, it also depends on environmental conditions, 
because once proteins are exposed to specific environmental changes such as 
increased temperature, high or low pH, agitation, elevated glucose, or oxidative 
agents, they can lose their native conformation more rapidly. The process wherein the 
native state is disrupted is called denaturation, and it generally results in the unfolding 
of the proteins. Because of the lack of arrangement, unfolded proteins are 
nonfunctional. Importantly, the unfolded state is thermodynamically unfavorable and 
unstable [Herczenik and Gebbink 2008]. Like intramolecular folding, aggregation, i.e., 
the association of two or more non-native protein molecules, is driven by hydrophobic 
forces and predominantly results in the formation of amorphous structures that lack 
long range order. Alternatively, aggregation can lead to the formation of ordered, 
fibrillar assemblies called amyloid, in which strands run perpendicular to the long fibril 
axis (cross structure) (Fig 3). Protein misfolding and aggregation are often coupled, 
with over 40 human diseases associated with formation of fibrillar aggregates. Such 
fibrillar structures are generally referred to as amyloid fibrils when they accumulate in 
the extracellular space of fundamental tissues, such as the liver, the heart, the spleen, 
or, in the case of neurodegenerative diseases like Alzheimer’s disease, the central 
nervous system [Bellotti and Chiti 2008]. 
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Figure 2 A combined energy landscape model for protein folding (left) and aggregation (right) starting 
from the unfolded ensemble. Both sides display considerable roughness, but amyloid fibrils display a 
remarkably higher stability and lower energy content than the natively folded structure. The picture 
highlights the multitude of the different conformational states available to a protein when they are 
stabilized by either intramolecular (monomeric protein) or intermolecular (aggregation intermediates 
and mature fibrils) contacts. From [Stefani M 2008] 
 
Although about 20 different and unrelated proteins are the precursors of the amyloid 
fibrils in different known types of amyloidosis, the fibrils themselves are always very 
similar, sharing the pathognomonic tinctorial property of binding the planar azo dye, 
Congo red, and then giving green-red birefringence when viewed in intense cross-
polarised light. This suggests a particular ordered environment for the bound dye 
molecules, and X-ray fibre diffraction studies identify the ordered, repeating core 
structure within all amyloid fibrils as an extensive cross-β conformation. Clinical 
amyloidosis occurs with overproduction, accumulation or even lifelong sustained 
normal production of inherently amyloidogenic normal proteins, or with the 
production of acquired or hereditary variant amyloidogenic proteins. Mature amyloid 
fibrils are 60-120 Å in diameter, rigid, non-branching, of indeterminate length, and 
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have similar dimensions, although the molecular mass of the protein subunit varies 
widely in different diseases. 
 
 
 
Figure 3 A schematic representation of some of the many conformational states that can be adopted by 
polypeptide chains and of the means by which they can be interconverted. The transition from β-
structured aggregates to amyloid fibrils can occur by addition of either monomers or protofibrils 
(depending on protein) to preformed β-aggregates. From [Chiti F and Dobson CM 2006] 
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In the electron microscope, the fibrils are seen to be assembled by lateral association 
of a number of smaller protofilaments, and sub-fibrillar levels of structure have been 
reported, arising from either the observation of detail along the length of amyloid 
fibrils or from cross-sectional views in fibril sections [Serpell et al 2000]. Protein 
aggregation can occur starting from any of the conformational states adopted by the 
initially monomeric protein, including the fully unfolded state, the folded state, and 
any partially folded states, although the latter have the highest propensity to 
selfassemble (Fig 3). Protein aggregation is deleterious for any living organism as it 
prevents a protein from adopting its functional state and because the resulting protein 
oligomers are inherently toxic. The end product of protein aggregation processes 
occurring in pathology is generally represented by extracellular amyloid fibrils or 
structurally equivalent intracellular inclusions, often associating further to form larger 
assemblies that are visible with optical microscopy. However, protein oligomers 
forming early during the process of amyloid fibril formation or, alternatively, released 
by mature fibrils, have acquired increasing importance over the past 10–15 years. This 
is first due to the fact that formation of protein oligomers is a key event of the overall 
process of amyloid fibril formation and has been long regarded as the rate-limiting 
step, responsible for the lag phase in aggregation kinetics. Second, oligomers are 
thought to be the pathogenic species associated with the formation of amyloid in 
diseases [Bemporad and Chiti 2012]. One of the most widely accepted mechanisms 
proposed for the assembly of monomers into oligomers is the so-called ‘‘nucleation 
growth’’ mechanism. According to this mechanism, monomers convert into a nucleus 
through a thermodynamically unfavorable process taking place in the lag phase of 
amyloid aggregation kinetics. The nucleus can be defined as the least 
thermodynamically stable species in solution. The nucleus could even be a monomer 
that acts as a template for the rapid growth of the amyloid aggregate through the 
association of further monomers. After the nucleation growth model was proposed, 
the concept of nucleus was investigated in further detail and other more accurate 
models were proposed. In the nucleated conformational conversion, native monomers 
initially convert into misfolded conformations, which initiate self-assembly through a 
template-independent mechanism, with formation of a molten oligomer lacking 
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persistent structure. This aggregated species then undergoes a structural 
reorganization into an amyloid-like oligomer, which acts as a nucleus. The nucleus 
rapidly triggers aggregation as other molten oligomers acquire the amyloid 
conformation through a templating or induced-fit mechanism at the aggregate ends. 
This leads to the formation of higher order oligomers and eventually fibrils [Bemporad 
and Chiti 2012]. Moreover, in many cases, normally folded proteins can access 
amyloidogenic states without the involvement of a global unfolding reaction, for 
example, as a result of thermal fluctuations of the native state or disruption of the 
quaternary structure. In these cases, the amyloidogenic state can be described as an 
ensemble of native-like conformations characterized by the presence of locally 
unfolded elements [Bemporad et al 2012]. 
The protein quality control system  
 
The functionality of the proteome depends on a delicate balance between the 
synthesis, folding and degradation of proteins. Cells possess a large network of 
proteins designed to maintain this balance. One essential group of proteins involved in 
proteome quality control comprises molecular chaperones, which facilitate protein 
folding, unfolding and remodelling. These molecular machines modulate the kinetic 
partitioning of polypeptides between pathways that lead to active proteins with native 
conformations and inactive proteins that are unfolded, misfolded or aggregated [Doyle 
et al. 2013]. Several different classes of structurally unrelated chaperones exist in cells, 
forming cooperative pathways and networks. Members of these protein families are 
often known as stress proteins or heat-shock proteins (HSPs), as they are up regulated 
under conditions of stress in which the concentrations of aggregation-prone folding 
intermediates increase. Chaperones are usually classified according to their molecular 
weight (HSP40, HSP60, HSP70, HSP90, HSP100 and the small HSPs). They are involved 
in a multitude of proteome-maintenance functions, including de novo folding, refolding 
of stress-denatured proteins, oligomeric assembly, protein trafficking and assistance in 
proteolytic degradation. The chaperones that participate broadly in de novo protein 
folding and refolding, such as the HSP70s, HSP90s and the chaperonins (HSP60s), are 
multicomponent molecular machines that promote folding through ATP and cofactor 
Chapter 1- Introduction 
| 10 
 
regulated binding and release cycles. They typically recognize hydrophobic aminoacid 
side chains exposed by non-native proteins and may functionally cooperate with ATP 
independent chaperones, such as the small HSPs, which function as ‘holdases’, 
buffering aggregation [Hartl et al 2011]. The various chaperones have differing actions 
and distinct functional roles in protein quality control. For example,Hsp70 plays a role 
early in the protein folding process, interacting with ribosomes, growing peptide 
chains, and newly synthesized polypeptides. In contrast, Hsp60 andHsp90 members 
act further downstream to provide an enclosed environment with hydrophobic 
surfaces to assist in the folding of specific protein clients. Once folded, a range of 
physiological stressors can cause a protein to partially unfold or misfold. Chaperones 
such as Hsp100 and the sHsps can recognize misfolded proteins and, in cooperation 
with folding chaperones such as Hsp70, allow them to refold. Cells contain several 
systems to remove damaged or misfolded proteins when maintenance of correct 
protein folding is no longer possible. The ubiquitin-proteasome system recognizes, 
labels, and degrades stubbornly misfolded proteins. There are many hundreds of 
ubiquitin ligases that, through a series of highly regulated events, covalently attach 
polyubiquitin chains to misfolded proteins; ubiquitinated proteins are subsequently 
transferred to the proteasome as substrates for degradation. In addition, lysosomes 
can degrade damaged cytosolic proteins via three distinct mechanisms: 
macroautophagy, microautophagy, and chaperone-mediated autophagy. Chaperones 
are involved in controlling the movement of intractably misfolded proteins toward 
degradation machinery. For example, Hsp70 can, depending on the cofactors involved, 
promote folding, degradation through the ubiquitin-proteasome system, and 
chaperone-mediated autophagy, or even actively partition misfolded proteins into 
inclusions such as the aggresome [Wyatt et al 2013]. 
It is well established that “holdase” chaperones are vital in targeting misfolded 
intracellular molecules for protease degradation or for repair by “foldase” chaperones. 
While normally intracellular chaperones may be present in the extracellular 
environment, their abundance is normally extremely low (e.g., Hsp70 is present in 
blood plasma at <10 ng/mL). Also, ATP, which is needed to fuel intracellular protease 
systems and foldase chaperones, is at least 1000 times less concentrated outside of 
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the cell than inside. Therefore, the efficient processing of misfolded extracellular 
proteins is likely to be managed by abundant, normally secreted, ATP-independent 
mechanisms that are constitutively present in blood plasma, cerebrospinal fluid, 
interstitial fluid and all extracellular spaces. Three secreted glycoproteins, namely, 
clusterin, haptoglobin and α2-macroglobulin (α2M), are known to have ATP-
independent chaperone activity in vitro. These structurally unrelated proteins have the 
ability to stably bind misfolded proteins and thereby inhibit inappropriate protein–
protein interactions, prevent aggregation and maintain proteins in solution. All three 
extracellular chaperones demonstrate the ability to influence amyloid formation in 
vitro and are found co-localised with clinical amyloid deposits in vivo. Two other 
secreted glycoproteins, apolipoprotein E (ApoE) and serum amyloid P (SAP), that are 
universally found associated with amyloid deposits are also known to influence 
amyloid formation in vitro; however, less is known about their ability to stabilise 
misfolded proteins [Wyatt et al 2012]. 
In eukaryotic systems, many of the proteins that are synthesized in a cell are destined 
for secretion to the extracellular environment. These proteins are translocated into the 
ER, where folding takes place before secretion through the Golgi apparatus. The ER 
contains a wide range of molecular chaperones and folding catalysts, and in addition 
the proteins that fold here must satisfy a ‘quality-control’ check before being exported. 
This quality-control mechanism involves a remarkable series of glycosylation and 
deglycosylation reactions that enables correctly folded proteins to be distinguished 
from misfolded ones. Like the ‘heat shock response’ in the cytoplasm, the ‘unfolded 
protein response’ in the ER is also stimulated (upregulated) during stress and is 
strongly linked to the avoidance of misfolding diseases [Dobson 2003]. 
Folding and unfolding are the ultimate ways of generating and abolishing cellular 
activities, and unfolding is also the precursor to the degradation of proteins. Moreover, 
it is increasingly apparent that some events in the cell, such as translocation across 
membranes, can require proteins to be in unfolded or partially folded states. Processes 
as apparently diverse as trafficking, secretion, the immune response and the 
regulation of the cell cycle, are in fact now recognized to be directly dependent on 
folding and unfolding [Radford and Dobson 1999]. Indeed, it is becoming increasingly 
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evident that a wide range of human diseases is associated with aberrations in the 
folding process [Dobson 2001]. Some of these diseases (e.g. cystic fibrosis) result from 
the simple fact that if proteins do not fold correctly they will not be able to exercise 
their proper functions. In other cases, misfolded proteins escape all the protective 
mechanisms discussed above and form intractable aggregates within cells or in the 
extracellular space. An increasing number of pathologies, including Alzheimer’s and 
Parkinson’s diseases, the spongiform encephalopathies and late-onset diabetes, are 
known to be directly associated with the deposition of such aggregates in tissue 
[Thomas et al 1995]. Diseases of this type are amongst the most debilitating, socially 
disruptive and costly diseases in the modern world, and they are becoming 
increasingly prevalent as our societies age and become more dependent on new 
agricultural, dietary and medical practices [Dobson 2004]. It is widely accepted that 
protein aggregation is the cause, rather than a epiphenomenon, of the clinical 
manifestation of the different amyloidoses, and that the latter, at least in the case of 
the neurodegenerative diseases, can ultimately be traced back to the cytotoxic effects 
of the aggregates [Stefani 2008]. 
Failure of protein quality control system: protein misfolding deseases 
 
Protein misfolding diseases comprise a group of disorders that have one central aspect 
in common: the appearance of non-native protein structure, which is accompanied by 
increased aggregation and deposition of proteins. The group contains diseases with 
dissimilar symptoms, and the affected organs and tissues can be drastically different 
[Herczenik and Gebbink 2008]. They include pathological states in which an 
impairment in the folding efficiency of a given protein results in a reduction in the 
quantity of the protein that is available to play its normal role. This reduction can arise 
as the result of one of several posttranslational processes, such as an increased 
probability of degradation via the quality control system of the endoplasmic reticulum, 
as occurs in cystic fibrosis [Amaral MD 2004], or the improper trafficking of a protein, 
as seen in early-onset emphysema [NLomas DA and Carrell RW 2002]. The largest 
group of misfolding diseases, however, is associated with the conversion of specific 
peptides or proteins from their soluble functional states ultimately into highly 
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organized fibrillar aggregates. These structures are generally described as amyloid 
fibrils or plaques when they accumulate extracellularly, whereas the term 
“intracellular inclusions” has been suggested as more appropriate when fibrils 
morphologically and structurally related to extracellular amyloid form inside the cell 
[Westermark P et al 2005]. However, recent studies suggest that prefibrillar 
aggregates, called micelles, protofibrils, or amyloid derived diffusible ligands rather 
than fibrils are the most potent mediators of cell damage, cytotoxicity, and 
neurotoxicity. These soluble oligomers are temporally unstable, and they can rapidly 
transform into more mature and eventually fibrillar forms. This action is supported by 
the finding that the severity of cognitive impairment in protein misfolding diseases 
correlates with the levels of small oligomeric aggregates and not with the large fibrillar 
species [Herczenik and Gebbink 2008]. 
Alzheimer desease 
 
Among the human disorders marked by protein misfolding and aggregation, 
Alzheimer’s disease looms large. This enormously common degeneration of limbic and 
associated cortices and related subcortical nuclei slowly robs its victims of their most 
human qualities: memory, reasoning, abstraction, and language. The disease has no 
doubt existed for millennia but was often confused with other syndromes that also 
presented as “senile dementia,” that is, progressive cognitive decline after middle age 
[Selkoe 2011]. The global prevalence of dementia places a considerable burden on 
society. Currently, the prevalence is estimated to amount to 24 million and predicted 
to quadruple by the year 2050. In the US alone, Alzheimer disease (AD) the most 
frequent cause of dementia is associated with estimated health-care costs of $172 
billion per year. The key pathological changes observed in AD brain tissue are amyloid-
β (Aβ) peptide deposited extracellularly in diffuse and neuritic plaques, and 
hyperphosphorylated tau (p-tau) protein, a microtubule assembly protein 
accumulating intracellularly as neurofibrillary tangles (NFTs). Additional changes 
include reactive microgliosis and widespread loss of neurons, white matter and 
synapses [Reitz and Mayeux 2014].  
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Aβ is formed by the proteolytic processing of the amyloid precursor protein (APP) 
[Vardy ERLC et al 2005]. The amyloidogenic pathway of APP processing involves the 
initial cleavage of APP by the β-secretase (BACE1; β-site APP cleaving enzyme-1), to 
release a soluble N-terminal fragment, sAPPβ (Fig 4). The residual short membrane-
bound C-terminal fragment of APP (C99) is subsequently cleaved by the presenilin-
containing γ-secretase complex to form Aβ and the amyloid intracellular domain 
(AICD). The amyloidogenic cleavage of APP results in a number of Aβ isoforms from 
39–43 amino acids in length. Of these isoforms, Aβ40 and Aβ42 are the most 
commonly found. Aβ42 is the more amyloidogenic isoform as it aggregates more 
readily and it is this isoform that is predominantly found in senile plaques. 
 
 
 
 
Figure 4 Proteolytic processing of APP. The amyloidogenic pathway involves the sequential cleavage of 
APP first by BACE1, producing sAPPβ and C99, and then by γ-secretase to release the amyloidogenic Aβ 
and the AICD. In the non-amyloidogenic pathway, α-secretase cleaves within the Aβ fragment, 
preventing the formation of Aβ peptides. From [Kellet and Hooper 2009] 
 
 
Aβ peptides can self-assemble into small soluble oligomers or larger protofibrils and 
fibrils. While monomeric Aβ is generally non-toxic, there is growing evidence that Aβ 
oligomers are responsible for the synaptic dysfunction that occurs in AD [Walsh DM et 
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al 2002; Cleary et al 2005]. APP can alternatively be processed via the non-
amyloidogenic pathway where the initial cleavage is by α-secretase, members of the 
ADAM (a disintegrin and metalloprotease) family [Vardy ERLC et al 2005] (Fig 4). This 
α-cleavage occurs within the Aβ region, thus precluding the formation of the Aβ 
peptide. 
Tau belongs to the family of microtubule- associated proteins (MAPs) that includes 
MAP2. As neurons develop, tau segregates into axons, and MAP2 into dendrites 
[Matus A 1990]. In the axon, tau stabilizes the microtubules. Under pathological 
conditions tau dissociates from the microtubules, causing them to collapse, and tau 
starts accumulating in the somatodendritic compartment. The precise steps of this 
process are not fully understood. The established axonal localization of tau does not 
exclude the fact that under physiological conditions, this protein exerts important 
functions outside of the axon, such as in the dendrite [Ittner LM et al 2010]. Tau 
contains an unusually high number of putative phosphorylation sites (45 serines, 35 
threonines, and 4 tyrosines), and for many of these, specific antibodies are available 
[Chen F et al 2004]. Under physiological conditions, there are on average 2–3 mol of 
phosphate per mol of tau, whereas under pathological conditions this ratio is increased 
to 7–8 mol [Kopke E et al 1993]. This posttranslational modification has been termed 
‘hyperphosphorylation’: some sites are phosphorylated to a higher degree in the 
diseased than in the healthy brain; others are de novo phosphorylated. 
Phosphorylation tends to dissociate tau from microtubules. Tau also undergoes a 
conformational change that is likely to assist in differential phosphorylation [Jicha GA 
et al 1997]. Both tau and Aβ undergo nucleation-dependent fibril formation [Harper JD 
and Lansbury PT 1997]. 
The link between neurodegeneration and presence of amyloid plaques in AD brain was 
first proposed in 1990, when it was shown that aggregated Aβ was neurotoxic in vitro 
[Yankner BA et al.1990]. At the same time seminal discoveries in the AD genetics pave 
the way to the formulation of the ‘‘amyloid cascade hypothesis’’, stating that Aβ 
peptides originating from the proteolytic cleavage of their precursor protein (APP) are 
the main culprits of AD symptoms at the molecular level [Selkoe 1991]. Rapidly, yet 
with diffuse resistances in AD scientists, the ‘‘amyloid cascade hypothesis’’ replaced 
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previous proposals such as the ‘‘cholinergic hypothesis’’; yet, the latter has recently 
been reproposed, though in a modified form [Craig et al. 2011]. 
What is causing AD is not understood, with the exception of the rare, familial (FAD) 
forms; the latter, however, account for less than 5% of all cases [Delacourte A et al 
2002]. In FAD, autosomal dominant mutations have been identified in three genes: in 
APP itself, and in the presenilin 1 (PSEN1) and presenilin 2 encoding (PSEN2) genes. In 
addition to the FAD genes, a series of susceptibility genes have been identified in 
sporadic AD (SAD); these include apolipoprotein E (APOE) as the most established risk 
gene [Bertram L and Tanzi RE 2008], CLU encoding clusterin, PICALM encoding the 
phosphatidylinositol-binding clathrin assembly protein, and CR1 encoding the 
complement component (3b/4b) receptor 1 [Lambert JC et al 2009]. Clinically and 
histopathologically, early-onset FAD cannot be discriminated from late-onset SAD 
[Gotz J 2001]. Moreover Alzheimer’s disease is believed to be a disease of the synapses 
and has hence been termed a ‘synaptic failure’ [Selkoe DJ 2002]. While Aβ can kill 
neurons, synaptotoxicity may be more relevant for the earlier stages of AD that are 
best characterized by synaptic loss rather than neuronal death. Loss of synaptic 
terminals or dendritic spines could cause the associated decline in cognitive functions 
that characterizes AD. At present, however, major research efforts of many groups 
concentrate on non-fibrillar soluble Aβ as the major toxic species in AD [Lambert MP et 
al 1998]. These have been given different names, including ADDLs, globulomers 
[Barghorn S et al 2005], and the dodecameric Aβ species Aβ *56 [Lesne S et al 2006]. 
Recent structural analysis has revealed that pentameric and hexameric oligomers may 
be the building blocks of the more toxic decameric and dodecameric complexes 
[Ahmed M et al 2010]. 
Neurotoxicity of Aβ 
 
The presence of toxic aggregates inside or outside cells can impair a number of cell 
functions that ultimately lead to cell death by an apoptotic mechanism [Ross CA 2002; 
Morishima Y et al. 2001]. Many pieces of data point to a central role of modifications 
to the intracellular redox status and free Ca2+ levels in cells exposed to toxic aggregates 
[Kourie JI 2001; Butterfield AD et al. 2001]. A modification of the intracellular redox 
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status in such cells is associated with a sharp increase in the quantity of reactive 
oxygen species (ROS) that is reminiscent of the oxidative burst by which leukocytes 
destroy invading foreign cells after phagocytosis. In addition, changes have been 
observed in reactive nitrogen species, lipid peroxidation, deregulation of NO 
metabolism [Kourie JI 2001], protein nitrosylation [Guentchev M et al. 2000] and 
upregulation of heme oxygenase- 1, a specific marker of oxidative stress [Choi YG et al. 
2000]. intracellular oxidative stress could be related to some form of destabilisation of 
cell membranes by toxic species leading to a failure to regulate appropriately plasma 
membrane proteins such as receptors and ion pumps [Mattson MP 1999] and/or to 
impairment of mitochondrial function. Mitochondria play a well recognised role in 
oxidative stress and apoptosis; in this regard, a key factor in Aβ peptide neurotoxicity 
could be the opening of mitochondrial permeability transition pores by Ca2+ entry in 
neuronal mitochondria [Moreira PI et al. 2002] followed by release of cytochrome c, a 
strong inducer of apoptosis. It has been suggested recently that intracellular ROS 
elevation following exposure to amyloid aggregates is a consequence of Ca2+ entry into 
cells followed by stimulation of oxidative metabolism aimed at providing the ATP 
needed to support the activity of membrane ion pumps involved in clearing excess Ca2+ 
[Squier TC 2001]. ROS elevation would in turn oxidise not only the proteins involved in 
ion transfer but also proteins such as calmodulin [Squier TC 2001] that when oxidised 
is unable to activate the Ca2+-ATPase. The down-regulation of the Ca2+-ATPase activity 
would then reduce the need for ATP, and hence ATP synthesis and ROS production by 
oxidative metabolism, leading to an increase in intracellular Ca2+ concentration [Squier 
TC 2001]. This hypothesis can explain the relationship between ROS, apoptosis, 
mitochondrial damage and intracellular free Ca2+ increase shown by cells exposed to 
toxic amyloid aggregates [Kawahara M et al. 2000, Selkoe DJ 2001]. 
As previously mentioned, studies from AD mouse models have lent further support to 
the hypothesis that Aβ causes ‘‘synaptic failure’’ before plaques develop and neuron 
death occurs [Selkoe 2002]. Excitatory synapses contain AMPA and NMDA ionotropic 
glutamate receptors as well as metabotropic type glutamate receptors (mGluRs) 
positioned on dendritic spines [Baude et al. 1993; Takumi et al. 1999]. Basal 
transmission is largely mediated by AMPA receptors. Brief periods of high synaptic 
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activity open NMDA receptors, leading to a long-lasting increase in postsynaptic AMPA 
receptor number, spine growth, and longterm potentiation (LTP) of synaptic 
transmission [Bliss and Lomo 1973]. Alternatively, low levels of synaptic stimulation 
can activate NMDA receptors to produce NMDA-dependent long-term depression 
(LTD) or mGluRs to produce mGluR-dependent LTD. These two forms of LTD can induce 
removal of postsynaptic AMPA receptors and loss of spines [Lee et al. 2002; Luscher et 
al. 1999; Man et al. 2000; Nagerl et al. 2004; Snyder et al. 2001; Xiao et al. 2001; Zhou 
et al. 2004]. It is generally believed that plasticity, such as LTP and LTD, are important 
processes for learning and memory. Multiple signaling pathways, which include several 
protein kinases and phosphatases, are required for the generation of LTP and LTD 
[Sheng and Kim 2002]. Neurons from transgenic APP mice that express genes encoding 
mutant APP or presenilin linked to familial, autosomal-dominant forms of AD (FAD) 
exhibit decreased synaptophysin and PSD95 staining as well as dendritic spine loss 
[Almeida et al. 2005; Hsia et al. 1999; Lanz et al. 2003; Mucke et al. 2000; Spires et al. 
2005]. These mice develop mature amyloid plaques, are impaired on learning tasks, 
and can show deficits in LTP [Billings et al. 2005; Chapman et al. 1999; Giacchino et al. 
2000; Larson et al. 1999; Moechars et al. 1999; Oddo et al. 2003; Stern et al. 2004]. 
Furthermore, application of Aβ, in vivo and in vitro, adversely affects LTP and synaptic 
transmission [Cleary et al. 2005; Cullen et al. 1997; Freir et al. 2001; Walsh et al. 2002]. 
Interestingly, learning and synaptic dysfunction appear before the formation of 
plaques, suggesting that a physiological deficit rather than a loss of neurons underlies 
the initial development of the disease [Hsia et al. 1999; Kamenetz et al. 2003; Mucke 
et al. 2000; Oddo et al. 2003].  
Amyotrophic lateral sclerosis  
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by the 
loss of both upper and lower motor neurons. Affected patients develop progressive 
muscle weakness eventually leading to death due to respiratory failure, typically 3–5 
years after symptom onset. ALS affects ~2 out of 100,000 individuals per year 
[Hardiman O et al 2011]. In the majority of patients the disease occurs sporadic and is 
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referred to as sporadic ALS (SALS). In 5 % of cases there is a family history of ALS (FALS) 
[Byrne S et al 2011]. The presence of protein aggregates in affected motor neurons is a 
characteristic, but still poorly understood hallmark of SALS and FALS patients. Recently, 
many new ALS causing gene defects have been identified including mutations in 
HNRNPA1, PFN1, C9ORF72, UBQLN2, OPTN, VCP, FUS and TARDBP [Al-Chalabi A et al 
2012; Kim HJ et al 2013]. Most of these mutations are rare and cause ALS in a small 
subgroup of patients. Remarkably, however, the proteins encoded by these genes are 
present in protein aggregates of a large proportion of non mutation carriers indicating 
a more widespread role for their abnormal localization in ALS pathogenesis. Moreover, 
some of these proteins are present in pathological aggregates of other 
neurodegenerative disorders such as frontotemporal lobar degeneration (FTLD), 
spinocerebellar ataxia (SCA), Huntington’s disease, Alzheimer’s disease and inclusion 
body myositis (IBM), indicating a more general involvement in neurodegeneration. The 
central pathological hallmark of ALS is the presence of cytoplasmic inclusions or 
aggregates in degenerating motor neurons and surrounding oligodendrocytes. 
Inclusions are not restricted to the spinal cord but also present in other brain regions 
such as the frontal and temporal cortices, hippocampus and cerebellum. The 
predominant aggregates found in ALS patients are ubiquitinated aggregates that are 
classified as either Lewy body like hyaline inclusions or skein like inclusions. At the 
ultrastructural level, Lewy body like or skein like inclusions appear as randomly 
oriented filaments covered by fine granules [Hasegawa M et al 2008; Lin WL and 
Dickson DW 2008]. Other cellular abnormalities include the presence of mitochondrial 
vacuolization, fragmentation of the Golgi apparatus and abnormalities at the 
neuromuscular junction. In 1993, SOD1 was the first protein to be identified to 
aggregate in FALS cases carrying a mutation in the SOD1 gene [Rosen DR et al 1993]. 
Later, mutations in VAPB were also shown to cause ALS in a group of FALS patients 
[Nishimura AL et al 2004].  
TAR DNA-binding protein 43 (TDP43) was identified 8 years ago as the major 
constituent of the proteinaceous inclusions that are characteristic of most forms of ALS 
and frontotemporal lobar degeneration [Neumann M et al 2006]. Since then, 
numerous groups have confirmed this finding [Buratti E and Baralle FE 2012; 
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Brandmeir N J et al 2008; Strong M J et al 2007]. With over 600 studies published on 
TDP43 and its role in ALS and FTLD, there is now an emerging consensus that TDP43 
protein is mechanistically linked to neurodegeneration. TDP43 is a 414 aminoacid 
protein with two RNA recognition motifs (RNA recognition motif 1 (RRM1) and RNA 
recognition motif 2 (RRM2)) and a carboxyterminal glycine rich domain. Nearly all of the 
described ALS-associated TDP43 mutations are dominant missense mutations within 
the glycine rich domain, suggesting that altering the function of this domain is 
sufficient to induce neurodegeneration [Kabashi E et al 2008; Sreedharan J et al 2008]. 
Normally TDP-43 predominantly localizes to the nucleus. In ALS patients, cytoplasmic 
aggregation is often accompanied by nuclear clearing of the protein [Mackenzie IRA et 
al 2007; Neumann M et al 2006]. Furthermore, the protein is cleaved in C-terminal 
fragments (CTFs) of 20-25 and 35 kDa and the full-length protein and 18-26 kDa 
fragments are hyperphosphorylated [Hasegawa M et al 2008]. Furthermore, the 
distribution of the TDP-43-positive aggregates is disease-specific with, for example, 
involvement of spinal cord motor neurons in ALS and a more widespread distribution 
in the brain in FTLD [Baloh RH 2011]. Mutations in TARDBP are unique to ALS and are 
not found in other neurodegenerative disorders [Brouwers N et al 2010; Van Deerlin 
VM et al 2008] with the exception of a small number of FTLD cases [Chio A et al 2010; 
Corrado L et al 2009]. TDP-43 is a DNA and RNA binding protein that binds around 30 % 
of the mouse transcriptome with a preference for long UG-rich sequences [Tollervey JR 
et al 2011]. Target sequences are mainly intronic, but also include non coding RNAs 
and 3′ UTRs. In line with this, TDP-43 plays a role in nuclear RNA metabolism including 
splicing, transcriptional repression, miRNA synthesis, mRNA nucleo-cytoplasmic 
shuttling and RNA transport [Lagier-Tourenne C et al 2010]. 
Like other proteins that form neurodegenerative disease-related intracellular 
inclusions, such as tau and α-synuclein, pathological TDP43 aggregates are 
ubiquitylated and phosphorylated [Neumann M et al. 2006]. Under normal 
circumstances, ubiquitylated and phosphorylated TDP43 is not readily detected in 
brain tissue. Thus, the very presence of these modified TDP43 species in ALS is 
abnormal and seems to be disease specific; however, it is not clear whether these 
modifications lead to aggregate formation and/or neurotoxicity, or whether they 
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represent a normal reaction to the presence of an intracellular aggregate and are 
therefore indirectly related to TDP43-mediated neurodegeneration. Interestingly, 
human tissue studies indicate that not all TDP43 inclusions are ubiquitin positive. In 
particular, so-called ‘pre-inclusions’ (granular, less dense cytoplasmic inclusions) are 
often not ubiquitin positive, suggesting that ubiquitylation is a relatively late 
phenomenon in the disease process [Giordana M T et a.l 2010; Strong M J et al. 2007). 
By contrast, antibodies that specifically detect TDP43 that is phosphorylated at serine 
residues 409 and 410 seem to recognize most TDP43 inclusions as well as the 
truncated 25 kDa TPD43 CTFs [Neumann, M. et al. 2009; Hasegawa, M. et al 2008] 
These studies suggest that phosphorylation precedes ubiquitylation, but they do not 
address whether these post-translational modifications are mechanistically involved in 
TDP43 mediated neurodegeneration. A major unresolved question is whether TDP-43-
mediated neuronal loss is caused by toxic gain of function of cytoplasmic aggregates, 
or by a loss of its normal function in the nucleus. We now have an idea of the key steps 
that occur from the onset of TDP43 mediated neurodegenerative disease through to 
the culmination of these events in dysfunction and death of affected neurons in ALS, 
FTLD-TDP and related TDP43 proteinopathies. As is often the case for disease 
processes, multiple pathways are likely to be involved, and the downstream 
consequences of TDP43 phosphorylation, aggregation, cleavage, mislocalization and 
clearance from the nucleus are unclear. Perhaps it is easiest to conjecture that the 
absence of normal nuclear TDP43 implies that there is a loss of normal TDP43 function. 
Given the plethora of normal nuclear TDP43 functions, this alone might lead to 
neurodegeneration. Alternatively, perhaps TDP43 retains its ability to bind RNA, and 
therefore its cytoplasmic localization acts as a peripheral sink, thereby implicating a 
toxic gain of function. Or maybe TDP43 CTFs act in a dominant negative fashion by 
occupying hnRNP binding sites without being able to bring along its usual RNA cargo.  
In an attempt to understand the mechanisms of neurodegeneration, we can consider 
two hypothetical models of TDP43-mediated neurodegeneration. The first model, “loss 
of function” was proposed by two groups independently. Although the initial insult is 
generally unknown (aside from cases that are linked to genetic mutations), one 
possible initiating event may be the presence of abnormal, toxic RNA species. Cellular 
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stress is thought to cause a redistribution of TDP43 from the nucleus to the cytoplasm. 
This is akin to the formation of stress granules that has been observed experimentally, 
although there is currently little evidence showing an upregulation of stress granules in 
ALS. Alternatively, RNA transport granules that are usually localized within peripheral 
neurites may be abnormally distributed. According to this model, this redistribution 
results in the aggregation of TDP43 into preinclusions that are phosphorylated, 
variably ubiquitylated and difficult to degrade. These cytoplasmic inclusions lead to 
further redistribution of normal TDP43 from the nucleus as protein is sequestered into 
inclusions, accounting for nuclear clearance. If TDP43 autoregulation occurs within the 
nucleus, there would be a loss of TDP43 autoregulation and increased TDP43 
expression, leading to increased aggregate formation. This would feed forward 
through a vicious cycle leading to cell death [Polymenidou M et al 2011].  
Alternatively, in the second model, “gain of function” a stressor can lead to 
redistribution of TDP43 into the cytoplasm resulting in aggregation (similar to the first 
model). If autoregulation of TDP43 mRNA is a cytoplasmic event and TDP43 aggregates 
retain the ability to bind RNA and therefore autoregulate its cognate RNA, then an 
increase in cytoplasmic TDP43 may lead to increased autoregulation, thereby 
decreasing TDP43 mRNA and decreasing newly synthesized TDP43 protein in affected 
cells. This decrease in synthesis may account for the nuclear clearance phenomenon 
(that is, aggregates represent the existing pool of TDP43 protein and not newly 
synthesized protein). Given the myriad of normal TDP43 functions, loss of normal 
nuclear TDP43 may further increase cellular stress, again resulting in a vicious cycle 
leading to cell death [Kabashi E et al 2010]. 
HypF-N 
 
A growing body of evidence suggests that protein aggregation is a capability of all 
polypeptide chains. [Chiti F et al 2002]. However, relative scarcity of aggregants in 
organisms and the wide range of aggregation rates under the same conditions 
measured in vitro show that the process of aggregation varies tremendously by 
sequence [Dubay, K F et al 2004]. This leads to the question of what determines a 
polypeptide chain’s propensity to aggregate. Recent work has shown a strong 
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correlation between aggregation rates and hydrophobicity, hydrophobic patterning, 
and charge of a sequence; [Zbilut J P et al 2004] additionally, helix and sheet 
propensity correlate significantly with mutational changes in aggregation rates within a 
sequence [Calamai M et al 2005]. One possible mechanism is that the aggregation 
precursor is fairly disordered and transiently exposes hydrophobic residues to the 
solvent for sufficient time to form bimolecular interactions. Therefore, there may be 
some correlation between intramolecular diffusion rates of aggregation precursors and 
aggregation propensity. One particularly favourable system for investigating the 
fundamental principles underlying protein aggregation is the N-terminal domain of 
HypF from Escherichia coli (HypF-N), a large globular protein factor of about 82 KDa, 
participating in the maturation of the prokaryotic [NiFe] hydrogenase that is involved 
in hydrogen metabolism [Colbeau A et al 1998]. HypF-N has been shown to have one 
of the fastest aggregation rates in vitro,[ Dubay, K F et al 2004)  and extensive work has 
been done to identify the nature of the aggregation precursor [Dumoulin, M et al 
2006] (Fig 5). This bacterial protein, not associated with any amyloid disease, 
aggregates into pre-fibrillar and fibrillar amyloid assemblies undistinguishable from 
those associated with amyloid diseases and endowed with the same cytotoxicity 
[Bucciantini, M et al 2002; Bucciantini, M et al 2004]. This conversion in amyloidlike 
fibrils was achieved incubation in the presence of moderate concentrations 30% (v/v) 
of trifluoroethanol (TFE) at pH 5.5 or 20 mM citrate buffer at pH 3.0, favoring the 
destabilization of hydrophobic interactions [Relini A et al. 2004; Chiti F et al. 2001]. The 
formation of a partially folded state is a key event in the aggregation pathway of this 
protein in vitro, even under mild destabilising conditions in which the folded state is by 
far the predominant species. Indeed, under mild denaturing conditions generated by 
moderate concentrations of trifluoroethanol [6–12% (v/v)], the partially folded state is 
in rapid equilibrium with the native state and populated to ca 1-2%. Indeed, a kinetic 
analysis has shown that aggregation does not result from those protein molecules that 
are in their fully native conformation, but  
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Figure 5 Three-dimensional structure of native HypF-N from X-ray crystallography. From [Campioni et al. 
2008] 
 
 
from the population of a partially unfolded conformational state that is in dynamic 
equilibrium with the former [Marcon G et al. 2005]. Recently, new aggregation 
conditions for HypF-N, allowing the characterization of the partially folded state 
populated prior undergoing aggregation, have been described, such as at pH 5.5 in the 
presence of 12% (v/v) TFE, or at pH 1.7 in the presence of salts (NaCl). A detailed 
structural investigation of this partially folded state has also been performed and 
achieved by means of different biophysical and biochemical methodologies [Campioni 
S et al. 2010]. The resulting species have been imaged with both transmission electron 
microscopy (TEM) and tapping mode atomic force microscopy (TM-AFM), have been 
shown to increase the fluorescence of thioflavin T (ThT) and to have a characteristic 
cross β-structure as revealed by X-ray diffraction studies, indicating the presence of 
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intermolecular β-sheet structure typical of amyloid aggregates [Relini A et al. 2004; 
Chiti F et al. 2001]. In general, the data obtained suggest that the aggregation process 
of this protein starts from a partially folded state that can be either fully populated or 
in rapid equilibrium with the native state when the latter is destabilized by mutations 
and/or mild unfolding conditions [Marcon G et al. 2005]. The results support an 
aggregation pathway in which the native protein first converts into a partially folded 
state separated from the native state by an energy barrier comparable to that of 
(un)folding. This monomeric state converts into globular small aggregates and small 
beaded fibrils that further associate into ring-like structures. Finally, the ring-like 
structures convert into ribbon-like fibrils that associate into fibrillar tangles [Relini A et 
al. 2004]. Since many disease-involved systems aggregate following similar pathways, 
HypF-N represents a valuable model system for investigating the structural basis of the 
amyloid formation. 
In the last years it has been increasingly suggested that the oligomers formed by 
proteins unrelated to any amyloid disease can be toxic when added to the extracellular 
medium of cultured cells, whereas the same proteins in monomeric or fibrillar forms 
are not [Bucciantini M et al. 2002]. These prefibrillar aggregates impair cell viability 
interacting with the macromolecular components of living organisms, such as 
membranes and proteins, and interfere with their normal function. The early 
prefibrillar aggregates of HypF-N formed in 30% TFE were shown to be able to interact 
with, insert into, and eventually disassemble synthetic membranes and supported 
phospholipid bilayers [Relini A et al. 2004; Canale C et al. 2006]. Furthermore, these 
species can interact with the plasma membrane of cultured cells and be internalized 
inside the cytoplasm, resulting in cell impairment and death [Bucciantini M et al. 2005; 
Cecchi C et al. 2005]. Similarly to the protofibrillar aggregates of disease-related 
proteins and peptides, treatment of the cells with HypF-N protofibrils leads to an 
increase of reactive oxygen species (ROS) and free Ca2+ levels inside the cells, which 
ultimately die by apoptosis or necrosis [Bucciantini M et al. 2005; Cecchi C et al. 2005]. 
Moreover, the increase of intracellular Ca2+ levels is associated with both the 
activation of plasma membrane receptors with Ca2+ channel activity, such as AMPA 
receptor and NMDA receptor, and unspecific membrane permeabilization, with the 
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former effect being more important at early times [Pellistri F et al. 2008]. The 
susceptibility of different cells to HypF-N oligomers was shown to depend on their 
ability to counteract these early impairments, which increases during cell 
differentiation [Cecchi C et al. 2005; Cecchi C et al. 2008]. Remarkably, HypF-N 
protofibrils can also induce a loss of cholinergic neurons when injected into rat brains, 
demonstrating that these species can act as toxins even in higher organisms [Baglioni S 
et al. 2006]. These data strongly support the hypothesis that a common mechanism of 
cytotoxicity exists, which is related to the misfolded nature and oligomeric state of a 
protein rather than to its sequence. In spite of this advancement, a structural 
characterization of the conformational properties of the oligomers finalized to an 
understanding of the relationship with their toxic effect is still lacking, mainly due to 
the fact that the transient formation of these species and their structural 
heterogeneity have hampered considerably their investigation. The structural 
determinants of the protein oligomers that are responsible for cell dysfunction are 
starting, only these days, to be elucidated. At different destabilizing conditions 
(presence of rifluoroacetic acid or trifluoroethanol), HypF-N misfolds and generates 
morphologically similar oligomers, yet with different structural features in terms of 
stability, exposure of hydrophobic surface, compactness and flexibility. Recently, the 
functional and structural properties of the spherical aggregates formed by HypF-N in 
two distinct environmental conditions can be compared. It is therefore nowadays 
essential to determine in detail the structure of the toxic oligomeric species in order to 
identify new therapeutical targets, and to understand whether it represents a single 
common fold or rather exhibits some polymorphism. It is well known that incubation 
of the same protein/peptide under different experimental conditions causes the 
formation of oligomers or fibrils with different morphologies and that such differences 
result in different degrees of toxicity [Petkova AT et al. 2005; Lee S et al. 2007; Kayed R 
et al. 2009]. Similarly, mutations or covalent modifications result in different levels of 
oligomers or different fibrillar structures with completely different toxicities [Hung LW 
et al. 2008]. However, little experimental information is available on the structural 
features of oligomers grown under different conditions and on the relationship 
between their structure and their ability to cause cell dysfunction. Recently, it has 
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been found that oligomers formed from the same protein (HypF-N) under different 
conditions (pH 5.5 in the presence of 12%(v/v) TFE or pH 1.7 in the presence of 330 
mM NaCl) exhibited similar morphological and tinctorial properties, yet differed in 
their molecular structure. 
Comparisons of the two types of aggregates, indicated that their structural differences 
resulted from different degrees of packing of the hydrophobic residues within their 
cores with a consequent different level of structural flexibility and solvent-exposure of 
such residues [Campioni S et al. 2010]. Thus, whilst the ability to form amyloid-like 
structures is generic to polypeptide chains, whether or not such species are pathogenic 
will depend on their structural features, notably the extent to which hydrophobic 
residues are flexible and exposed on their surfaces within the environment of a living 
organism. These findings, however, do not seem to be limited to the HypF-N 
aggregates, and could indeed explain the toxic properties of the oligomers formed by 
disease-related systems. In fact, several studies indicated a correlation between the 
size and surface hydrophobicity of Aβ40 aggregates and their ability to decrease the 
bilayer fluidity of model membranes [Kremer JJ et al. 2000], suggesting that the 
exposure to the solvent of hydrophobic surfaces determines the ability of these 
species to interact with cell membranes. A correlation between hydrophobicity, 
tendency to form aggregates and aggregate cytotoxicity has also been observed in 
comparative studies where the behavior of different homopolymeric amino acid 
(HPAA) stretches was investigated [Oma Y et al. 2005]. It has been recently reported 
that expanded huntingtin-exon1 forms fibrillar aggregates at two different 
temperatures that have different structural and physical properties as well as different 
cytotoxicities [Petkova AT et al. 2005]. The structures and toxicities of both forms of 
the aggregates are comparable with those extracted from regions of mouse brains 
affected to different extents by huntingtin deposition. In both pairs of structures a 
direct relationship between structural flexibility and cytotoxicity of amyloid assemblies 
was found, supporting the generality of previous conclusions [Petkova AT et al. 2005]. 
Finally, all these data lend support to the idea that a key feature in the generation of 
toxicity is the conversion of a species of aggregates where stability is associated with 
extreme burial of hydrophobic residues to one where such residues are substantially 
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exposed and disorganized [Cheon M et al. 2007]. Recently, it has been suggested that 
for therapeutic purposes the toxicity can be dramatically reduced if the hydrophobic 
residues are incorporated to a greater extent within the interior of the oligomeric 
assemblies, even in the absence of an effective change in morphology [Campioni S et 
al. 2010]. Approaches of this type will facilitate the elucidation of the causative link 
between the molecular structure of aberrant protein oligomers and their ability to 
cause cell dysfunction, with the aim of understanding the pathogenesis of protein 
deposition diseases and identifying therapeutic strategies to combat them. Moreover, 
a detailed understanding of the forces that determine the structure of amyloid-like 
oligomers will also enable to identify the factors that can modulate it, and eventually 
alter the biological activities of these species. 
Transthyretin 
 
Transthyretin (TTR) is a homotetrameric protein of 55 kDa found mainly in plasma and 
cerebrospinal fluid and previously thought to be synthesized only in liver, choroid 
plexus, retinal pigment epithelium, and pancreas [Jacobsson B et al 1989; Cavallaro T 
et al 1990]. In the plasma TTR transports thyroxine (T4) and the retinol binding protein 
charged with retinol (RBP), whereas in the cerebrospinal fluid (CSF) TTR is the primary 
transporter of T4 [Reixach N et al 2008]. The binding sites for its normal ligands, T4 and 
RBP have been well defined [Raz AJ et al. 1969; Andrea TA et al. 1980; Monaco HL 
2002]. TTR is encoded by a single copy of gene located on chromosome 18 in human 
and chromosome 4 in mouse. The gene contains four exons with the first exon 
encoding the leader sequence [Buxbaum JN 2007]. In 1981, the International Union of 
Biochemists adopted the name ‘‘transthyretin’’ for the molecule previously designated 
as ‘‘thyroxine binding prealbumin’’ [Goodman DS et al 1986]. Until recently, TTR had 
its established clinical significance in two settings. TTR serum concentration has been 
utilized as a marker of nutritional/inflammatory status in a variety of conditions 
[Ingenbleek Y and Young VR 2002; Potter MA and Luxton G 2002]. More importantly, 
as an etiologic agent, TTR is one of the 30 human proteins associated with the 
amyloidoses, a group of disorders originally defined pathologically by the formation 
and aggregation of misfolded proteins which result in extracellular deposits that impair 
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organ function [Westermark P et al 2007]. The clinical syndromes associated with TTR 
aggregation are senile systemic amyloidosis (SSA), a late onset disease in which the 
wild-type protein deposits primarily in the heart, but also in the gut and carpal tunnel 
[Pitkanen P et al 1984; Kyle RA et al 1992; Rocken C et al 1994], and the familial 
amyloidotic polyneuropathies (FAP) and cardiomyopathies (FAC) in which point 
mutations in the gene encoding the protein result in deposition of aggregates in 
peripheral and autonomic nerves and heart, respectively [Buxbaum JN 2007]. FAP and 
FAC usually have an earlier onset than SSA presumably due to the decreased stability 
of variant TTR with respect to the wild-type protein, with the most aggressive variants 
depositing as early as the second decade of life [Jacobson DR et al. 1992]. 
In vitro studies have demonstrated that TTR forms amyloid fibrils through a process 
that involves tetramer dissociation followed by misfolding of the released monomers 
into an aggregation-prone conformation by which oligomers, soluble aggregates, 
insoluble amorphous aggregates, and amyloid fibrils are formed in a downhill 
polymerization process [Hurshman AR et al. 2004]. Whether the insoluble amorphous 
aggregates described first in transgenic animals [Teng MH et al. 2001 ] and then in 
humans [Sousa MM et al. 2001] are in on- or off-pathway towards the amyloidogenic 
structure is still a matter of debate. Tissue culture studies using cell lines derived from 
tissues that are targets of TTR deposition have shown that TTR monomers or small 
oligomers are cytotoxic to the cells, whereas the native tetramer, large soluble 
aggregates (100 kDa), and amyloid fibrils are not. Furthermore, amyloidogenic TTR 
variants were toxic to the cells whereas non-amyloidogenic TTR was not [Reixach N et 
al. 2004]. These results support the notion that cell death in the protein misfolding 
diseases is caused not by amyloid fibrils, which are the end product of the aggregation 
process, but rather by the intermediate oligomers that are formed during that process. 
The most common amyloidogenic TTR variant is V30M-TTR, which was first isolated 
from a Portuguese kindred. L55P-TTR is the variant associated with the most 
aggressive form of FAP. Comparison between the crystal structures of WT and V30M-
TTR showed a very similar global fold for both proteins. Substitution of valine 30 by 
methionine forces the β-sheets of the monomer resulting in the distortion of the 
thyroxine-binding cavity [Hamilton J A et al 1993; Terry C J et al 1993]. However, the 
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small differences between the crystal structures of WT and V30M-TTR have not clearly 
pointed out the causes for the amyloidogenicity of V30M-TTR. Very recently, based on 
the crystal structure of the highly amyloidogenic L55P-TTR, a model for TTR amyloid 
fibrils has been proposed consisting of a tubular structure with inner and outer 
diameters of ;30 and 100 Å, respectively, and four monomers per cross-section 
[Sebastião M P et al 1998]. Westermark and co-workers [Gustavsson Å et al 1990] have 
reported the formation of amyloid by TTR in vitro at low pH. This observation has led 
to the proposal of a low pH environment as a prerequisite for amyloid formation in 
vivo [Colon W and Kelly J W 1992]. These authors proposed that the low pH medium 
(present for example in the lysosomes) would induce tetramer rearrangement and 
dissociation to a monomeric amyloidogenic intermediate with altered tertiary 
structure, which in turn would self-assemble to form amyloid fibrils [Lai Z et al 1996]. 
However, this proposal, with lysosomal involvement, implies the formation of amyloid 
intermediates intracellularly, which is not consistent with the observation that TTR 
amyloid deposits are extracellular. Furthermore, in FAP, amyloid deposition occurs 
predominantly in the peripheral nerves, and both TTR mRNA and protein are not 
detected in the cellular components of nerves. Thus, amyloid assembly and deposition 
must take place extracellularly. Additionally, at low pH, both amyloidogenic and non-
amyloidogenic TTR variants form amyloid in vitro [Adams D and Said G 1996]. 
Transthyretin and AD 
 
The frequency of many of the amyloidoses increases with aging but their deposition 
appears to be independent, i.e. each has its own anatomically predisposed site and 
pattern [Wright JR et al 1969]. Thus, while there are reported instances of mixed 
precursor deposition, they are relatively uncommon, e.g. [Bergstrom J et al 2001; de 
Sousa MM et al 2000]. Nonetheless the commonality of structure that leads precursor 
proteins to form fibrils suggests that interaction could occur, perhaps accelerating fibril 
formation. The example of transthyretin (TTR) and β-amyloid (Aβ) raises the question 
as to whether the effect may be, in truth, to reduce fibrillogenesis. Wild type and 
mutant forms of TTR are the precursors in the systemic human diseases, FAP, FAC and 
SSA [Buxbaum JN 2007]. In contrast, Alzheimer’s disease (AD) is a localized amyloid 
Chapter 1- Introduction 
| 31 
 
disease of the brain. AD and the TTR amyloidoses share age dependence and are 
manifested as both autosomal dominant, mutation-related and sporadic (wild type 
protein associated) diseases. In the TTR amyloidoses the precursor is synthesized 
primarily by hepatocytes distant from the main sites of deposition in peripheral nerve 
and heart. However local synthesis and deposition can be seen in the eye, gut, kidney 
and choroid plexus. In AD the β-amyloid protein (Aβ) is synthesized ubiquitously but 
deposition and tissue compromise are restricted to the brain and even more so to 
specific brain regions. The first association of TTR with AD was the observation that 
cerebrospinal fluid (CSF) could inhibit Aβ fibril formation in vitro [Wisniewski T et al 
1993]. TTR was the third CSF protein found to interact with Aβ after apolipoprotein E 
(ApoE) [Strittmatter WJ et al 1993] and ApoJ (clusterin) [Ghiso J et al 1993]. It was 
hypothesized at that time that these three extracellular proteins could “sequester” Aβ, 
thereby preventing neuronal damage, although there was little evidence presented as 
to how or where such sequestration could take place. Perhaps “chaperone” in the 
sense of “protector” might have been a better term than “sequester”, but the 
oxymoronic phrase “pathologic chaperone” had already been utilized to describe the 
co-deposition of ApoE in AD plaques [Wisniewski T et al 1992]. Early 
immunopathologic studies, based on the premise that TTR might be the amyloid 
precursor in AD, gave conflicting results with respect to the presence of TTR in plaques 
in human AD brains [Eikelenboom P and Stam FC 1984; Shirahama T et al 1982]. More 
recent analyses found TTR co-localized in hippocampal plaques and vessels of AD 
patients [Schwarzman AL and Goldgaber D 1996; Stein TD et al 2004]. Anti-TTR serum 
stained the majority of neuronal bodies in AD brains but only 10% of neurons in age-
matched non demented controls [Li X et al 2011]. The latter finding may be responsible 
for the many reports of TTR synthesis only in the choroid plexus in the normal brain 
since the TTR signal from the choroid plexus, ependyma and leptomeninges is much 
stronger than that from normal neurons [Sousa JC et al 2007; Ng L et al 2009]. TTR, 
ApoE and ApoJ (clusterin) are major Aβ-binding proteins in human CSF [Schwarzman 
AL et al 1994]. The mean CSF TTR level has been reported to be decreased in several 
series of AD patients [Serot JM et al 1997; Castano EM et al 2006]. However not all 
investigators have found this to be true [Schultz K et al 2010]. The significance of the 
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decrease is not clear. It has been proposed, on the basis of the decrease, that TTR 
sequesters Aβ but no site of sequestration has been identified. It is also possible that 
the CSF TTR concentration may be determined in part by neuronal TTR synthesis [Li X 
et al 2011], particularly in AD (as well as choroid plexus production) and that the 
observed reduction is related to neuronal loss. Also plausible is the possibility that 
patients with AD have a genetic or acquired low CSF TTR level independent of Aβ 
binding, which conceivably could put them at greater risk for AD. A recent analysis of 
TTR single nucleotide polymorphisms (SNPs) has associated 5 TTR SNPs with 
hippocampal atrophy [Cuenco KT et al 2011]. A prior single small study did not identify 
AD in carriers of amyloidogenic TTR mutations, but there is no a priori reason why such 
mutations would predispose to Aβ deposition [Palha JA et al 1996]. Reduced CSF TTR 
levels have also been reported in patients with depression (although not in those who 
committed suicide), normal pressure hydrocephalus and most recently in ALS 
[Brettschneider J et al 2010]. The variability of the finding has made it an unsuitable 
CSF marker for AD and made it more difficult to understand its role in AD 
pathogenesis. An in vivo interaction between Aβ/TTR was also noted in human kidneys 
[Tsuzuki K et al 2000], and in the muscle of a single patient with inclusion body 
myositis [Askanas V et al 2000]. However its significance in these circumstances is 
unclear since the subjects did not have clinical AD. It was hypothesized that TTR could 
inhibit Aβ related toxicity by sequestration of Aβ thus preventing Aβ aggregation and 
fibril formation based on the observation that first identified TTR as an Aβ-binding 
protein in CSF [Schwarzman AL et al 1996]. In subsequent studies of the capacity of a 
series of recombinant mutant TTR’s to inhibit Aβ fibril formation at neutral pH in vitro 
was analyzed. The investigators found that the amount of Congo red binding material 
formed over a 24-36 hour period was reduced in the presence of many of the 
recombinant TTR’s (at a 5:1 molar ratio of Aβ:TTR). However, the experiments suffered 
from the lack of non-TTR e.g. albumin, controls and the use of a relative measure of 
inhibitory capacity that was never quantified in terms of protein concentration. In 
addition the nature of the Aβ1-42 when it was added to the assay was not precisely 
defined. Given current knowledge regarding the propensity of Aβ to aggregate on 
standing, it is not clear from the publications whether the different TTR’s were actually 
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seeing the same Aβ conformers. Nonetheless in retrospect the observation that TTR 
bound Aβ and inhibited fibril formation was correct, although the detailed results 
regarding the relative capacities of different variants are less likely to be valid. The 
hypothesis itself was attractive since TTR is abundant in Human CSF (5-20 μg/ml or 0.1-
0.36 μM) and serum (174-420 μg/ml or 3-7 μM) [Vatassery GT et al 1991]; while 
Aβconcentration in CSF is relatively low (3 nM or less) [Price JM et al 2001]. However it 
inferred, as a second hypothesis, that the interaction would be responsible for 
lowering the CSF TTR concentration. 
Transthyretin and Aβ interaction 
 
Schwarzman et al studied 47 recombinant TTR variants. Most (except G42 and P55) 
bound to Aβ and inhibited Aβ aggregation in vitro [Schwarzman AL et al 2004]. Wild 
type human TTR binds to all forms of soluble Ab, monomer, oligomer and fibrils [Liu L 
et al 2006]. TTR binds to Ab better at 37°C than 25° C [Buxbaum JN et al 2008], binds to 
Ab aggregates better than Ab monomer [Liu L et al 2006; Du J, Murphy RM et al 2010], 
and Ab1-42 better than Ab1-40 [Buxbaum JN et al 2008]. The binding is highly 
dependent on the quarternary structure of TTR [Du J et al 2010]. It has been suggested 
that human monomeric TTR binds Aβ better than the TTR tetramer. The interaction 
between TTR and Aβ interferes with Ab aggregation in vitro and inhibits Ab fibril 
formation [Buxbaum JN et al 2008; Liu L et al 2006]. The interaction between TTR and 
Aβ species is apparently beneficial to cultured cells under Aβ stress. TTR prevented 
accumulation of the Aβ in cultured vascular smooth muscle cells [Mazur-Kolecka Bcdae 
et al 1995]. In the human neuroblastoma cell line SK-N-BE, TTR inhibited ultrastructural 
changes characteristic of apoptosis [Giunta S et al 2005]. Pre-incubation of Aβ with TTR 
also suppressed caspase- 3 activation in the undifferentiated human neuroblastoma 
SH-SY5Y cell line [Costa R et al 2008] and the cytotoxicity induced by Aβ oligomers on 
SH-SY5Y cells differentiated by retinoic acid treatment [Li X et al 2011]. Moreover, TTR 
also inhibited cytotoxicity and the induction of reactive oxygen species (ROS) by 
Aβspecies in cultured embryonic mouse neurons [Li X et al 2011]. 
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Aim of the Study 
 
We are painfully aware that the basis of that group of disorders known as protein 
misfolding desease is the failure of a specific peptide or protein to adopt, or remain in, 
its native functional conformational state. These pathological conditions include 
neurodegenerative disorders, systemic amyloidoses and cystic fibrosis. The 
pathological alterations of protein involved in these group of deseases are caused by 
mutations, aging or other modification of the chemical environment and ultimately 
leads to the formation of insoluble highly organized fibrillar aggregates, often called 
amyloid fibrils. There is increasing evidence that the oligomeric assemblies that 
precede the formation of amyloid fibrils, often kinetic intermediates in the process of 
amyloid fibril formation or off-pathway species, are the primary pathogenic species in 
many protein deposition diseases. The toxicity of these early oligomers appears to 
result from their intrinsic ability to impair fundamental cellular processes, for example 
by interacting with cellular membranes and disassembling. To better clarify this issue, 
in the present research, the molecular bases of cell damage induced by prefibrillar 
forms of different aggregates after the interaction with plasma membrane was 
investigated in depth. In particular, the oligomer-induced cytotoxicity throught 
alteration of membrane permeability, oxidative stress and apoptotic pathway 
activation in human SH-SY5Y neuroblastoma cells and primary neurons from rat brains 
were checked.  
Hippocampal neurogenesis appears to play an important role in learning and memory 
processes and mood regulation and its abnormal regulation might account for 
cognitive impairments associated with Alzheimer’s disease (AD). We showed that two 
types of extracellular chaperones (clusterin and α2-macroglobulin) suppress Aβ42-
mediated impairment of rat’s spatial memory, when microinjected in their brains. In 
addition, chaperones suppress Aβ42–induced glia inflammation and colocalization with 
postsynaptic markers in cultured rat hippocampal and cortical primary neurons. Our 
results support the idea that chaperones can protect against all the effects caused by 
Aβ oligomers associated with the early symptoms of AD (Result I). 
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Transthyretin (TTR) is an evolutionarily conserved serum and cerebrospinal fluid 
protein that transports the holo-retinol binding protein (RBP) and thyroxine (T4). 
Human TTR is an homotetrameric protein which can disassemble into its monomers, 
that can misfold and aggregate into fibrils whose growth is considered the cause of 
TTR amyloidoses. More than 100 mutations have been linked to TTR pathologies and a 
general trend is that the more destabilized the quaternary structure by the mutation, 
the more pathological is the variant. Nevertheless, an anti-amyloidogenic effect that 
prevents Aβ formation in vitro has recently been proposed for TTR. Thus, it is possible 
that TTR ability to bind many classes of compounds allows it to serve as an 
endogenous detoxifier of molecules with potential pathologic effects. Here we study 
the ability of three different types of TTR to suppress the toxicity of soluble oligomers 
formed by three different peptides/proteins. Our results show that TTR can protect SH-
SY5Y cells and rat primary neurons against oligomer-induced cytotoxicity and this 
ability correlates with the capability of TTR to adopt a monomeric state (Result II). The 
implication emerging from the pieces of evidence described above is that while the 
physiological function of TTR is linked to the packing of its folded state into a well-
defined quaternary structure, different monomeric TTR conformations may play other 
biological roles, be they negative/pathological or positive/protective. Although 
tetrameric TTR is far more populated in vivo than the monomer, small amounts of 
misfolded monomers may be sufficient to trigger aggregation, while the interaction of 
monomeric TTR with its target may shift the equilibrium between tetramers and 
monomers towards the latter. Consequently, the elucidation of the different 
monomeric conformational states that can be populated by TTR represents a crucial 
step towards understanding the properties of the protein and the relationships 
between those properties and its in vivo function (Result III). 
TDP-43 is the main component of the ubiquitin-positive, tau-negative and α-synuclein-
negative protein inclusions accumulating in the fronto-temporal cortex and 
hippocampus of the brain and in the motor neurons of the spinal cord of patients 
suffering from frontotemporal lobar degeneration with ubiquitin-positive inclusions 
(FTLD-U) and amyotrophic lateral sclerosis (ALS). Pathological TDP-43 aggregation is 
associated with a dislocation of this protein from the nucleus, where the protein 
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normally resides and plays its functions, to the cytoplasm, where the inclusions 
accumulate. In such cytoplasmic inclusions TDP-43 is hyperphosphorylated, 
ubiquitinated and cleaved to form C-terminal fragments, although in the spinal cord 
motor neurons the inclusions consist rather of full-length TDP-43. In this work we have 
overexpressed full-length and C-terminal TDP-43 in E. coli, purifying the resulting TDP-
43 containing inclusion bodies (FL TDP-43 IBs and Ct TDP-43 IBs, respectively) and 
subjecting them to a number of biophysical analyses to assess their structure and 
morphology. In addition to performing a biophysical investigation of the TDP-43 IBs, 
we have transfected human SH-SY5Y neuroblastoma cells with FL TDP-43 IBs to 
evaluate their inherent toxicity (Result IV). 
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Chapter 2- Materials & Methods 
Materials 
Chemicals 
All reagents were of analytical grade or the highest purity available. Tissue plastic ware 
was obtained from PBI international (Milan, Italy). Ampicillin, 8-anilino-1-
naphthalenesulfonic acid (ANS), bovine serum albumin (BSA), Bradford reagent, 
chloroquin, congo red (CR), fetal bovine serum (FBS), dithiothreitol (DTT), hen egg 
white lysozyme (HEWL), hexafluoro-2-isopropanol (HFIP), hygromycin B, human and 
bovine Cyclophilin A, 3-MA, media for cell cultures, MG-132, phosphate buffer saline 
(PBS), pluronic acid F-127, proteinase K (PK), tetracycline, Vitamin E (Vit E), ATP, 
thioflavin T (ThT), urea and other chemicals were from Sigma (Milan, Italy). Neurobasal 
medium and B-27 were from Gibco (Invitrogen Corporation, Milan, Italy), and were 
purchased from Sigma-Aldrich. 
Fluorescent probes  
 
Calcein-acetoxymethyl (Calcein-AM), 2’,7’-dichlorodihydrofluorescein diacetate,acetyl 
ester (CM-H2DCFDA), fluo3-acetoxymethyl ester (Fluo3-AM) and wheat germ 
agglutinin-conjugated with fluorescein or with Alexa Fluor 633 were purchased 
fromMolecular Probes (Eugene, OR, USA). All the fluorescent probes were prepared as 
stock solutions in DMSO, purged with nitrogen and stored in light-protected vessels at 
−20 °C until use. 
Aβ42 and HyPF-N: aggregation protocols and pre-incubation with chaperons or TTR 
 
Aβ42 were purchased from Sigma (Milan, Italy). Lyophilized Aβ42 was initially incubated 
in 1 mM in hexafluoro-2-propanol (HFIP) at least for 1 h at room temperature to allow 
complete peptide monomerization. Then, aliquots of peptide solutions were dried 
under nitrogen and stored at −80 °C. Prefibrillar aggregates of the Aβ42 peptide were 
obtained according to Lambert’s protocol [Lambert MP et al. 2001]. Briefly, aliquots of 
Aβ42 were dissolved in DMSO to a final concentration of 5.0 mM, incubated in ice-cold 
F12 medium to a concentration of 100 μM at 4°C for 24 h and then centrifuged at 
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14,000 x g for 10 min to remove insoluble structures. The supernatant, defined as the 
amyloid β-derived diffusible ligand (ADDL) preparation, consisted of a fibril-free 
solution of globular assemblies, as routinely assessed by atomic force microscopy 
[Cecchi C et al. 2009]. Lyophilized amylin 1–37 (Sigma, Milan, Italy) was stored as 
powder at −20 °C until reconstitution in HFIP at a concentration of 1.25 mM. The 
reconstituted peptide was stored as 10 μl aliquots at -80 °C until used. 
HypF-N protein, expressed and purified as previously reported [Campioni S et al. 2010], 
was converted into stable oligomers by incubation to 48 μM for 4 h or for 3 and 9 days 
at 25 °C in two different experimental conditions: 50 mM acetate buffer, 12% (v/v) 
trifluoroethanol (TFE), 2 mM dithiothreitol (DTT), pH 5.5 (condition A) and 20 mM 
trifluoroacetic acid (TFA), 330 mM NaCl, pH 1.7 (condition B). Both types of HypF-N 
oligomers were centrifuged at 16100 g, dried under N2 to remove the TFE and TFA 
when necessary, dissolved in the appropriate culture media at 48 μM concentration 
and immediately added to cultured cells at differing final concentrations. Native HypFN 
was tested by diluting the protein stock solution in the same cell media. Tappingmode 
atomic force microscopy revealed the presence of spherical bead-like aggregates with 
heights in the range of 2-6 nm and 2-7 nm under conditions A and B, respectively 
[Campioni S et al. 2010]. 
Human clusterin and α2-macroglobulin (α2M) were purified as described [Wilson MR et 
al. 1992; French K et al. 2008; Yerbury JJ et al. 2005]. The three TTR variants were 
prepared and purified in an E. Coli expression system as described elsewhere [White JT 
et al. 2001; Jiang X et al 2001; Hammarstrom P et al 2003].  
All oligomers were incubated in the appropriate media for 1h at 37°C while shaking, in 
the absence or presence of chaperones or TTRs, and then added to cultured cells or 
injected in rat brains. The HypF-N (Aβ42/IAPP):chaperone molar ratio was 10:1 
(clusterin),) and 100:1 (α2- macroglobulin), unless stated otherwise (HypF-N, Aβ42, 
IAPP, are considered as monomers, clusterin as αβ dimers and α2-macroglobulin as a 
tetramer, according to the functional oligomeric state). The HypF-N:TTR molar ratio 
was 10:1, unless stated otherwise (hTTR, mTTR or M-TTR are considered as a tetramer, 
according to the functional state). 
FL and Ct TDP-43 gene cloning and protein expression 
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The genes for full length (FL TDP-43) and its C-terminal fragment 208-414 were cloned 
downstream of the glutathione S-transferase (GST) gene in the pGEX-2T plasmid. In 
brief, the sequence coding for FL TDP-43 and that coding for Ct TDP-43 were amplified 
from the pINCY vector (EuroClone, Milan, Italy) by PCR, using forward and reverse 
primers containing the restriction sites for BamHI and EcoRI enzymes, respectively. 
Each amplified sequence and the pGEX-2T plasmid were digested with BamHI and 
EcoRI (Fermentas, Milan, Italy) and combined with the T4 DNA ligase (Fermentas) to 
obtain the constructs coding for the GST/FL TDP-43 and the GST/Ct TDP-43 fusion 
proteins. Their correct nucleotide sequence was verified by DNA sequencing. Cultures 
of E. coli XL1 Blue cells (Agilent Technologies, Milan, Italy) were transformed with the 
resulting plasmids containing FL TDP-43 or Ct TDP-43 and were grown overnight at 37 
°C in LB medium with 100 μg/mL ampicillin under vigorous shaking. Cells were then 
diluted 1:10 in fresh medium and grown at 37 °C in LB until OD600nm ~ 0.6. Protein 
expression was induced using 1 mM isopropyl β-D-1-thiogalactoside (IPTG; Inalco, 
Paris, France). Cells were harvested by centrifugation, resuspended in PBS buffer (137 
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 1 mM EDTA, 1 mM β-
mercaptoethanol, 0.1 mM PMSF, at pH 7.3) and then lysed by 30 min incubation with 1 
mg/mL HEWL in ice, followed by sonication at 40 kHz (five cycles of 30 s each). The 
expression of FL and Ct TDP-43 and their presence in the supernatant or in the pellet 
fractions after cell lysis were checked by SDS-PAGE, using 12% (w/v) polyacrylamide 
gels. 
Inclusion bodies purification  
 
Inclusion bodies (IBs) were purified from IPTG induced cells harbouring the pGEX-2T/FL 
TDP-43 plasmid, the pGEX-2T/Ct TDP-43 plasmid and the only pGEX-2T plasmid by 
detergent-based procedures. Briefly, cells obtained from 1 L cultures were harvested 
by centrifugation at 29000 × g for 15 min at 4 °C, resuspended in 40 mL of lysis buffer 
(50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, at pH 8.0) and maintained overnight at 
−80 °C. ATer thawing, 35 μL of 100 mM PMSF and 280 μL of 10 mg/mL HEWL were 
added and the samples were incubated for 45 min at 37 °C under gentle agitation. To 
cause the membrane lysis, IGEPAL was added to a final concentration of 1% (v/v) and 
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the mixture maintained in ice for 1 h under agitation. Then, 600 μL of 1 mg/mL DNase I 
and 600 μL of 1 M MgSO4 were added and the resulting mixture was incubated at 37 °C 
for 40 min. IBs were separated by centrifugation at 29000 × g for 15 min at 4 °C. The 
resulting IBs were washed once with lysis buffer containing 0.5% Triton X-100 and 
twice with water. After a final centrifugation at 29000 × g for 15 min at 4 °C, the pellet 
was stored at −80 °C and reconsUtuted in PBS buffer (137.0 mM NaCl, 2.7 mM KCl, 4.3 
mM Na2HPO4, 1.4 mM KH2PO4, at pH 7.3). 
IBs internalization 
 
FL TDP-43 IBs were labeled with fluorescein-5-isothiocyanate (5-FITC) using AnaTagTM 
5-FITC Microscale Protein Labeling Kit (AnaSpec, San Jose, CA, USA). Transfection of 
both labeled and unlabeled FL TDP-43 IBs and unlabeled control IBs into SH-SY5Y 
neuroblastoma cells was performed using a total protein concentration of 5.7 μg/mL 
and 4.0 μg/mL, respectively, and the PULSin protein delivery reagent (Polyplus-
transfection, Illkirch, France). Cells were also transfected with R-phycoerythrin (R-PE), 
a green fluorescent protein used as a positive control (excitation and emission at 488 
and 575 nm, respectively). After 3 h transfection, the incubation medium without 
serum was replaced with fresh complete medium. After washing with PBS, cells 
treated with unlabeled IBs were counterstained for 10 min with 50 μg/mL Alexa Fluor 
633-conjugated wheat germ agglutinin and fixed in 2% (w/v) buffered 
paraformaldehyde for 10 min at room temperature (20 °C). After plasma membrane 
permeabilization with a 3% (v/v) glycerol solution for 5 min, the coverslips were 
incubated for 60 min with 1:350 diluted rabbit polyclonal anti-TDP-43 antibodies 
(Sigma-Aldrich) and then for 90 min with 1:1000 diluted Alexa Fluor 488-conjugated 
anti-rabbit antibodies incubated at 37 °C. Cells were analyzed using a Leica TCS SP5 
confocal scanning microscope (Leica Microsystems, Mannheim, Germany), equipped 
with an argon laser source and a Leica Plan Apo 639 oil immersion objective.  
The colocalization of FL TDP-43 IBs or phosphorylated TDP-43 with ubiquitin was 
monitored using 1:350 rabbit polyclonal anti-TDP-43 antibody or 1:500 rabbit anti-TDP-
43 phosphorylation sites 409/410 (Cosmo Bio Co., Ltd., Tokio, Japan) for 60 min at 37 
°C, 1:150 mouse monoclonal anti-ubiquitin antibodies (Life Technologies, CA, USA) for 
Chapter 2- Materials & Methods 
| 41 
 
60 min at 37 °C, and then with 1:1000 Alexa Fluor 488-conjugated secondary 
antibodies (Life Technologies, CA, USA) for 60 min at 37°C and 594-conjugated 
secondary antibodies (Life Technologies, CA, USA) for 60 min at 37°C. 
Rat models and cell culture 
 
Three-month-old (220–250 g) male Wistar rats (Harlan Nossan, Correzzana, Italy) were 
housed in macrolon cages until surgery and maintained on a 12-hours light/dark cycle 
at 23°C. All animal manipulations were performed in vivo, according to the European 
Community guidelines for animal care (DL 116/92).  
Primary hippocampal and cortical neurons were obtained from embryonic day (ED)-17 
Sprague-Dawley rats (Harlan, Italy) as described in Bongers et al. [Bongers G. et al. 
2007]. The experimental procedure were in accordance with the standards set forth in 
the Guide for the Care and Use of laboratory Animals (published by the National 
Academy of Science, National Academy Press, Washington, D.C.). The uteri were 
removed from the gravid rat under anesthesia. Cerebral hippocampi and cortices 
were dissociated in sterile Dulbecco’s phosphate-buffered saline (D-PBS; Sigma), and 
neurons isolated in the same medium containing trypsin (0.5% in sterile Dulbecco’s 
phosphate-buffered saline) for 10 min at 37° C. After centrifugation, dissociated 
neurons were re-suspended in neurobasal medium (NBM; Gibco, Invitrogen 
Corporation, Milan, Italy) supplemented with 2% B-27 (Gibco) and 0.5 mmol/L 
glutamine (Gibco), and then plated in poly-L-lysine-coated 96 or 24-well plates at a 
density of approximately 1.0 x 10
4
 and 2.0 x 10
4
/well, respectively. Cultures were 
maintained in NBM at 37° C in a 5% CO2-humidified atmosphere. Neurons were 
exposed to 12.0 μM toxic oligomers 14 days after plating. 
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cultured in 
DMEM/F-12 Ham with 25 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 
(HEPES) and NaHCO3 (1:1) supplemented with 10% FBS, 1.0% glutamine and 1.0% 
antibiotics. The cell culture was maintained in a 5.0% CO2 humidified atmosphere at 37 
°C and grown until 80% confluence for a maximum of 20 passages. 
Methods 
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Analyses on rat models: Morris water maze test (MWM) 
 
For in vivo studies, Aβ42 oligomers and chaperones were suspended in F12-medium 
with 0.1% DMSO at final concentrations of 0.45 mg/ml (100 µM) and 0.7 mg/ml (10 
µM for Clu and 1 µM for α2M), respectively, and incubated for 1 h at 37 °C while 
shaking. 1.5 µl aliquots of F12-medium, F12-medium with Aβ42 oligomers, F12-medium 
with Aβ42 oligomers and Clu and F12-medium with Aβ42 oligomer and α2M, all 
containing 0.1% DMSO, were injected into the Cornu Ammonis (CA) 1 molecular layer 
of the right hippocampus of anaesthetised (Zoletyl, 45 mg/kg plus Carprofen, 5 mg/kg) 
rats for each condition, using a Hamilton microsyringe, at the following stereotaxic 
coordinates (in mm): AP,-3.7; L,-2.5 from bregma; and H, 3.5 below the dura [Paxinos 
G et al. 1980]. The injections lasted 3 min, and the microsyringe was left in the place 
for 5 min after completing the infusion. Rats were behaviourally tested in the MWM 1 
week after the intrahippocampal injection of the different oligomers (n=6/group). This 
was considered a reasonable time period to allow us to detect long-term effects of the 
injected aggregates in light of their likely persistence in tissue. 
The water maze apparatus consisted of a circular pool (160 cm diameter and 45 cm 
high) made of plastic. The pool was filled to a depth of 30 cm with water (22±1 °C) that 
was made dark by the addition of non-toxic dark paint, and virtually divided into four 
equivalent quadrants. Rats were tested in the reference
 
memory version of MWM with 
the procedure previously described [Inostroza M et al. 2011]; briefly, all rats 
underwent a reference memory training
 
with a hidden platform (13 cm diameter, 
submerged 0.5 cm under the water level), placed in the centre of one quadrant of
 
the 
pool (northwest) for 4 days, with 4 trials per day, with the four starting locations varied 
between trials. Upon release into the water, the rat was allowed to search the 
platform for 60 s; if the platform was not located within the maximum time of 60 s, the 
rat was guided to the location. The rat was allowed 20 s on the platform. Extra-maze 
visual cues around the room remained in fixed positions throughout the experiment. 
For each trial, latency to find the platform (maximum 60 s) was recorded by a video-
tracking/computer-digitising system (HVS Image, Hampton, UK). On day 4, five hours 
after the last trial, the platform was removed from the pool
 
and each rat received one 
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30 s swim "probe trial". The starting point was set in the south-east quadrant. 
Percentage of time spent in each quadrant and the number of crossing over the 
platform section were recorded. 
Fluorescence immunohistochemical analyses of glial activation and Neu-N 
 
After behavioural evaluations, all rats were deeply anaesthetised with chloral hydrate 
(400 mg/kg, i.p.) and killed by decapitation. Four brains for each conditions were 
quickly extracted and fixed in phosphate-buffered 4% paraformaldehyde (pH 7.4) for 
24 h at 4 °C, subsequently rinsed with PBS, dehydrated using an automated machine 
and embedded in paraffin. Coronal sections (5.0 µm) were cut using a microtome and 
mounted on slides. Sections were then incubated in xylene for 20 min at room 
temperature, to allow removal of paraffin, and subsequently rehydrated.  
Fluorescent labeling followed previously described protocols [Rosi MC et al. 2010]. 
Briefly, 5 µm paraffin-embedded coronal sections (3 sections of each brain for each 
condition) were rinsed 3 times and placed in blocking solution (PBS, pH 7.4 + 0.3% (v/v) 
Triton X-100, 2 g/l bovin serum albumin (BSA) and 5% (v/v) normal goat serum (NGS)) 
for 30 min at room temperature (RT). Analysis of glial fibrillary acidic protein (GFAP)-
immunoreactive astrocytes and ionised calcium binding adaptor molecule 1 (Iba-1)-
labeled microglial cells were carried out overnight at 4 °C using 1:500 diluted rabbit 
polyclonal anti-GFAP (Dako, Glostrup, Denmark) or 1:300 diluted rabbit polyclonal anti-
Iba 1 (Wako, Fuggerstrasse, Germany) antibodies diluted in fresh blocking solution. 
Sections were then washed in PBS (3x 10 min) at RT and subsequently incubated for 2 
h with Alexa Fluor 488-conjugated anti-rabbit or Alexa Fluor 594-conjugated anti-
rabbit polyclonal antibodies (Invitrogen, Eugene, OR), diluted 1:400 in blocking 
solution. Following further rinses, sections were cover-slipped using Vectashield water-
based mounting medium containing DAPI (Vector Laboratories, Burlingame, CA).  
Analysis of neuronal nuclei (Neu-N) were carried out overnight at 4 °C using 1:100 
diluted mouse polyclonal anti-Neu-N (Chemicon, Millipore, Italy) antibodies diluted in 
fresh blocking solution. Sections were then washed in PBS (3x 10 min) at room 
temperature and subsequently incubated for 2 h with Alexa Fluor 594-conjugated anti-
mouse polyclonal antibodies (Invitrogen) diluted 1:400. Following further rinses, 
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sections were cover-slipped using Vectashield water-based mounting medium 
containing DAPI (Vector Laboratories). In each study the analysis of negative controls 
(omission of primary antibody) was simultaneously performed in order to exclude the 
presence of non-specific immunofluorescent staining, cross-immunostaining, or 
fluorescence bleed-through. Neu-N-positive cells in the hippocampus were counted 
under a 10 x objective lens of an Olympus Optical (Tokyo, Japan) BX63 microscope 
equipped with an Olympus Optical DP50 digital camera and a cellSens Dimension 
software. The total number of counted Neu-N-positive cells, carried out on 3 sections 
of each brain for each condition, was averaged, expressed as percentage of that in the 
F-12-injected rats, assumed as 100% and analyzed using Prism 3.0 (GraphPad Software, 
San Diego, CA). 
Lipid peroxidation analysis and caspase-3 activity assay in rat hippocampus 
 
The analyses of lipid peroxidation and caspase-3 levels were performed on rat 
hippocampal homogenates. We microinjected 1.5 µl aliquots of F12-medium, Aβ42 
oligomers and Aβ42 oligomer pre-incubated with Clu or α2M for 0 h and 1 h, into the 
right hippocampus of anaesthetised rats. Three hippocampi for each condition were 
quickly extracted from rat brains and immediately stored at -80 °C. Each hippocampus 
was transferred to ice-cold microcentrifuge tubes with 200 µl of lysis buffer (50 mM 
Tris–HCl, pH 7.5, 50 mM NaCl, 10 mM EGTA, 5 mM EDTA, 2 mM sodium 
pyrophosphate, 4 mM para-nitrophenylphosphate, 1 mM sodium orthovanadate, 1 
mM phenylmethylsulfonyl fluoride (PMSF), plus 20 µg/ml leupeptin and 30 µg/ml 
aprotinin), and tissues were homogenised on ice (with a Potter-Elvehjem homogeniser) 
directly into the Eppendorf tube (20 strokes, 1 stroke/s). Immediately after 
homogenisation, protein determination was performed using the method of Bradford 
[Bradford MM 1976]. To assess the rate of lipid peroxidation, the 8-OH isoprostane 
levels were measured in rat hippocampal homogenates (5 µg of proteins per well) 
using the 8-isoprostane EIA kit (Cayman Chemical Company, Ann Arbor, MI) at 405 nm, 
as previously described [Zampagni M et al. 2012]. 
The caspase-3 activity assay homogenates were prepared using a different buffer 
composition (20 mM Tris-HCl buffer, pH 7.4, containing 250 mM NaCl, 2 mM EDTA, 
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0.1% Triton X-100, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.5 mM phenylmethylsulfonyl 
fluoride, 4 mM sodium vanadate, and 1 mM dithiothreitol (DTT)) [Donati C et al. 2007]. 
To evaluate the caspase-3 activation, 50 μg of total proteins were diluted in 50 mM 
HEPES-KOH buffer, pH 7.0, containing 10% glycerol, 0.1% 3-[(3-
cholamidopropyl)dimethylammonio]- 1-propanesulfonate, 2 mM EDTA, 10 mM DTT 
and incubated for 4 h at 37 °C in presence of 30 μM Ac-DEVD-AFC (excitation, 400 nm; 
emission, 505 nm) (Biomol Research Laboratories Inc., Plymouth Meeting, PA, 
http://www.biomol.com). 
Analyses on cell cultures 
Cell exposure to aggregates 
 
The effect of protein oligomers on cell viability was assessed using primary neurons 
from rat brains and SH-SY5Y cells seeded in 96-well plates. Preformed oligomers of 
Aβ42 and HypF-N (12 µM monomer concentration) were incubated in cell culture 
medium for different time lengths (0, 5, 15, 30 and 60 min) in the absence or presence 
of Clu, α2M, hTTR, muTTR, M-TTR, HEWL or BSA (protein: Clu and protein:TTR molar 
ratio were 10:1 unless otherwise stated; protein:α2-macroglobulin was 100:1, 
protein:haptoglobin, protein:HEWL and protein:BSA molar ratio was 5:1), and then 
added to the cells. Each TTR (1.2 µM tetramer concentration) or 12 µM native HypF-N 
and Aβ42 were also used as controls. In additional experiments, 1 µM staurosporine 
(Sigma Aldrich, Milan, Italy) was incubated for 1 h in cell culture medium in the 
absence or presence of each TTR and then added to the cells.  
60 min at 37 °C, and then with 1:1000 Alexa Fluor 488-conjugated secondary 
antibodies (Life Technologies, CA, USA) for 60 min at 37°C and 594-conjugated 
secondary antibodies (Life Technologies, CA, USA) for 60 min at 37°C. 
Evaluation of intracellular ROS production 
 
Intracellular ROS production was detected by using CM-H2DCFDA, a ROS-sensitive 
fluorescent dye. CM-H2,DCFDA esterified derivative is loaded more effectively within 
the cytoplasm of the cells because it is more cell permeant before ester groups are 
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hydrolyzed by the cellular esterases. Only a negligible leakage of the probe occurred, 
since chloromethyl-DCF is negatively charged at physiological intracellular pH. SHSY5Y 
cells were first cultured on glass coverslips and exposed to native protein or to HypF-N 
aggregates for different times at 37°C. Cells were also exposed to HypF-N aggregates in 
a Ca
2+ 
free medium or pre-treated for 24 hours with 100 μM vitamin E prior to 
aggregate exposure in Ca
2+ 
containing medium. In other set of experiments, SH-SY5Y 
cells and rat neurons were incubated for 60 min with 12 μM HypF-N type A oligomers 
or Aβ42 oligomers pre-incubated with or without different chaperones or TTRs for 
different lengths of time. The cells were then incubated with 5 μM CMH2DCFDA, 
dissolved in 0.1% DMSO and Pluronic acid F-127 (0.01% w/v), in the final 10 min of 
aggregate exposure. The cells were then fixed in 2.0% buffered paraformaldehyde for 
10 min at room temperature and the emitted CM-H2DCFDA fluorescence was detected 
at 488-nm excitation by the confocal Leica TCS SP5 scanning microscope (Mannheim, 
Germany) equipped with an argon laser source for fluorescence measurements at 488 
nm and 633 nm and a Leica Plan Apo 63 x oil immersion objective. A series of optical 
sections (1024 X 1024 pixels) 1.0 μm in thickness was taken through the cell depth for 
each examined sample. 
The levels of intracellular ROS production were analysed also 24 h after transfection or 
extracellular addition of FL TDP-43 IBs and control IBs to SH-SY5Y cells seeded on glass 
coverslips and loaded with CM-H2DCFDA. Final protein concentration were 4.0 µg/mL 
and 215 µg/mL (plus 30% for FL TDP-43 IBs) for the intracellular and extracellular 
analyses, respectively. Aβ42 oligomers at a final protein concentration of 60 µg/mL 
were also used as a positive control. To quantify the signal intensity of CM-H2DCFDA, 
10-22 cells were analyzed using ImageJ software (NIH, Bethesda, MD), and the 
fluorescence intensities were expressed as arbitrary units. 
Analysis of membrane permeability 
 
In order to assess whether HypF-N aggregates disrupt cell membrane integrity, 
neuroblastoma cells were pre-treated for 20 min at 37°C with 2.0 μM calcein-AM, 
dissolved in DMSO and resuspended in cell culture medium [Cecchi C et al. 2008]. The 
decay in fluorescence was analyzed by confocal microscopy at 488 nm excitation 
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wavelength after cell exposure to 12 μM HypF-N aggregates at 37°C for differing length 
of time. In a set of experiments, SH-SY5Y cells were incubated for 60 min with 12 μM 
HypF-N type A oligomers pre-incubated with or without different chaperones or TTRs 
for different lengths of time. 
Analysis of cytosolic Ca
2+
 dyshomeostasis 
 
The effect of HypF-N aggregates on cytosolic free Ca
2+
 levels was analyzed in SH-SY5Y 
cells plated on glass coverslips and loaded with Fluo3-AM, a Ca
2+
 specific fluorescent 
probe. The cells were first exposed to 12 μM HypF-N aggregates for differing length of 
times at 37°C. Cytosolic Ca
2+
 levels were also examined in SH-SY5Y cells exposed to 
HypF-N aggregates in Ca
2+
 free medium or in cells pre-treated for 24 h with 100 μM 
vitamin E prior to aggregate exposure in Ca
2+
 containing medium. In a set of 
experiments SH-SY5Y cells and rat neurons were exposed for 60 min at 37°C to 12 μM 
HypF-N type A aggregates or Aβ42 oligomers pre-incubated with or without different 
chaperones/TTRs for for different lengths of time. The cells were then loaded for 30 
min at 37°C with 10 μM Fluo3-AM, 0.01% (w/v) pluronic acid F-127 in Hank’s Balanced 
Salt Solution (HBSS) and subsequently fixed in 2.0% buffered paraformaldehyde for 10 
min at room temperature. Fluorescence was detected at 488 nm excitation by 
collecting the emitted fluorescence with the confocal scanning system described 
above. 
Apoptotic and necrotic markers 
Caspase-3 activity 
 
The extent of the apoptotic program activation in SH-SY5Y cells was evaluated by 
confocal microscope and flow cytometric analyses of caspase-3 activity, which is the 
main effector caspase in apoptosis. The cells were exposed to 12 μM native or 
aggregated HypF-N aggregates for 24 h at 37 °C in culture medium. In a series of 
experiments, the cells were also treated with HypF-N type A oligomers pre-incubated 
with or without different chaperones/TTRs for different lengths of time. After the 
appropriate treatment, the culture media were removed and replaced with FAM-FLICA 
Chapter 2- Materials & Methods 
| 48 
 
Caspases 3&7 solution (Caspase 3&7 FLICA kit; FAM-DEVDFMK; Immunochemistry 
Technologies, LLC, Bloomington, MN, USA) for 60 min and the emitted fluorescence 
was detected at 488 nm excitation by the confocal scanning system described above. 
The levels of caspase-3 activity were analysed also 24 h after transfection or 
extracellular addition of FL TDP-43 IBs and control IBs to SH-SY5Y cells seeded on glass 
coverslips. Final protein concentration were 4.0 µg/mL and 215 µg/mL (plus 30% for FL 
TDP-43 IBs) for the intracellular and extracellular analyses, respectively. Aβ42 oligomers 
at a final protein concentration of 60 µg/mL were also used as a positive control. To 
quantify the signal intensity of CM-H2DCFDA, 10-22 cells were analyzed using ImageJ 
software (NIH, Bethesda, MD), and the fluorescence intensities were expressed as 
arbitrary units 
Hoechst staining 
 
Nuclear alterations eventually induced by HypF-N aggregates were investigated by 
Hoechst 33342 dye staining. Briefly, SH-SY5Y cells were exposed to 12 μM HypF-N type 
A oligomers pre-incubated with or without different TTRs for 24 h at 37 °C. Then, the 
cells were incubated with 20 μg/ml Hoechst for 15 min at 37 °C and fixed in 2% 
buffered paraformaldehyde for 10 min at room temperature. Blue fluorescence 
micrographs of cells were obtained under UV illumination in an epifluorescence 
inverted microscope (Nikon, Diaphot TMD-EF) with an appropriate filter set. 
Mitochondrial status 
Cytotoxicity assay 
 
The toxic effect of the differing aggregates on metabolic cell functions was assessed in 
cell models by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay in 96-well plates [Cecchi C et al. 2007]. Native or aggregated HypF-N (12 μM) 
were added to the SH-SY5Y or rat neuron cell culture media for 24 h at 37 °C. In a set 
of experiments, SH-SY5Y cells were exposed for 24 h at 37 °C to 12 μM HypF-N type A, 
Aβ42 or IAPP oligomers, pre-incubated with or without chaperones, TTRs, HEWL or 
BSA for 1 h. In another set of experiments SH-SY5Y cells were exposed 1 μM 
Chapter 2- Materials & Methods 
| 49 
 
staurosporine pre-incubated with or without chaperones or TTRs, for 24 h at 37°C. Rat 
neurons were exposed for 24 h at 37°C to 12 μM HypF-N type A or Aβ42 oligomers 
pre-incubated with or without chaperones. 
The MTT assay was also carried out 24 h after cell transfection or addition to the 
extracellular medium of SH-SY5Y cells of FL TDP-43 IBs, control IBs and R-PE. The final 
protein concentrations were 4.0 µg/mL for the cell internalization analysis and ranged 
from 7.5 to 860 µg/ml for the extracellular analysis (plus 30% for FL TDP-43 IBs). In a 
set of experiments cells were treated with either 5 μM MG-132, 10 mM 3-MA or 40 
μM chloroquin, which were added immediately after cell transfection with FL TDP-43 
IBs and control IBs. After cell treatments, 100 μl of 0.5 mg/ml MTT solution in PBS was 
added to the cell cultures and the samples were incubated for 4 h at 37°C. Finally, 100 
μl of cell lysis buffer (20% SDS, 50% N,N-dimethylformamide, pH 4.7) was added to 
each well and the samples were incubated for at least 3 h at 37°C in a humidified 
incubator, before determination of absorbance value of blue formazan at 590 nm with 
an ELISA plate reader. Cell viability was expressed as a percentage of MTT reduction in 
aggregate or transfected cells compared to untreated cells (assumed as 100%). 
Colocalization of Aβ42 aggregates with PSD-95 in cultured neurons  
 
Preformed oligomers of Aβ42 (12 µM monomer concentration) were incubated for 1 h 
in the cell culture medium with or without Clu or α2M (Aβ42:chaperone molar ratio as 
described above) and then added to rat neurons seeded on glass coverslips for 1 h or 
24 h at 37 °C. Immunolabeling of cultured primary neurons was performed as 
previously described [Lacor PN et al. 2004]. The colocalization of Aβ42 aggregates with 
PSD-95 was monitored using 1:200 mouse monoclonal 6E10 antibody and 1:500 rabbit 
polyclonal anti-PSD-95 antibody (Pierce Biothecnology, USA) for 60 min at 37 °C, and 
then with Alexa Fluor 488- and 594-conjugated antibody (Sigma-Aldrich, St. Louis, MO) 
for 2 h at room temperature. Cell fluorescence was analyzed by confocal Leica TCS SP5 
scanning microscope (Mannheim, Germany) equipped with laser sources for 
fluorescence measurements at 488 and 594 nm and a Leica Plan Apo 63X oil 
immersion objective. A series of optical sections (1024x1024 pixels), 1.0 µm in 
thickness, were taken through the cell depth for each examined sample. Settings were 
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maintained constant for each analysis. The colocalization of oligomers with PSD-95 was 
estimated on regions of interest (12–13 cells) using the ImageJ (NIH, Bethesda, MD, 
USA) and JACOP plugin (rsb.info.nih.gov) softwares [Rasband WS 1997-2008]. 
Confocal microscopy analysis for TTR-HypF-N oligomer binding 
 
HypF-N oligomers (at a corresponding monomer concentration of 48 μM) were 
incubated for different time lengths (0, 5, 15, 30 and 60 min) in the absence or 
presence of TTRs and then centrifuged to obtain pellet that were resuspended and 
incubated subsequently for 30 min at 37 °C in solutions containing: (I) 1:4,000 rabbit 
polyclonal anti–HypF-N antibodies (Primm) and mouse monoclonal anti-TTR antibodies 
(Santa Cruz Biotechnology), (II) 1:1,000 Alexa Fluor 488-conjugated anti-rabbit 
secondary antibodies (Life technologies, CA, USA), and (III) Alexa Fluor 594-conjugated 
anti-mouse secondary antibodies (Life technologies, CA, USA). After every incubation, 
samples were centrifuged for 10 min at 16,100 × g, washed in PBS, and centrifuged 
again. Finally, the pellet was resuspended in 20 μl PBS and spotted on glass coverslips. 
The cross-reactivity of oligomers was tested by subsequent incubations with primary 
and secondary anti-TTR antibodies. Confocal microscope images were acquired as 
described above. 
Confocal microscopy analysis for TTR- Aβ42 oligomer binding  
 
Aβ42 oligomers (at a corresponding monomer concentration of 48 μM) were incubated 
for different time lengths (0, 5, 15, 30 and 60 min) in the absence or presence of M-
TTR, spotted on glass coverslips and incubated for 30 min at 37 °C in solutions 
containing (i) 1:300 diluted rabbit polyclonal A11 anti-Aβ antibodies (Life technologies, 
CA, USA) and mouse monoclonal anti-TTR antibodies (Santa Cruz Biotechnology), (ii) 
1:1,000 Alexa Fluor 488-conjugated anti-rabbit secondary antibodies (Life 
technologies, CA, USA), and (iii) Alexa Fluor 594-conjugated anti-mouse secondary 
antibodies (Life technologies, CA, USA). After every incubation, samples were washed 
in PBS. The cross-reactivity of oligomers was tested by subsequent incubations with 
primary and secondary anti-TTR antibodies. Confocal microscope images were 
acquired as described in the Material and Methods section. 
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Biophysical methods 
Thioflavin T assay 
 
Preformed HypF-N oligomers (12 µM monomer concentration) were incubated for 1 h 
at 37 °C with shaking in the presence or absence of each TTR (HypF-N:TTR molar ratio 
as described above). Aliquots of these samples were added to a solution of 25 μM 
Thioflavin T (ThT) dissolved in 25 mM phosphate buffer at pH 6.0, in order to obtain a 
3.7-fold molar excess of dye. Final protein concentration was 6 μM. The steady-state 
intensity of fluorescence emission at 485 nm (excitation at 440 nm) was recorded at 37 
°C. Each TTR (1.2 µM tetramer concentration) and 12 µM native HypF-N were also 
used as controls. 
In a set of experiment FL TDP-43 IBs, Ct TDP-43 IBs and control IBs at the same 
concentrations were incubated at 25 °C and an aliquot of 60 µL of each sample was 
mixed with 440 µL of a 25 mM NaH2PO4 buffer at pH 6.0 containing 25 µM ThT. The 
resulting fluorescence was measured at 25 °C using a Perkin-Elmer LS 55 
spectrofluorimeter (Waltham, MA, USA) equipped with a thermostated cell holder 
attached to a Haake F8 water bath (Karlsruhe, Germany), using excitation and emission 
wavelengths of 440 and 450-600 nm, respectively. A 2 x 10 mm quartz cuvette was 
used. The ThT spectrum obtained in the presence of the same buffer without IBs was 
subtracted from those acquired in the presence of FL TDP-43 IBs, Ct TDP-43 IBs and 
control IBs. The ThT fluorescence obtained after incubation with native HypF-N is 
reported as negative control. 
Pyrene fluorescence emission spectra 
 
HypF-N variants carrying a single cysteine residue were labeled with N-(1-
pyrene)maleimide and converted into toxic aggregates as previously reported 
[Zampagni M et al. 2011] and then 4-fold diluted into 20 mM potassium phosphate 
buffer at pH 7.0. Fluorescence emission spectra of these samples were measured after 
1 h of incubation at 37 °C under shaking in the absence and presence of each TTR. The 
spectra were acquired with 12 μM HypF-N, at 37 °C, with an excitation of 344 nm using 
a Perkin-Elmer LS 55 spectrofluorimeter (Wellesley, MA) equipped with a 
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thermostated cell holder attached to a Haake F8 water bath (Karlsruhe, Germany), and 
a 1.5 × 1.5 mm quartz cell. The spectra were normalized to the intensity of the peak 
centered at 375 nm. 
Intrinsic fluorescence 
 
HypF-N oligomers and each TTR incubated in isolation and in combination as described 
before were centrifuged for 10 min at 16100 rcf. The intrinsic fluorescence of the 
supernatants (SNs) were measured at 37 °C with excitation at 280 nm using a Perkin-
Elmer LS 55 spectrofluorimeter (Wellesley, MA) equipped with a thermostated cell 
holder attached to a Haake F8 water bath (Karlsruhe, Germany), and a 2 × 10 mm 
quartz cell. The spectrum of HypF-N oligomers has been subtracted from that of 
TTR+HypF-N oligomers.  
SDS-PAGE 
 
HypF-N oligomers and each TTR incubated in isolation and in combination as described 
above were centrifuged for 10 min at 16100 rcf. Pellets and SN aliquotes were 
collected and mixed with 4× sample buffer with 20 % 2-mercaptoethanol. Sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis was performed 
in accordance with Laemmli [Oberg K et al. 1994] using a 16% polyacrylamide gels. 
Proteins were visualized by Coomassie Blue staining (0.1% Coomassie Blue, 10% acetic 
acid, 40% methanol). The densitometric analysis was obtained using ImageJ software 
(NIH, Bethesda, MD,USA).  
Atomic force microscopy 
 
HypF-N/Aβ42 oligomers (12 µM monomer concentration) were incubated for 1 h at 37 
°C under shaking in 20 mM potassium phosphate buffer at pH 7.0, in the presence or 
absence of each TTR. Samples were diluted 1000-fold and immediately deposited on a 
freshly cleaved mica substrate and dried under a gentle nitrogen flux. Non-contact AC 
mode atomic force microscopy (AFM) images were acquired in air using a PicoSPM 
microscope equipped with an AC-mode controller (Molecular Imaging, Phoenix, AZ). 
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Rectangular non-contact cantilever (model NSG01, NT-MDT Moscow, Russia), with 
typical resonance frequency of 150 Khz, were used. Oligomer sizes were measured 
from the height in cross section of the topographic AFM images.  
In another set of experiment purified IBs were resuspended in water at a protein 
concentration of 2 mg/mL and diluted 10 or 100 times. A 10 µL aliquot was deposited 
on freshly cleaved mica and dried under mild vacuum. Digestion with PK was 
performed by incubating 40 µL of undiluted IBs with 3.2 µL of a 10 mg/mL PK stock 
solution for 60 min at 37 °C. Digested samples were then diluted 100 times and a 10 µL 
aliquot was deposited on freshly cleaved mica and dried under mild vacuum. Tapping 
mode AFM images were acquired in air using a Dimension 3000 SPM, equipped with a 
“G” scanning head (maximum scan size of 100 μm) and driven by a Nanoscope IIIa 
controller, and a Multimode SPM equipped with a “E” scanning head (maximum scan 
size of 10 μm) and driven by a Nanoscope V controller (Digital Instruments, Veeco). 
Single-beam uncoated silicon cantilevers (type OMCL-AC160TS, Olympus) were used. 
The drive frequency was between 260 and 330 kHz; the scan rate was 0.4-0.8 Hz. CR 
absorbance 
CR absorbance 
 
CR interaction with IBs was tested using a Jasco V-630 spectrophotometer (Tokyo, 
Japan) by recording the absorbance spectra from 400 nm to 700 nm using a 10 mm 
quartz cell. FL TDP-43 IBs, Ct TDP-43 IBs and control IBs at 1.0, 1.0 and 0.7 mg/mL 
concentrations, respectively, were incubated at 25 °C and an aliquot of 60 µL of each 
sample was mixed with 440 µL of a 5 mM NaH2PO4, 150 mM NaCl buffer at pH 7.4 
containing 20 µM CR. Spectra were also recorded for similar samples devoid of CR and 
similar samples devoid of IBs. The difference spectrum obtained by subtracting the 
spectra of CR alone and IBs alone from that of CR plus IBs indicated the spectrum of CR 
bound to β-sheet structure. The CR spectra obtained for the native HypF-N protein are 
also reported as a further control. 
Far-UV CD 
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FL TDP-43 IBs, Ct TDP-43 IBs and control IBs at 2.8, 2.8 and 2 mg/mL concentrations, 
respectively, were prepared in 25 mM NaH2PO4 buffer at pH 7.3, 25 °C. The far-UV 
circular dichroism (far-UV CD) spectra were collected over the 190-260 nm wavelength 
range at 25 °C using a Jasco J-810 Spectropolarimeter (Tokyo, Japan) equipped with a 
thermostated cell holder attached to a Thermo Haake C25P water bath (Karlsruhe, 
Germany). A 1 mm path-length cell was used. All spectra were blank subtracted. For 
the calculation of the molar ellipticity [θ] we used the following formula: 
 
[θ]  (1) 
 
were [θ] is the molar ellipticity in deg cm
2
dmol
−1
, θ is the ellipticity in mdeg, optical 
path is in cm, concentration is in g/L, molecular weight is in g/mol. 
Fourier transformed infrared spectroscopy (FTIR) 
 
Purified IBs were resuspended in D2O to achieve a final protein concentration of 21 
mg/mL for FL TDP-43 IBs and Ct TDP-43 IBs and 15 mg/mL for control IBs. Each sample 
was deposited on a potassium bromide window in a semipermanent liquid cell using a 
spacer of 25 μm, and the Fourier transformed infrared spectroscopy (FTIR) spectrum 
was recorded at room temperature using a Jasco FTIR 4200 spectrophotometer 
(Tokyo, Japan). The system was constantly purged with N2. The resulting spectra were 
background subtracted and baseline corrected. 
PK proteolysis 
 
FL TDP-43 IBs and control IBs were prepared in water at a final protein concentration 
of 14.3 mg/mL and 10 mg/mL, respectively, and digested with 250 μg/mL PK at 37 °C. 
The digestion was followed for 500 s observing the turbidity decrease at 350 nm using 
a Jasco V-630 spectrophotometer (Tokyo, Japan) and a 5 mm quartz cell. The digestion 
kinetics were analysed using a procedure of best fitting obtained with the following 
single exponential equation: 
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N(t) = k + (N0 − k)e−λt (2) 
 
where N(t) is the turbidimetry at time t, k is the final value of the turbidimetry, N0 is 
the initial turbidimetry, t is the time in s, λ is the rate constant in s
−1
. The FL TDP-43 IBs 
and Ct TDP-43 IBs digestions were also followed by SDS-PAGE. The FL TDP-43 IBs 
sample at a total protein concentration of 14.3 mg/mL was treated at 37 °C with 250 
μg/mL and 20 μg/mL PK, for a total time of 300 s, while the Ct TDP-43 IBs sample at 
the same concentration of FL TDP-43 was treated at 37 °C with 20 μg/mL PK, for a 
longer time (1200 s). Aliquots of both samples were taken at defined times and tested 
by SDS-PAGE using 12% (w/v) polyacrylamide gels. The progressive FL TDP-43 and Ct 
TDP-43 digestions were monitored observing the intensity changes of their 
corresponding bands. 
Thermal Unfolding Experiments 
 
Thermal unfolding measurements were carried out following the CD signal emitted by 
M-TTR at 216 nm using a Jasco J-810 spectropolarimeter (Tokyo, Japan) equipped with 
a thermostated cell holder attached to a Thermo Haake C25P water bath (Karlsruhe, 
Germany). Thermal unfolding was achieved by heating the protein sample from 25 to 
80°C in a 1 mm path length quartz cell at a rate of 1 degree/minute. Sample was then 
kept at this temperature for 20 minutes and subsequently cooled down to 25°C at a 
rate of 1 degree/minute. Conditions were 29.1 μM M-TTR in phosphate buffer. The 
reversibility of the unfolding transitions was checked by measuring the CD signal at 
room temperature upon cooling down after the end of the transition. Each spectrum 
was recorded as the average of many scans, blank-subtracted and smoothed. 
Dynamic Light Scattering (DLS) measurements 
 
DLS measurements were performed using a Zetasizer Nano S device from Malvern 
Instruments (Malvern, Worcestershire, UK) thermostated with a Peltier system. Low-
volume 12.5×4.5-mm disposable cells were used. Refractive index and viscosity of 
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phosphate buffer was calculated using the software provided with the instrument; a 
refractive index of 1.45 was used for M-TTR. Samples were prepared at a final protein 
concentration of 29.1 μM in phosphate buffer. Before the measurements, the protein 
sample was heated from 25 to 80°C, maintained at this temperature for 20 minutes 
and subsequently cooled to 25°C and filtered with an anotop filter having a cut-off of 
20 nm. Protein concentration was 29.1 μM. The presented size distributions were the 
average of three consecutive measurements. 
In another set of experiment HypF-N oligomers (12 µM monomer concentration) were 
incubated for 1 h at 37 °C under shaking in 20 mM potassium phosphate buffer at pH 
7.0 in the absence or presence of each TTR. Samples containing TTRs were also used as 
controls and filtered using 20 nm anotop filters (Sigma-Aldrich, Milan, Italy). Size 
distributions by intensity and total light-scattering intensity were determined at 
regular time-intervals over a period of 10 minutes. The temperature was maintained at 
37° C and the parameters were set manually on the instrument to allow the same 
settings in the various distributions acquired at different time-values. These included 
ten acquisitions each of ten seconds duration, with cell position 4.2 cm and attenuator 
index 7. The reported data are the average of three consecutive measurements. 
Equilibrium unfolding experiments 
 
Equilibrium denaturation studies were performed exploiting tryptophan fluorescence 
and CD in the near-UV and far-UV as probes. 28 to 34 samples were prepared 
containing M-TTR in phosphate buffer with urea at concentrations ranging from 0 to 
7.6 M. Measurements were carried out at 37 °C. Resulting plots were analysed with 
the method provided by Santoro & Bolen [Santoro MM and Bolen DW 1988] in order 
to obtain quantitative measurements of the free energy change upon denaturation in 
the absence of denaturant the concentration of middle denaturation (Cm) and 
dependence of free energy change upon denaturation on urea concentration (m). In 
the case of fluorescence, spectra from 300 to 450 nm (excitation at 280 nm) were 
acquired for 28 equilibrated samples containing 2.9 μM M-TTR. A 10x2 mm quartz 
cuvette was used. Spectra were acquired using a PerkinElmer LS 55 (Waltham, 
Massachusetts). The ratio between the fluorescence intensity at 365 and 335 was used 
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to analyse the collected data as previously described [Jiang X et al. 2001]. CD spectra 
from 200 to 260 nm were also acquired for 34 equilibrated samples containing 29.1 
μM M-TTR. Spectra were acquired using a Jasco J-810 spectropolarimeter (Tokyo, 
Japan) and a 1 mm path length cuvette. Mean residue ellipticity at 219 nm was 
calculated and plotted Vs urea concentration. CD spectra were also measured from 
275 to 300 nm for 28 equilibrated samples containing 145.5 μM M-TTR. The Jasco J-
810 spectropolarimeter was used with a 0.1 mm path length cuvette. Mean residue 
ellipticity at 290 nm was calculated and plotted versus urea concentration. 
Stopped flow kinetics coupled to intrinsic fluorescence 
 
Unfolding and refolding reactions were followed using a Bio-logic SFM-3 stopped-flow 
device equipped with an FC-15 cuvette and coupled to a fluorescence detection 
system (Claix, France). An excitation wavelength of 280 nm and a band-pass filter to 
monitor emitted fluorescence above 320 nm were used. All the experiments were 
performed in phosphate buffer at 37 °C, at final protein concentrations of 1.5-2.9 μM. 
For the unfolding experiments native M-TTR was diluted into solutions containing urea 
at final concentrations ranging from 3.5 to 6.5 M. Refolding reactions were initiated by 
a 10-fold dilution of the urea denatured protein into solutions containing low 
concentrations of urea. Final [urea] ranged from 0.2 M to 3.5 M. The dead time was 
generally 10.4 ms. In another set of experiments, the equilibrium signal measured at 
the end of unfolding kinetics was plotted Vs urea concentration so as to linearly 
extrapolate the fluorescence of the unfolded protein under native conditions. 
T-jump experiments 
 
Relaxation kinetics was measured as a function of urea concentration by using a Hi-
Tech PTJ-64 capacitor-discharge T-jump apparatus (Hi-Tech). Temperature was rapidly 
changed from 28 °C to 37 °C. 10 to 20 individual traces were averaged at given 
denaturant concentrations. Protein concentration was typically 29.1 μM. The 
excitation wavelength was 280 nm, and the fluorescence emission was measured using 
a 320 nm cut-off glass filter. 
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Kinetic analysis 
 
Unfolding and refolding traces were fitted to multi exponential functions to determine 
the rate constants of unfolding and of folding, together with their relative amplitudes. 
The fitting procedure was made using the general equation  
()=∙++Σ=1	
(−∙)     (3) 
where () is the fluorescence signal recorded as a function of time, t is the time,  
and  are the apparent amplitude and rate constant of the ith phase, respectively,  is 
the fluorescence value at equilibrium, m is the dependence of equilibrium 
fluorescence on time and n is the number of observed phases. 
We then plotted the apparent rate constants of the major refolding phase (λ2) 
observed in stopped-flow kinetics together with the rate constants obtained from T-
jump experiments (λ1). The logarithm of each rate constant was assumed to vary 
linearly with denaturant concentration. The observed chevron plots were fitted 
globally with shared m-values using three-state on-pathway and off-pathway models 
[Gianni S et al. 2007]. Data of λ1 were also analysed with a two state model [Jackson 
SE and Fersht AR 1991]. In the latter case refolding rate constants in the absence of 
denaturant was linearly extrapolated from unfolding kinetics at high urea 
concentration. Free energy change upon denaturation in the absence of denaturant 
( ) was obtained from equilibrium unfolding. The global fit was obtained with 
Prism software (Graphpad). Values obtained from this analysis were then used to run 
numerical simulations of the refolding process with the COPASI software and to 
calculate the equilibrium concentrations of each species. 
Stopped-flow CD 
 
Folding of M-TTR was also monitored by far-UV CD at 219 nm using a Bio-Logic SFM-20 
stopped-flow device coupled to the Jasco J-810 CD detection system described 
previously. Final conditions were 0.585 M urea in the phosphate buffer at 37 °C, at a 
protein concentration of 14.5 μM. The dead time of the experiment was 19 ms. The 
signal of the buffered solution with no protein was subtracted from the averaged 
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trace. In the same experiment, the CD signal of the unfolded protein was measured at 
different urea concentrations in order to extrapolate the signal of the unfolded protein 
under native conditions. 
Stopped-flow ANS 
 
Kinetic measurements were performed in the presence of ANS using the Bio-logic SFM-
3 stopped-flow device. An excitation wavelength of 370 nm and a band-pass filter to 
monitor emitted fluorescence above 475 nm were used. All the experiments were 
performed in phosphate buffer with 100 μM ANS, 0.5 M urea, pH 7.4, 37 °C, at final 
protein concentrations of 2.91 μM. 
Double jump experiments 
 
Two sets of double jump experiments were employed. Interrupted refolding 
experiments were carried out on an Applied Photophysics DX-17MV stopped-flow 
instrument with double jumpfacility (Leatherhead, UK) in order to assess the time 
dependence of accumulation of the native state. Refolding (first jump) and unfolding 
(second jump) were initiated by a symmetric mixing of the denatured and native 
protein with the appropriate buffer. In the first jump 16 μM M-TTR denatured in 3 M 
urea with 2 mM DTT at pH 3.2 was diluted into a phosphate buffer at pH 7.4 to a final 
urea concentration of 5 M. After a given delay time, the solution obtained at the end 
of the first jump was diluted 1:1 into another solution containing 8.5 M urea to achieve 
denaturation. Final conditions were 4 μM M-TTR in phosphate buffer pH 7.4 with 5 M 
urea. Delay time ranged from 12 to 350 ms. Excitation wavelength was 280 nm and the 
fluorescence emission was measured using a 320 nm cut-off glass filter. 
Interrupted unfolding experiments were performed with the Bio-logic SFM-3 stopped-
flow to assess the occurrence of X-Pro peptide bonds isomerism during refolding. In 
the first jump M-TTR in 1 M urea was diluted 1:4 into a buffer containing 6 M urea to a 
final urea concentration of 5 M. After the delay time, the solution was diluted 1:4 into 
phosphate buffer. Final conditions were 2.2 μM M-TTR in phosphate buffer pH 7.4 with 
1 M urea. Delay time ranged from 44 ms to 30 s. 
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Folding in the Presence of CypA 
 
Folding of M-TTR was studied in the presence of human and bovine CypA on the Bio-
Logic SFM-3 stopped-flow apparatus by monitoring intrinsic fluorescence emission 
above 320 nm with excitation wavelength of 280 nm. Folding was initiated at 37 °C by 
mixing 21.8 μM TTR denatured in 5 M urea into a refolding buffer containing 
phosphate buffer and 0.5 M urea, pH 7.4 and CypA concentrations ranging from 0 to 
0.67 μM. Obtained traces were fitted to equation (3). 
Statistical analysis 
 
All data are expressed as mean ± standard deviation (SD). Comparisons between the 
different groups were performed by ANOVA followed by Bonferroni’s t-test. A p value 
less than 0.05 was accepted as statistically significant. 
Chapter 3- Results 
| 61 
 
Chapter 3- Results 
Results I: Extracellular chaperones prevent Aβ42-induced toxicity in rat 
brains 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterised 
by cognitive decline, formation of the extracellular amyloid β (Aβ42) plaques, 
neuronal and synapse loss, and activated microglia and astrocytes. Extracellular 
chaperones, which are known to inhibit amyloid fibril formation and promote 
clearance of misfolded aggregates, have recently been shown to reduce efficiently 
the toxicity of HypF-N misfolded oligomers to immortalized cell lines, by binding and 
clustering them into large species. However, the role of extracellular chaperones on 
Aβ oligomer toxicity remains unclear, with reports often appearing contradictory. In 
this study we microinjected into the hippocampus of rat brains Aβ42 oligomers pre-
incubated for 1 h with two extracellular chaperones, namely clusterin and α2-
macroglobulin. The chaperones were found to prevent Aβ42-induced learning and 
memory impairments, as assessed by the Morris Water Maze test, and reduce Aβ42-
induced glia inflammation and neuronal degeneration in rat brains, as probed by 
fluorescent immunohistochemical analyses. Moreover, the chaperones were able to 
prevent Aβ42 colocalization with PSD-95 at post-synaptic terminals of rat primary 
neurons, suppressing oligomer cytotoxicity. All such effects were not effective by 
adding pre-formed oligomers and chaperones without preincubation. Molecular 
chaperones have therefore the potential to prevent the early symptoms of AD, not 
just by inhibiting Aβ42 aggregation, as previously demonstrated, but also by 
suppressing the toxicity of Aβ42 oligomers after they are formed. These findings elect 
them as novel neuroprotectors against amyloid-induced injury and excellent 
candidates for the design of therapeutic strategies against AD. 
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Chaperones prevented learning and memory impairment in intra-hippocampus Aβ42 
injected rats  
 
Aβ42 oligomers were incubated for 1 h in F-12 medium in the absence or presence of 
two types of extracellular chaperones, namely clusterin (Clu) and α2-macroglobulin 
(α2M). 1.5 µl aliquots (0.7 µg Aβ42 with. 1 µg Clu or α2M) were microinjected into the 
right hippocampus of rat brains. Seven days after unilateral injection into the 
hippocampus, rats were trained for four days in the Morris water maze (MWM) to 
learn where the hidden platform was located. The ability of rats to acquire, process, 
and recall spatial information was assessed by evaluation of the time required to find 
the platform (escape latency), time in quadrant where the platform is located (target 
quadrant), time in the opposite quadrant, time in the small area where the platform is 
located (platform section) and number of crossings over the platform section. The 
animals were naive to the water maze and showed no deficiencies in swimming 
abilities, directional swimming toward the platform, or climbing onto a hidden 
platform during training trials. Rats injected only with F12-medium shortened the 
escape latency during the 4-days training phase (Fig. 6A). They were good swimmers 
and responded to being placed in water with an appropriate swim-search response. 
Conversely, Aβ42 oligomer-injected rats showed only a slow decrease in escape latency 
during the 4 days of training (Fig. 6A). When we pre-incubated Aβ42 oligomers with Clu 
or α2M for 1 h and then injected these solutions intra hippocampus, we obtained a 
significant decrease (p<0.05) in escape latency, compared with the Aβ42 oligomer-
administered group, particularly at day 3 and 4 (Fig. 6A). Five h after the last test on 
day 4 it was found that rats treated with Aβ42 oligomers pre-incubated with Clu or α2M 
for 1 h spent a significantly higher percentage of time in the target quadrant (p<0.05), 
with respect the animals treated with only Aβ42 oligomers (Fig. 6B, top left). We also 
observed a marked reduction of the percentage of time spent in the opposite quadrant 
(P<0.05) in rats treated with Aβ42 oligomers plus Clu or α2M, compared to Aβ42 
oligomer-injected rats (Fig. 6B top right). The percentage of time spent in the adjacent 
quadrants and the swim speed in target quadrant during this session was comparable 
among the groups (data not shown), indicating that the motility of rats injected with 
the different samples was not impaired. The analysis of the percentage of time in the  
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Fig. 6 Effect of hippocampal injection of Aβ42 oligomers pre-incubated with two extracellular chaperones 
(Clu and α2M) on MWM performance of rats. Rats were injected with 1.5 μl of 0.45 mg/ml Aβ42 
oligomers in the absence or presence of 0.7 mg/ml chaperones (protein:Clu molar ratio was 10:1; 
protein:α2M molar ratio was 100:1). Control rats were injected with 1.5 μl of medium. (A) Time lengths 
employed to find the platform during the training session (escape latencies) are reported as mean ± 
SEM. Each point represents the mean daily value of four trials of each experimental group (n=6 per 
group). (B) Percentage of time in the target and opposite quadrants (top panels), percentage of time in 
the platform section and number of crossings over the platform position (bottom panels) measured for 
30 s on day 4. Data are expressed as mean ± SEM. (n=6 per group). The asterisks and the double 
asterisks indicate significant differences (p≤0.05 and p≤0.01, respectively) versus Aβ42-injected rats. 
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platform section showed a significant increase in rats treated with Aβ42 oligomers plus 
chaperones, with respect to the Aβ42 oligomer-treated group (Fig. 6B, bottom left). 
Finally, the number of crossings over the platform position revealed a significant 
increase in rats injected with Aβ42 oligomers plus chaperones, compared to the Aβ42 
oligomer-administered group (Fig 6B, bottom right). Taken together, these data 
demonstrated that both types of extracellular chaperones have the ability to prevent 
the learning and memory impairment mediated by the intra hippocampus injection of 
Aβ42 oligomers. 
Chaperones reduced glial reaction in Aβ42 exposed rat hippocampus 
 
We then investigated whether chaperones could neutralise Aβ42-mediated glial 
inflammation, by evaluating glial fibrillary acidic protein (GFAP)-immunoreactive 
astrocytes and Iba 1-labelled microglial cells. Immunofluorescence analyses revealed 
diminished glial reaction in rats treated with Aβ42 oligomers and chaperones compared 
to rats treated with Aβ42 oligomers only (Fig. 7). Such a decrease was evident by 
monitoring both GFAP-immunoreactive astrocytes (Fig. 7A) and Iba 1-labelled 
microglial cells (Fig. 7B). Hypertrophic astrocytes with long, thick branches were 
detected by GFAP immunostaining in Aβ42-injected rats (Fig. 7A). In contrast, in rats 
treated with Aβ42 and chaperones, astrocyte activation occurred to a much lesser 
extent (Fig. 7A). Labeling with anti-Iba-1 antibodies revealed microglia with small cell 
bodies and thin, elongated processes in rats treated with Aβ42 plus Clu or α2M, 
compared to Aβ42-injected rats, where microglia with enlarged cell bodies and short, 
thickened processes were found (Fig. 7B). This data therefore suggests that these two 
extracellular chaperones can protect against the Aβ42 oligomer-mediated glial 
inflammation. 
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Fig. 7 Analyses of glial activation in the hippocampus of 3-month-old male Wistar rats treated with Aβ42 
oligomers pre-incubated with extracellular chaperones. Representative photomicrographs (10 x and 40 x 
magnifications) of fluorescence immunohistochemical analyses of GFAP immunoreactivity (A) and Iba-1-
labeled microglial cells (B) obtained 14 d after injection of 1.5 µl medium, or 1.5 μl of 0.45 mg/ml Aβ42 
oligomers in the absence or presence of 0.7 mg/ml chaperones (protein:chaperone molar ratios as 
described in the Materials and Methods section). GFAP immunoreactivity and Iba-1-labeling are 
indicated by red and green colours, respectively. 
 
 
Chaperones prevented neuronal degeneration in Aβ42 exposed rat hippocampus 
 
In AD, the aggregated species of Aβ peptides interact with the plasma membrane of 
the affected cells, triggering a free radical-mediated injury that ultimately results in cell 
degeneration [Varadarajan S et al. 2000]. The survival of neurons after treatment with 
Aβ42 oligomers plus Clu or α2M was examined by using the Neu-N marker. The group 
injected with Aβ42 oligomers showed a decreased number of mature neurons 
compared to the medium-administered group (Fig. 8A). Conversely, rats treated with 
Aβ42 oligomers preincubated for 1h with Clu or α2M showed a high improvement in 
neuron survival, suggesting that chaperones can prevent Aβ42-mediated 
neurodegeneration. 
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We next evaluated the protective role of the two extracellular chaperones against 
Aβ42-induced lipid peroxidation, determined by measuring 8-OH isoprostane levels. 
The results showed that 8-OH isoprostane levels were significantly higher in the  
 
Fig. 8 Analyses of neuronal degeneration, lipid peroxidation and apoptosis in the hippocampus of 3-
month-old male Wistar rats treated with Aβ42 oligomers pre-incubated with extracellular chaperones. 
(A) Representative photomicrographs (40 x magnifications) of fluorescence immunohistochemical 
analysis of Neu-N obtained 14 d after injection of 1.5 µl medium, or 1.5 μl of 0.45 mg/ml Aβ42 oligomers 
in the absence or presence of 0.7 mg/ml chaperones (protein:chaperone molar ratio as described in the 
Materials and Methods section). The quantification of Neu-N immunoreactivity in the hippocampus 
after the injections are shown below the images. (B) 8-OH isoprostane levels, a correlate of lipid 
peroxidation, in rat hippocampal homogenates (5 µg of proteins per well) at the indicated time lengths 
of pre-incubation between Aβ42 oligomers and chaperones. (C) Caspase-3 levels assessed by a 
fluorimetric assay using the Ac-DEVD-AFC probe, at the indicated time lengths of pre-incubation 
between Aβ42 oligomers and chaperones. The reported values (means ± SD) are representative of three 
independent experiments carried out in triplicate for each experimental group (n=6 per group). The 
double and the triple asterisks indicate significant differences (p≤0.01 and p≤0.001, respectively) versus 
Aβ42-injected rats. 
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hippocampal homogenates of rats treated with Aβ42 oligomers, compared to the 
medium-injected groups (Fig. 8B), suggesting an oxidative-stressed condition 
associated with Aβ42 oligomer exposure. 8-OH isoprostane levels were also high after 
injection of Aβ42 oligomers with Clu or α2M in the absence of pre-incubation (Fig. 8B). 
In contrast, the hippocampi of rats treated with Aβ42 oligomers and either chaperone 
in the presence of preincubation for 1 h before injection showed no difference in the 
lipid peroxidation levels with respect to medium-injected rats (Fig. 8B). 
We then analyzed whether the two chaperones can prevent the Aβ42-induced cell 
death, by measuring the activity of caspase-3, a well-recognised apoptotic marker, in 
rat hippocampal homogenates [Donati C et al. 2007]. Caspase-3 activation was 
significantly increased in the hippocampal homogenates of rats injected with Aβ42 
oligomers, with respect to the rats injected only with F12-medium (Fig. 8C), indicating 
apoptotic cell death associated with Aβ42 oligomer treatment. Caspase-3 activation 
was also increased in the hippocampal homogenates of rats injected with Aβ42 
oligomers plus Clu or α2M in the absence of pre-incubation (Fig. 8C). On the other 
hand, the level of caspase-3 activation in hippocampi of rats treated with Aβ42 
oligomers pre-incubated with chaperones for 1 h was not significantly different to that 
of rats injected only with F12-medium (Fig. 8C).  
These results suggest that the pre-incubation of Aβ42 oligomers with chaperones 
prevents the oxidative-stress conditions associated with Aβ42 oligomer exposure, 
avoiding the induction of apoptosis by the oligomers. 
Chaperones suppress Aβ42 oligomer-induced cytotoxicity in rat hippocampal and 
cortical neurons 
 
To assess the protective role of the two extracellular chaperones against Aβ42 
oligomers, we also used cultures of hippocampal and cortical neurons extracted from 
embryonic day (ED)-17 rats and analyzed in their mature form at day 21. In a first set 
of experiments we incubated preformed oligomers of Aβ42 in the cell culture medium 
in the absence or presence of Clu or α2M for different time lengths, and then added 
the resulting mixture to the extracellular medium of cultured primary hippocampal 
neurons. Aβ42 oligomers showed their toxic action (Fig. 9A), whereas the neurons 
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treated with oligomers pre-incubated with Clu or α2M were found to reduce MTT to 
levels similar to medium-administered cells (Fig. 9A) and to cells treated with native  
 
Fig. 9 Suppression of Aβ42 oligomer toxicity by chaperones in rat primary neurons. Preformed Aβ42 
oligomers were incubated in the absence or presence of the indicated chaperones (Aβ42:chaperone 
molar ratios as described in the Materials and Methods section) for the indicated time lengths (A) and 
for 1 h (B) and then added to the extracellular medium of hippocampal (A) or cortical (B) neurons for 24 
h. (C,D) Representative confocal scanning microscope images showing intracellular ROS levels in primary 
hippocampal (C) and cortical (D) neurons from rat brains. Preformed Aβ42 oligomers were incubated in 
the absence or presence of the indicated chaperones (protein:chaperone molar ratio as described in the 
Materials and Methods section) for the indicated time lengths and then added to the extracellular 
medium of hippocampal (C) or cortical (D) neurons for 1 h. The green fluorescence arises from the CM-
H2DCFDA probe that has reacted with ROS. The corresponding semi-quantitative values of the green 
fluorescence signal are shown below the confocal images. In all histograms, the values reported are 
means ± SD of three independent experiments carried out in triplicate. The single, double and triple 
asterisks indicate significant differences (p≤0.05, p≤0.01 and p≤0.001, respectively) versus neurons 
treated with Aβ42 oligomers. 
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Aβ42 (data not shown), with an effect dependent on the time of preincubation of the 
oligomers with the chaperones. Similar data was obtained by pre-incubating Aβ42 
oligomers plus chaperones for 1 h in cultured primary cortical neurons (Fig. 9B). 
Comparable results were achieved with preformed oligomers of the N-terminal 
domain of the HypF protein from Escherichia coli (HypF-N) (Fig. 10A and B). HypF-N is 
a valuable model system for investigating the structural basis of the cellular 
dysfunction caused by misfolded protein oligomers, because this protein have the 
same morphological and tinctorial features as those formed by disease-related 
peptides and proteins [Campioni S et al. 2010].  
Then we compared the ability of the two extracellular chaperones to suppress the 
intracellular ROS production and Ca2+ dyshomeostasis induced by Aβ42 oligomers. Aβ42 
oligomers induced a sharp increase in ROS (Fig. 9C,D) and cytosolic free Ca2+ (Fig. 11) in 
rat neurons, which was inhibited by Clu and α2M (Fig. 9C and D and Fig. 11). Such 
inhibitory effects were not found when the oligomers and the chaperones were added 
to the rat neurons in the absence of pre-incubation (Fig. 9C and Fig. 11A), suggesting 
the importance of the pre-incubation time. Comparable results were obtained with 
HypF-N oligomers (Fig. 10C and D and Suppl. Fig. 8).  
These results therefore indicate that pre-incubation of Aβ42 oligomers with the two 
chaperones can suppress or decrease markedly the oxidative stress, calcium 
dishomeostasis and toxicity caused by Aβ42. 
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Figure. 10. Suppression of HypF-N oligomer toxicity by chaperones in rat primary neurons. Preformed 
HypF-N oligomers were incubated for 1 h in the absence or presence of the indicated chaperones 
(protein:chaperone molar ratio as described above) and then added to the extracellular medium of 
hippocampal (A) or cortical (B) neurons for 24 h. Cell viability was expressed as percent of MTT 
reduction in treated cells with respect to medium-administered cells (taken as 100%). (C,D) 
Representative confocal scanning microscope images showing intracellular ROS levels in primary 
hippocampal (C) and cortical (D) neurons from rat brains. Preformed HypF-N oligomers were incubated 
in the absence or presence of the indicated chaperones (protein:chaperone molar ratio as described 
above) and then added to the extracellular medium of the neurons for 1 h. The green fluorescence 
arises from the CM-H2DCFDA probe that has reacted with ROS. The corresponding semi-quantitative 
values of the green fluorescence signal are shown below the confocal images. The values reported are 
means ± SD of three independent experiments carried out in triplicate. The asterisk and the triple 
asterisks indicate significant differences (p≤0.05 and p≤0.001, respectively) vs neurons treated with 
HypF-N oligomers. 
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Figure. 11. Representative confocal scanning microscope images showing intracellular Ca2+ levels in 
primary hippocampal (A) and cortical (B) neurons from rat brains. (A) Preformed Aβ42 oligomers were 
incubated in the absence or presence of the indicated chaperones (protein:chaperone molar ratio as 
described in the Materials and Methods section) for the indicated time lenghts and then added to the 
extracellular medium of the hippocampal neurons for 1 h. (B) Preformed Aβ42 oligomers were incubated 
in the absence or presence of the indicated chaperones (protein:chaperone molar ratio as described in 
the Materials and Methods section) for 1 h and then added to the extracellular medium of cortical 
neurons for 1 h. In all images the green fluorescence arises from the intracellular Fluo3 probe bound to 
Ca2+. The corresponding semi-quantitative values of the green fluorescence signal are shown below the 
confocal images. The values reported are means ± SD of three independent experiments. The triple 
asterisks indicate significant differences (p≤0.001) vs neurons treated with Aβ42 oligomers. 
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Figure. 12. Representative confocal scanning microscope images showing intracellular Ca2+ levels in 
primary hippocampal (A) and cortical (B) neurons from rat brains. Preformed HypF-N oligomers were 
incubated in the absence or presence of the indicated chaperones (protein:chaperone molar ratio as 
described above) and then added to the extracellular medium of the neurons for 1 h. In all images the 
green fluorescence arises from the intracellular Fluo3 probe bound to Ca2+. The corresponding semi-
quantitative values of the green fluorescence signal are shown below the confocal images. The values 
reported are means ± SD of three independent experiments. The triple asterisk indicates significant 
differences (p≤0.001) vs neurons treated with HypF-N oligomers. 
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Chaperones inhibit colocalization of Aβ42 aggregates with PSD-95 preventing synaptic 
dysfunction 
We next investigated by confocal microscopy whether chaperones prevent the 
colocalization of Aβ42 aggregates with PSD-95. The scatter plots of fluorescence signals 
over the highlighted areas are shown in Fig. 13. A notable degree of colocalization 
between Aβ42 oligomers and PSD-95 was observed in neurons treated for 1 h with Aβ42 
oligomers, with respect to medium-administered neurons (Fig. 13).  
 
Fig. 13 Representative confocal scanning microscope images showing Aβ42 oligomers colocalizing with 
post synaptic densities in rat primary hippocampal neurons. Preformed Aβ42 oligomers were incubated 
in the absence or presence of the indicated chaperones (protein:chaperone molar ratios as described in 
the Materials and Methods section) for 1 h and then added to the extracellular medium of rat neurons 
for 1 h or 24 h, as indicated. Aβ42 aggregates and PSD-95 were monitored using mouse monoclonal 6E10 
antibody and rabbit polyclonal anti-PSD-95 antibody, respectively, and then with Alexa Fluor 488- and 
Alexa Fluor 594-conjugated antibody (red and green fluorescence, respectively). The first line showed 
medium-administered neurons; the second line shows neurons treated for 1 h (left) or 24 h (right) with 
Aβ42 oligomers (12 µM monomer concentration); the third and fourth lines shows neurons treated for 1 
h (left) or 24 h (right) with Aβ42 oligomers plus Clu (third line) or α2M (fourth line). The cytofluorograms 
of dendrite sections show the red fluorescence intensity (as pixel intensity, y axis) versus green 
fluorescence intensity (x axis). For each sample, 18 cytofluorograms were analyzed, each considering 
one dendrite section. The histograms show the percentage of colocalization on regions of interest (12–
13 cells) using the ImageJ (NIH, Bethesda, MD, USA) and JACOP plugin (rsb.info.nih.gov) softwares. Data 
are expressed as mean ± S.D. (n=18 per group). The asterisks indicate significant differences (p≤0.05) 
with respect to neurons treated for 1 h with Aβ42 oligomers.  
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Conversely, when we treated the neurons for 1 h with Aβ42 oligomers pre-incubated 
with either Clu or α2M, the chaperones were found to inhibit oligomer binding to the 
cell membrane thus preventing the colocalization with PSD-95 (Fig. 13, 18 dendrite 
sections were analyzed for each samples).  
 
 
 
Figure. 14. Representative confocal scanning microscope images showing HypF-N oligomers colocalising 
with post synaptic densities in rat primary hippocampal neurons. Preformed HypF-N oligomers were 
incubated in the absence or presence of the indicated chaperones (protein:chaperone molar ratio as 
described above) for 1 h and then added to the extracellular medium of rat neurons for 1 h or 24 h, as 
indicated. HypF-N aggregates and PSD-95 was monitored using 1:200 diluted rabbit polyclonal anti-
HypF-N antibody and 1:500 mouse monoclonal anti-psd-95 antibody, respectively, and then with Alexa 
Fluor 488- and Alexa Fluor 594-conjugated antibody (green and red fluorescence, respectively). The first 
line showed medium-administered neurons, the second line shows neurons treated for 1 h (left) or 24 h 
(right) with HypF-N oligomers (12 µM monomer concentration) the third and fourth lines shows neurons 
treated for 1 h (left) or 24 h (right) with HypF-N oligomers plus Clu (third line) or α2M (fourth line). The 
cytofluorograms of dendrite sections show the green fluorescence intensity (as pixel intensity, y axis) vs 
red fluorescence intensity (x axis). For each samples, 18 cytofluorograms were analysed, each 
considering one dendrite section. The histograms show the percentage of colocalisation. Data are 
expressed as mean ± S.D. (n=18 per group). The asterisk indicates significant differences (p≤0.05) with 
respect to neurons treated for 1 h with HypF-N oligomers. 
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The fraction of Aβ42 puncta colocalizing with PSD-95 puncta was 1.2 ± 0.5% for 
medium-administered neurons, 59.9 ± 2.0% for neurons treated for 1 h with Aβ42 
oligomers, 26.3 ± 1.8% for neurons treated for 1 h with Aβ42 oligomers plus Clu, 26.9 ± 
1.9% for neurons treated for 1 h with Aβ42 oligomers plus α2M. Similar data was 
achieved analyzing the colocalization between HypF-N oligomers and PSD-95 (Fig. 14). 
The concentration of PSD-95 has been found to be significantly lower in the brain of 
AD patients with respect to normal brains [Lovell MA et al. 2006]. Thus, we evaluated 
whether the prolonged treatment of rat hippocampal neurons with Aβ42 oligomers 
decrease PSD-95 levels. When we treated the neurons with Aβ42 oligomers for 24 h, we 
observed a lower degree of colocalization with PSD-95 caused by a decreased 
expression of PSD-95 (Fig. 13). In particular, in neurons treated for 24 h with Aβ42 
oligomers the fraction of Aβ42 puncta colocalizing with PSD-95 puncta (29.3 ± 2.8%) 
was comparable to that observed in neurons treated for 24 h with Aβ42 oligomers plus 
Clu or α2M (24.6 ± 1.9% or 24.5 ± 1.7%, respectively). Similar data was achieved 
analyzing the colocalization between HypF-N oligomers and PSD-95 (Fig.14).  
These results show that Aβ42 oligomers induce a decrease in PSD-95 levels in a time-
dependent manner, as previously reported with Aβ40 [Roselli F et al. 2005], supporting 
a model of AD pathogenesis in which soluble Aβ may be responsible for the cognitive 
impairment through synaptic dysfunction [Walsh DM et al. 2004]. In addition, the two 
extracellular chaperones studied here are able to recover PSD-95 expression, avoiding 
oligomer binding to the synapses, suggesting an important protective effect of 
chaperones against oligomer-induced synaptic dysfunction. 
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Results II: Transthyretin suppress the toxicity of oligomers formed by 
misfolded proteins in vitro 
 
Although human transthyretin (TTR) is associated with systemic amyloidoses, an 
anti-amyloidogenic effect that prevents Aβ fibril formation in vitro and in animal 
models has been observed. Here we studied the ability of three different types of 
TTR, namely human tetramers (hTTR), mouse tetramers (muTTR) and an engineered 
monomer of the human protein (M-TTR), to suppress the toxicity of oligomers 
formed by two different amyloidogenic peptides/proteins (HypF-N and Aβ42). muTTR 
is the most stable homotetramer, hTTR can dissociate into partially unfolded 
monomers, whereas M-TTR maintains a monomeric state. Preformed toxic HypF-N 
and Aβ42 oligomers were incubated in the presence of each TTR then added to cell 
culture media. hTTR, and to a greater extent M-TTR, were found to protect human 
neuroblastoma cells and rat primary neurons against oligomer-induced toxicity, 
whereas muTTR had no protective effect. The thioflavin T assay and site-directed 
labeling experiments using pyrene ruled out disaggregation and structural 
reorganization within the discrete oligomers following incubation with TTRs, while 
confocal microscopy, SDS-PAGE, and intrinsic fluorescence measurements indicated 
tight binding between oligomers and hTTR, particularly M-TTR. Moreover, AFM, light 
scattering and turbidimetry analyses indicated that larger assemblies of oligomers 
are formed in the presence of M-TTR and, to a lesser extent, with hTTR. Overall, the 
data suggest a generic capacity of TTR to efficiently neutralize the toxicity of 
oligomers formed by misfolded proteins and reveal that such neutralization occurs 
through a mechanism of TTR-mediated assembly of protein oligomers into larger 
species, with an efficiency that correlates inversely with TTR tetramer stability. 
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TTRs prevent oligomer-induced cytotoxicity in SH-SY5Y cells 
 
We incubated oligomers formed from HypF-N and Aβ42 in cell culture medium in the 
absence or presence of hTTR, muTTR or M-TTR for 1 h, then added the resulting 
mixtures to SH-SY5Y cells and measured the resulting cell viability using the MTT 
reduction assay. The two types of oligomers were toxic (Fig. 15A,B), as previously 
demonstrated [Mannini B et al 2012]. The cells treated with oligomers preincubated 
with hTTR and M-TTR displayed no toxic effect showing MTT reduction similar to that 
of untreated cells, to cells treated with the native proteins or to cells treated with 
oligomers preincubated with haptoglobin or α2-macroglobulin, two well known 
extracellular chaperones used here as positive controls for inhibition of oligomer 
toxicity (Fig. 15A,B). Conversely, muTTR shows a small insignificant protective effect 
(Fig. 15A,B). In addition, when the two oligomer types were incubated in the cell 
culture medium for 1 h with proteins that are not expected to possess chaperone 
properties, such as hen egg white lysozyme (HEWL) or bovine serum albumin (BSA), 
the oligomers maintained their toxicity (Fig. 15A,B). In these studies we did not 
examine the effect of the various TTRs on Aβ42 and HypF-N oligomer formation. 
We repeated the experiments described above for HypF-N and Aβ42 oligomers by 
varying the concentration of each TTR in the 1 h preincubation solution, while 
maintaining a constant concentration of HypF-N and Aβ42. M-TTR was found to 
suppress the toxicity of HypF-N and Aβ42 oligomers even at low concentration with an 
efficacy similar to haptoglobin and α2-macroglobulin, (Fig. 15C,D). M-TTR remained 
effective even at an HypF-N:TTR and Aβ42:TTR molar ratio of 400:1, becoming 
ineffective at a molar ratio of 1000:1 both for HypF-N and Aβ42 (Fig. 15C,D). hTTR is 
also effective, but at higher concentrations; indeed, hTTR inhibited toxicity until a 
HypF-N:TTR and Aβ42:TTR molar ratio of 40:1 and 100:1, respectively, only becoming 
ineffective at molar ratios of 100:1 for HypF-N and 200:1 for Aβ42. muTTR did not show 
any protective effect, even at low molar ratios (Fig. 15C,D). 
 
 
 
Chapter 3- Results 
| 78 
 
 
 
Fig. 15 Suppression of protein oligomer toxicity by TTRs. Preformed oligomers of HypF-N (A) and Aβ42 (B) 
were resuspended in the cell culture medium, incubated for 1 h at a corresponding monomer 
concentration of 12 µM in the absence or presence of the indicated TTRs (protein:TTR molar ratio was 
10:1), human haptoglobin (protein:haptoglobin molar ratio was 15:1), human α2-macroglobulin 
(protein:α2-macroglobulin molar ratio was 100:1), HEWL (protein:HEWL molar ratio was 5:1), or BSA 
(protein:BSA molar ratio was 5:1) and then added to SH-SY5Y cells. (C-D) Dose-dependent suppression 
of HypF-N (C) and Aβ42 (D) oligomer toxicity by TTRs. Preformed oligomers of HypF-N and Aβ42 were 
resuspended in the cell culture medium, incubated for 1 h in the absence (●) or presence of the 
indicated HypF-N:TTR/chaperone (C) and Aβ42:TTR/chaperone (D) molar ratios and then added to SH-
SY5Y cells. TTRs were always considered as tetramers in all HypF-N/Aβ42:TTR molar ratio values. The 
scale on the x axis is logarithmic. Cell viability was expressed as percent of MTT reduction in treated cells 
with respect to untreated cells (taken as 100%). The values shown are means ± SD of three independent 
experiments carried out in quadruplicate. The single, double and triple asterisks indicate a significant 
difference (p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, respectevily) relative to the experiment with oligomers only. 
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We also evaluated the intrinsic cytotoxic effect of each TTR variant in the absence of 
the oligomers. Our results showed that under our experimental condition 
(preincubation for 1 h at 37 °C) M-TTR significantly decreased the MTT reduction of the 
SH-SY5Y cells by ca. 20% (Fig. 16A); conversely, hTTR and muTTR did not show 
significant toxic effects (Fig. 16A), whereas it has been demonstrated that hTTR is 
cytotoxic if produced or exposed to cold temperature [Sörgjerd K et al.2008, Choi S et 
al. 2010]. These results indicate that M-TTR alone is toxic to cells, as previously 
demonstrated [Reixach N et al.2004], whereas preincubation of M-TTR with toxic 
HypF-N and Aβ42 oligomers suppresses both toxic effects, suggesting an interaction 
between oligomers and monomeric TTR with mutual suppression of toxicity. 
 
 
 
 
Figure. 16. (A) Intrinsic cytotoxic effect of TTRs. Each TTR was dissolved in the cell culture medium, 
incubated for 1 h at a corresponding tetramer concentration of 1.2 µM (M-TTR concentration was 4.8 
µM) and then added to SH-SY5Y cells. (B) Effect of TTRs on staurosporine toxicity. 1 µM staurosporine 
was incubated for 1 h in the cell culture medium in the absence or presence of the indicated TTRs 
(staurosporine:TTR molar ratio was 10:1) and then added to SH-SY5Y cells. In both panels cell viability 
was expressed as percent of MTT reduction in treated cells with respect to untreated cells (taken as 
100%). The values shown are means ± SD of three independent experiments carried out in triplicate. 
The asterisk indicates a significant difference (p ≤ 0.05) relative to the untreated cells. 
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To assess whether the three types of TTR can protect the cells from other forms of 
stress, or if they are specific for protein oligomers, we incubated the cells with 
staurosporine, a well-known apoptosis inducer. We found that a concentration of 1 
µM of staurosporine decreased the MTT reduction of the cells to a level similar to that 
of preformed protein oligomers under our conditions. The staurosporine toxicity was 
not reduced by any of the three TTRs (Fig. 16B). 
These results indicate that hTTR and M-TTR can suppress or markedly decrease the 
toxicity of oligomers formed by two different peptides and proteins. The suppression is 
specific for TTRs or chaperones (relative to other proteins) with respect to toxicity 
induced by preformed protein oligomers (not other forms of stress).  
TTRs inhibit oligomer-mediated intracellular Ca
2+
 influx, ROS production and 
membrane permeabilization 
 
The influx of Ca2+ ions from the extracellular space into the cytosol across the cell 
membrane has been recognised to be an early biochemical change undergone by cells 
exposed to deleterious protein oligomers including HypF-N and Aβ42 oligomers 
[Zampagni M et al. 2011, Orrenius S et al.2003, Demuro A et al. 2005, Canale C et al. 
2006, Bojarski L et al. 2008, Evangelisti E et al.2012]. Here we compared the ability of 
the different types of TTR to inhibit the influx of Ca2+ caused by soluble oligomers of 
HypF-N and Aβ42 after their preincubation for 1 h in the cell culture medium before 
addition to the SH-SY5Y cells. Both HypF-N and Aβ42 oligomers induced a sharp 
increase in cytosolic free Ca2+ levels (Fig. 17). Preincubation with hTTR and M-TTR was 
found to inhibit the increase of intracellular Ca2+ levels caused by the oligomers, 
whereas muTTR showed a lower protective effect (Fig. 17). In addition, the degree of 
Ca2+-derived fluorescence was found to decrease exponentially with the time of 
preincubation with M-TTR and hTTR (Fig. 18); in particular, M-TTR prevented the Ca2+ 
spike after only 15 min of preincubation (Fig. 18). 
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Fig. 17 Representative confocal scanning microscope images showing intracellular Ca2+ levels in SH-SY5Y 
cells. Preformed oligomers of HypF-N (A) and Aβ42 (B) were resuspended in the cell culture medium, 
incubated for 1 h at a corresponding monomer concentration of 12 µM with or without the indicated 
TTRs (protein:TTR molar ratio was 10:1) and then added to SH-SY5Y cells for 1 h. The figure also shows 
untreated cells, cells exposed for 1 h to the native protein, to toxic oligomers (12 µM monomer) and to 
the indicated TTRs alone (1.2 µM tetramer or 4.8 µM monomer). The green fluorescence arises from the 
intracellular Fluo3 probe bound to Ca2+. The corresponding semi-quantitative values of the green 
fluorescence signals are shown below each set of images. Statistics as in Fig. 15. 
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Figure. 18. Representative confocal scanning microscope images showing intracellular Ca2+ levels in SH-
SY5Y cells. Preformed oligomers of HypF-N were resuspended in the cell culture medium, incubated at a 
corresponding monomer concentration of 12 µM in the absence or presence of the indicated TTRs 
(protein:TTR molar ratio was 10:1) for the indicated time lengths and then added to SH-SY5Y cells for 1 
h. The green fluorescence arises from the intracellular Fluo3 probe bound to Ca2+. The kinetic plots show 
the fluorescence associated with intracellular Ca2+ versus time elapsed after preincubation of oligomers 
with TTRs. 
 
 
Similar results were obtained analysing intracellular ROS production and membrane 
permeability. HypF-N oligomers induced a sharp increase in ROS levels in our cell 
model (Fig. 19A). hTTR and M-TTR inhibited the increase of intracellular ROS levels 
caused by the oligomers, with the degree of ROS-derived fluorescence decreasing 
exponentially with the time of preincubation (Fig. 19A); M-TTR prevented the ROS 
production after only 15 min of preincubation (Fig. 19A). In contrast, mTTR did not 
show any protective effect (Fig. 19A).  
Confocal microscopy analysis of SH-SY5Y cells pre-loaded with calcein-AM showed that 
cell exposure to HypF-N toxic oligomers resulted in a significant decrease of 
fluorescence intensity in our cells, indicating increased membrane permeabilization 
(Fig. 19B). In contrast, the reduction in calcein fluorescence was prevented when  
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Figure. 19. Representative confocal scanning microscope images of SH-SY5Y cells showing intracellular 
ROS levels (A) and the release of intracellular calcein (B). Preformed oligomers of HypF-N were 
resuspended in the cell culture medium, incubated at a corresponding monomer concentration of 12 
µM in the absence or presence of the indicated TTRs (protein:TTR molar ratio was 10:1) for the indicated 
time lengths and then added to SH-SY5Y cells for 1 h. The kinetic plots show the fluorescence associated 
with intracellular ROS or calcein versus time elapsed after pre-incubation of oligomers with TTRs. Top 
panel images show untreated cells, cells exposed for 1 h to the native protein, to toxic oligomers (12 µM 
monomer concentration) and to the indicated TTRs without oligomers (1.2 µM tetramer or 4.8 
monomer concentration). The green fluorescence arises from the CM-H2DCFDA probe that has reacted 
with ROS (A) and calcein (B) entrapped inside cells, respectively. 
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the cells were treated with oligomers preincubated with hTTR and M-TTR, with the 
degree of calcein-derived fluorescence increasing exponentially with the time of 
preincubation (Fig. 19B). In particular, the reduction of permeabilization occurred even 
more quickly in the presence of M-TTR. mTTR did not show any protective effect (Fig. 
19B). 
TTRs prevent oligomer-induced apoptosis 
 
We then evaluated whether the different capacities of TTRs to protect cytosolic Ca2+ 
influx, ROS production and membrane permeabilization induced by HypF-N and Aβ42 
oligomers also resulted in different abilities to prevent cell death. We measured 
caspase-3 activity, a well recognised apoptotic marker, using confocal microscopy (Fig. 
20) [Thornberry N.A. et al.1997]. Fluorescence microscopy images and the 
corresponding semi-quantitative values of the green fluorescence signal show that 
hTTR and M-TTR significantly prevented the apoptotic response induced by HypF-N 
and Aβ42 oligomers (Fig. 20A,B; p<0.01). muTTR also showed a significant protection 
but it was less marked than that of the other TTRs (Fig. 20A,B; p<0.05). A similar trend 
was observed analyzing chromatin condensation by using the Hoechst 33342 dye, a 
fluorescent marker that binds to the highly condensed chromatin present in the nuclei 
of apoptotic cells [Yerbury JJ et al.2007] (Fig. 21). 
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Fig. 20 Representative confocal microscope images showing caspase-3 activation in SH-SY5Y cells. 
Preformed oligomers of HypF-N (A) and Aβ42 (B) were resuspended in the cell culture medium, 
incubated at a corresponding monomer concentration of 12 µM with or without the indicated TTRs 
(protein:TTR molar ratio was 10:1) for 1 h and then added to SH-SY5Y cells for 24 h. The figure also 
shows untreated cells, cells exposed for 1 h to the native protein, to toxic oligomers (12 µM monomer) 
and to the indicated TTRs alone (1.2 µM tetramer or 4.8 µM monomer). Caspase-3 activity, assessed 
using the fluorescent probe FAM-FLICA™ Caspase 3&7, is indicated by green fluorescence. The 
corresponding semi-quantitative values of the green fluorescence signals are shown below each set of 
images. Statistics as in Fig. 15. 
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Figure. 21 Representative microscope images showing chromatin condensation using the Hoechst 
staining test in SH-SY5Y cells. Preformed oligomers of HypF-N were resuspended in the cell culture 
medium, incubated at a corresponding monomer concentration of 12 µM in the absence or presence of 
the indicated TTRs (protein:TTR molar ratio was 10:1) for 1h and then added to SH-SY5Y cells for 24 h. 
The figure also shows untreated cells, cells exposed for 1 h to the native protein, to toxic oligomers (12 
µM monomer concentration) and to the indicated TTRs alone (1.2 µM tetramer or 4.8 monomer 
concentration). Small and bright nuclei indicate apoptosis. The corresponding semi-quantitative values 
of the blue and green fluorescence signals are shown below each set of images, respectively. The values 
reported are means ± S.D. of three independent experiments. In both panels the asterisk and the double 
asterisk indicate significant differences (p≤0.05 and p≤0.01, respectively). 
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TTRs prevent oligomer-induced toxicity and inhibit colocalization of HypF-N 
aggregates with PSD-95 in rat primary neurons 
 
We assessed the relative protective capacity of the three different TTRs for rat 
hippocampal and cortical neurons using the MTT reduction assay. The HypF-N 
oligomers were toxic to rat hippocampal and cortical neurons (Fig. 22A,B). The neurons 
treated with HypF-N oligomers pre-incubated with hTTR and M-TTR were found to 
reduce MTT to levels similar to untreated cells and to cells treated with the native 
protein (Fig. 22A,B); conversely, muTTR showed a small and non-significant protective 
effect (Fig. 22A,B). We also evaluated the intrinsic cytotoxic effect of each TTR variant 
in the absence of the oligomers. M-TTR significantly decreased the MTT reduction of 
neurons by 25% (Fig. 22A,B); conversely hTTR and muTTR did not show any significant 
toxic effect (Fig. 22A,B). These results indicate that as previously shown for Aβ induced 
cytotoxity, hTTR and M-TTR are able to suppress HypF-N oligomer-induced toxic 
effects in both immortalized cell cultures and primary neurons. 
To investigate the mechanism of action by which TTRs protect cultured primary 
neurons from toxic HypF-N oligomers, we examined the colocalization between 
oligomers and PSD-95 in cultured primary hippocampal neurons. It has previously been 
shown that binding sites of Aβ42 and HypF-N oligomers on neurons overlap with PSD-
95 [Cascella R et al. 2013, Lacor PNet al.2004, Tatini F et al. 2013]. A remarkable 
degree of colocalization was observed between HypF-N oligomers and PSD-95, 
whereas no colocalization was observed in untreated cells or in cells treated with 
native HypF-N (Fig. 22C). Preincubation of HypF-N oligomers with hTTR or M-TTR for 1 
h was found to inhibit oligomer binding to the cell membrane, thus preventing the 
colocalization with PSD-95 (Fig. 22C). Preincubation of HypF-N oligomers with muTTR 
also decreased colocalization, but to a lower level than observed for the other TTRs 
(Fig. 22C). In particular, the fraction of HypF-N puncta colocalizing with PSD-95 puncta 
was 21.4±3.1% (n=18) for oligomers preincubated with hTTR for 1 h, 35.7±1.2% (n=18) 
for oligomers preincubated with muTTR for 1 h and 16.5±1.2% (n=18) for oligomers 
preincubated with M-TTR for 1 h.  
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Figure. 22 Suppression of protein oligomer toxicity by TTRs in rat hippocampal (A) and cortical (B) 
neurons. See Fig. 1 legend for details. (C) Representative confocal scanning microscope images at high 
magnification showing oligomer colocalization with PSD-95 in rat primary hippocampal neurons. 
Preformed oligomers of HypF-N were resuspended in the cell culture medium, incubated at a 
corresponding monomer concentration of 12 µM in the absence or presence of the indicated TTRs 
(protein:TTR molar ratio was 10:1) for 0 h and 1 h and then added to neurons for 30 min. The 
colocalization of HypF-N aggregates with PSD-95 was monitored using anti-HypF-N and anti-PSD-95 
antibodies and then with Alexa Fluor 488- and 594-conjugated secondary antibodies (green and red, 
respectively). Top panel images showed untreated cells, cells exposed to the native protein and toxic 
oligomers (12 µM monomer concentration). The cytofluorograms of dendrite sections show the green 
fluorescence intensity (as pixel intensity, y axis) versus red fluorescence intensity (x axis). For each 
sample, 18 cytofluorograms were analysed, each considering one dendrite section. The histograms show 
the percentage of colocalization, also reported in the table. 
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Figure. 23. (A, B) Representative confocal scanning microscope images showing intracellular Ca2+ levels 
in primary hippocampal (A) and cortical (B) neurons from rat brains. Preformed oligomers of HypF-N 
were resuspended in the cell culture medium, incubated at 12 µM with or without the indicated TTRs 
(protein:TTR molar ratio was 10:1) for 1 h and then added to rat neurons for 1 h. Each panel also show 
untreated cells, cells exposed for 1 h to the native protein, toxic oligomers (12 µM monomer 
concentration) and to the indicated TTRs without oligomers (1.2 µM tetramer or 4.8 monomer 
concentration). In all images the green fluorescence arises from the intracellular Fluo3 probe bound to 
Ca2+. (C) Representative confocal scanning microscope images showing intracellular ROS levels in 
primary hippocampal neurons from rat brains. Conditions as in A, B. The green fluorescence arises from 
the CM-H2DCFDA probe that has reacted with ROS.  
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hTTR and M-TTR were also found to prevent the oligomer-mediated intracellular Ca2+ 
increase in both hippocampal (Fig. 23A) and cortical neurons (Fig. 23B). They also 
inhibited intracellular ROS production in hippocampal neurons (Fig. 23C). These results 
show that preincubation of the HypF-N oligomers with hTTR and M-TTR, and to a 
lesser extent muTTR, inhibit the binding of the oligomers at PSD-95 containing sites 
and reduce the toxicity of the oligomers for neurons. 
The molecular structure of HypF-N oligomers is preserved in the complexes with 
TTRs  
 
In order to investigate the mechanism by which TTRs suppress the toxicity of protein 
oligomers, we have chosen to focus on the toxic oligomers of HypF-N. Indeed, under 
different experimental conditions, HypF-N can aggregate into toxic (type A, the same 
used in the present work) or non toxic (type B) oligomers; using atomic force 
microscopy (AFM) the two species are morphologically similar (ca. 2-6 nm in height) 
and bind ThT to similar levels, making it possible to carry out valuable control 
experiments [Campioni S et al. 2010]. Thus, HypF-N oligomers appear to be highly 
stable, making them easy to handle in our experiments [Campioni S et al. 2010]. We 
have, however, carried out the key experiments also on Aβ42 oligomers (see below). 
To shed light on the behaviors of the various TTRs and on the molecular mechanism by 
which they exert their protection against HypF-N oligomers we investigated the 
oligomeric state and the molecular structure of HypF-N oligomers after preincubation 
with various TTRs. To assess whether the oligomers can be dissolved by the different 
types of TTR, we exploited the ability of the HypF-N oligomers, unlike native HypF-N, to 
bind to ThT and increase its fluorescence [S. Campioni et al.2010] (Fig. 24A). HypF-N 
oligomers incubated for 1 h in a phosphate buffer at neutral pH cause a seven to eight 
fold increase of ThT fluorescence, and the same increase was observed when the 
oligomers were preincubated in the same buffer for 1 h with each of the TTRs (Fig. 
24A). To exclude the possibility that TTRs bind ThT, in parallel we also analysed 
samples containing only TTRs under identical conditions and detected no increase of 
ThT fluorescence in these cases (Fig. 24A). Overall, these results show that HypF-N 
oligomers remain stable and do not undergo disaggregation after TTR treatment. 
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Fig. 24 TTRs do not dissolve and do not remodel HypF-N oligomers. (A) ThT fluorescence at 485 nm 
(excitation 440 nm) in the presence of the indicated protein components following preincubation for 1h 
in 20 mM phosphate buffer at pH 7.0 in the absence or presence of different types of TTR. The ratio 
between the ThT fluorescence in the presence (F) and absence (F0) of proteins is reported; data are 
means ± SD of three independent experiments. The HypF-N concentration was 48 µM (in monomer 
units) and the HypF-N:TTR molar ratio was 10:1. (B) Fluorescence emission spectra of samples 
containing HypF-N oligomers labeled with pyrene at positions 25 (top), 55 (middle) and 87 (bottom). The 
spectra were acquired at 12 μM HypF-N concentration following 1 h incubation in the absence (green) 
or presence (pink) of hTTR (left panels), muTTR (middle panels) or M-TTR (right panels). For comparison, 
the corresponding spectra of nontoxic oligomers are reported in each graph (black). The spectra have 
been normalized to the intensity of the peak centered at 375 nm. The molar ratio of HypF-N:TTR was 
10:1. On the right, the exicimer-to-monomer fluorescence intensity (FI440nm/FI375nm) of each sample 
and of the nontoxic oligomers is reported. 
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Subsequently, we asked whether the oligomers are structurally re-organised at the 
molecular level by the TTRs (Fig. 24B). Differences in the structure of toxic and non 
toxic oligomers have been detected using the fluorescent probe pyrene, a structural 
probe for changes in oligomers exposed to chaperones [Campioni S et al. 2010]. We 
determined the degree of packing of the oligomers through the acquisition of 
fluorescence spectra of oligomers labeled with pyrene. This method consists in 
creating HypF-N variants containing a single cysteine at different positions along the 
sequence, label them with pyrene and allow the labeled mutants to aggregate. When 
two pyrene molecules are close to each other (within 10 Å of distance), excited state 
dimers called excimers form and can be detected as a peak at 440-470 nm [Birks J.B et 
al 1967, P. Hammarström et al.1999, R. Krishnan et al.2005]. It has been shown that 
toxic and non toxic HypF-N oligomers can be distinguished by differences in their 
pyrene emission spectra [Campioni S et al.2010]. 
Three variants of HypF-N containing a single cysteine residue at position 25, 55 or 87, 
all located in the major hydrophobic regions, were labeled with pyrene, allowed to 
aggregate and transferred to phosphate buffer at neutral pH for 1 h with or without 
the different forms of TTR. The fluorescence spectra acquired for the oligomers in 
either the presence or absence of the TTRs were very similar with none showing an 
excimer band (Fig. 24B). Moreover, the ratio of the excimer-to-monomer fluorescence 
intensity (FI440nm/FI375nm) did not change following preincubation with any TTR, 
remaining lower in all cases than the corresponding value measured for the nontoxic 
oligomers (Fig. 24B). These results show that none of the TTRs promotes structural re-
organization of the toxic HypF-N oligomers. 
TTRs bind to the oligomers 
 
To determine whether TTRs bind to the oligomers we used TTR-derived intrinsic 
fluorescence and SDS-PAGE. HypF-N oligomers sediment at relatively low centrifugal 
force; therefore, if the TTRs bind to the oligomers and the interaction between them is 
stable, the concentration of the TTRs in the supernatant will decrease following 
centrifugation, depending on the strength of the interaction. HypF-N oligomers and 
TTRs were incubated for 1h in phosphate buffer at pH 7.0 then centrifuged to separate 
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the pellet fraction (P), which contains the TTR bound to the oligomers, from the 
supernatant (SN), which contains the soluble unbound TTR. The amount of TTR in the 
SN was measured by its intrinsic fluorescence (Fig. 25A-C).  
 
 
 
 
Fig. 25 TTRs interact with HypF-N oligomers. (A-C) Intrinsic fluorescence spectra of the SN fractions 
obtained after centrifugation of samples containing preformed HypF-N oligomers (blue), TTR (red) and 
HypF-N oligomers + TTR (purple). The fluorescence emission spectra (excitation at 280 nm) were 
acquired at 37 °C. The spectrum of HypF-N oligomers has been subtracted from that of TTR + HypF-N 
oligomers to eliminate its contribution. (D-F) SDS-PAGE analysis of the insoluble (P) and soluble (SN) 
fractions obtained from samples containing preformed HypF-N oligomers (lanes 2, 3), TTR (lanes 4, 5) 
and preformed oligomers treated for 1 h with TTR (lanes 6, 7). The HypF-N concentration was 48 µM (in 
monomer units) and the molar ratio of HypF-N:TTR was 10:1. 
 
 
The fluorescence spectra of the SNs collected from the samples in which oligomers and 
hTTR or M-TTR were present were less intense than the corresponding ones in which 
only the TTRs were present, indicating that a fraction of hTTR, and to a greater extent 
M-TTR, is bound to the oligomers. In contrast, the fluorescence spectrum of the SN 
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collected from the sample containing oligomers and muTTR was similar to that in 
which only muTTR was present. 
As a further evidence of binding, the pellet and supernatant fractions collected in each 
experiment were analysed by SDS-PAGE. In the samples containing oligomers or TTR 
alone, the HypF-N monomer (MW ~10.5 kDa) and the TTR monomer (MW ~14 kDa) 
were found only in the Pellet and SN fractions, respectively (Fig. 25D-F). In the sample 
containing both HypF-N oligomers and M-TTR, the HypF-N band was present only in 
the pellet fraction, whereas M-TTR was found to partition between the pellet (49.8 % ± 
2.6) and SN fractions (Fig. 25F). This result confirms that a fraction of M-TTR is bound 
to the oligomers. Similar results, but with evidence of a smaller fraction bound in the 
pellet (24.1 % ± 3.1), were obtained with hTTR (Fig. 25D). In contrast, we found muTTR 
only in the SN fraction, suggesting that muTTR did not bind to HypF-N oligomers under 
these conditions (Fig. 25E). These results suggest that the ability of TTRs to bind HypF-
N oligomers correlates inversely with TTR tetramer stability. 
TTRs promote the assembly of the oligomers into larger species 
 
To investigate whether the binding of TTRs to the oligomers promotes their further 
assembly, we first used AFM. Discrete HypF-N oligomers with a height of 1–4 nm were 
observed by AFM in the absence of TTR (Fig. 26A), but significantly larger aggregates 
were evident after 1 h incubation in the presence of M-TTR and, to a lower extent, 
hTTR (Fig. 26A). More complex structures were observed in the presence of M-TTR, 
consisting of very large aggregates of irregular shape with typical heights of a few tens 
of nanometers. Large assemblies were not observed in samples containing oligomers 
with muTTR (Fig. 26A), or in samples containing only TTR. Similar results were obtained 
with Aβ42 oligomers and TTRs (Fig. 28A). 
As additional evidence of the ability of TTRs to promote oligomer assembly, we took 
advantage of light scattering measurements. In the presence of M-TTR, and hTTR to a 
lower extent, light scattering intensity increased, indicating that the oligomers were 
larger in size (Fig. 26B). Accordingly, these results were confirmed with turbidimetry 
measurements at 500 nm, which revealed a similar trend, presumably related to the 
lower sensitivity of this method (Fig. 26C).  
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Fig. 26 Assembly of HypF-N oligomers induced by TTRs. (A) AFM images and corresponding height 
analysis of HypF-N oligomers preincubated with or without TTRs. Preformed oligomers of HypF-N were 
resuspended in phosphate buffer pH 7.0, incubated for 1 h at a corresponding monomer concentration 
of 48 µM in the absence or presence of the indicated TTRs (HypF-N:TTR molar ratio was 10:1) and then 
deposited on mica; the scan size is 1 µm. Z range: 5 nm (oligomers), 24 nm (oligomers + hTTR), 6 nm 
(oligomers + muTTR), 36 nm (oligomers + M-TTR). (B) Light scattering intensity measurements of HypF-N 
oligomers preincubated with or without TTRs and TTRs alone. The light scattering intensity were 
measured at 48 μM HypF-N and at a HypF-N:TTR molar ratio of 10:1. (C) Measurements of turbidimetry 
at 500 nm of HypF-N oligomers incubated with or without TTRs and TTRs alone. Conditions as in (B). The 
values shown are means ± SEM of five independent experiments. The single and the triple asterisks 
indicate significant difference (p ≤ 0.05 and p ≤ 0.001, respectively) relative to the experiment with 
oligomers only. 
 
 
The AFM, light scattering and turbidity results show that M-TTR and hTTR promote the 
assembly of the HypF-N oligomers into larger species but do not provide information 
on whether or not the large HypF-N aggregates include the TTRs. The oligomers can 
also be observed with confocal microscopy because, unlike free TTRs, they readily 
adhere to the glass coverslips (Fig. 27). 
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Fig. 27 Colocalization of HypF-N oligomers and TTRs. Representative confocal microscope images with 
HypF-N oligomers incubated for the indicated time lengths in the absence or presence of the indicated 
TTRs and treated with anti-HypF-N (green) and anti-TTR (red) antibodies. The colocalization of oligomers 
and TTRs is shown in the merged images (yellow dots). The HypF-N concentration was 48 µM (in 
monomer units) and the molar ratio of HypF-N:TTR was 10:1. 
 
Images obtained using HypF-N oligomers incubated for 1 h with TTRs show larger 
aggregates, with M-TTR and hTTR colocalizing with the large oligomer clusters (Fig. 27). 
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By contrast, images obtained using HypF-N oligomers and TTRs in the absence of 1 h 
incubation showed no large oligomers (Fig. 27). Indeed, incubation of HypF-N 
oligomers with M-TTR promoted formation of large aggregates in a time-dependent 
manner (Fig. 27, bottom panel). Interestingly, the TTRs appear within the structural 
core rather than on the surface of these larger aggregates, suggesting that they 
promote the formation of such large aggregates rather than binding and stabilizing 
them after they are formed (Fig. 27). On the other hand, mTTR did not colocalize with 
the oligomers. This technique also showed that the M-TTR and hTTR were bound only 
to the large clusters of oligomers, not to single oligomers, confirming that the binding 
promotes their further assembly into clusters. Similar results were obtained with Aβ42 
oligomers and M-TTR (Fig. 28B). 
 
Figure. 28. Assembly of Aβ42 oligomers induced by TTRs. (A) AFM images and corresponding height 
analysis of Aβ42 oligomers preincubated with or without TTRs. Preformed oligomers of Aβ42 were 
resuspended in phosphate buffer pH 7.0, incubated for 1 h at a corresponding monomer concentration 
of 48 µM in the absence or presence of the indicated TTRs (Aβ42:TTR molar ratio was 10:1) and then 
deposited on mica; the scan size is 1 µm. Z range: 3 nm (oligomers), 7 nm (oligomers + hTTR), 4 nm 
(oligomers + muTTR), 50 nm (oligomers + M-TTR). (B) Colocalization of Aβ42 oligomers and M-TTR. 
Representative confocal microscope images with Aβ42 oligomers incubated for the indicated time 
lengths in the presence of M-TTR and treated with A11 anti-Aβ (green) and anti-TTR (red) antibodies. 
The colocalization of oligomers and M-TTR is shown in the merged images (yellow dots). The Aβ42 
concentration was 48 µM (in monomer units) and the molar ratio of Aβ42:M-TTR was 10:1. 
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Results III: A complex equilibrium between partially unfolded 
conformations in monomeric transthyretin 
 
Aggregation and deposition of the homotetrameric protein transthyretin (TTR) is 
known to be linked to the onset of several localised amyloidoses. It is also emerging 
that TTR exerts a protective role against aggregation of the Aβ peptide, a process 
linked to Alzheimer’s disease. Both processes correlate with the ability of TTR to 
populate a monomeric state, yet a complete description of the possible 
conformational states populated by monomeric TTR under physiological conditions is 
missing. Using an array of biophysical method and kinetic tests, we show that once 
monomers of transthyretin are released by the quaternary structure, an equilibrium 
is established between a set of conformational states possessing different amounts 
of disorders. A molten globular state appears in equilibrium with the fully folded 
monomer, whereas an off-pathway species accumulates transiently during refolding 
of TTR. These two conformational ensembles are distinct in terms of structure, 
dynamics, kinetics and pathway of formation. Further subpopulations of the protein 
fold slower due to the occurrence of proline isomerism. The identification of two 
conformational states remained undisclosed in previous studies paves the way to the 
characterization of the amyloidogenicity and protective role of TTR. 
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Thermal denaturation of M-TTR is an irreversible process 
 
In order to characterize the unfolding/refolding pathway of M-TTR, we first studied 
thermal unfolding of the protein in phosphate buffer by means of CD spectroscopy at 
216 nm, where the biggest difference between the signal of native and thermally 
unfolded protein was observed (Figure 29A). The CD signal did not vary as the sample 
was heated up to a temperature of about 50 °C (Figure 29B). After that, the protein 
denatured and the transition was complete at 70 °C in our experimental setup. 
However, when the sample was cooled down to 25 °C, the CD signal did not recover 
the initial value (Figure 29B). The irreversibility of thermal denaturation was further 
confirmed by the differences observed between CD spectra recorded at 25 °C before 
and after thermal denaturation, which revealed a decrease in β-sheet structure and an 
increase in disordered segments following denaturation (Figure 29A). 
 
 
 
 
Figure 29 Thermal denaturation of M-TTR. (A) CD spectra of M-TTR recorded at different temperatures. 
Spectra are shown for the protein at 25 °C before (black continuous line) and after (black dashed line) 
thermal unfolding and for thermally unfolded protein at 79 °C (grey continuous line). (B) CD signal at 216 
nm Vs temperature during unfolding (black) and refolding (grey). (C) DLS distribution of M-TTR before 
(continuous line) and after (dashed line) thermal denaturation. (D) ThT fluorescence measured at 25°C 
in the presence of M-TTR before (continuous line) and after (dashed line) thermal unfolding. 
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In order to get insight into this thermally unfolded state we investigated the process by 
means of DLS. DLS analysis revealed that M-TTR is prevalently monomeric before 
thermal denaturation, with an apparent hydrodynamic diameter of 4.5 ± 1.0 nm 
(Figure 29C), which is compatible with that determined with X-ray crystallography 
[Jiang, X et al.2001]. By contrast, M-TTR was converted into oligomers exhibiting an 
apparent hydrodynamic diameter of about 100 nm after thermal denaturation and 
cooling (Figure 29C). Unlike native M-TTR, these aggregated particles bound to the dye 
Thioflavin T (Figure 29D), a fact reminiscent of the presence of amyloid-like structure in 
the sample [Biancalana, M. et al.2010]The same set of experiments was repeated in 
the presence of 1.5 M urea so as to verify whether small amounts of the denaturant 
might be able to inhibit aggregation in the sample. However, the results showed that 
thermal denaturation of M-TTR is irreversible even in the presence of urea (Figure 30). 
 
 
Figure 30 Thermal denaturation of M-TTR in phosphate buffer containing 1.5 M urea. (A) CD spectra of 
M-TTR recorded at different temperatures. Spectra are shown for the protein at 25 °C before (black 
continuous line) and after (black dashed line) thermal unfolding and for thermally unfolded protein at 79 
°C (grey continuous line). (B) CD signal at 216 nm Vs temperature during unfolding (black) and refolding 
(grey). (C) DLS distribution of M-TTR at 25° C before (continuous line) and after (dashed line) thermal 
denaturation. (D) ThT fluorescence measured at 25° C in the presence of M-TTR before (continuous line) 
and after (dashed line) thermal unfolding. 
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Urea induced denaturation of M-TTR revealed a molten globule 
 
Given the difficulties associated with studying M-TTR unfolding by means of thermally 
induced denaturation, we investigated the process by means of urea equilibrium 
titration experiments. Different probes were used for the analysis, namely CD in the 
far-UV to assess secondary structure changes and CD in the near–UV and tryptophan 
fluorescence to investigate tertiary structure. Spectra at urea concentrations ranging 
from 0 to 7.6 M and obtained with the three spectroscopic probes are shown in figure 
31A, 31B and 31C; the corresponding unfolding traces (spectroscopic signal Vs [urea]) 
are shown in figure 32A, 32B and 32C while the corresponding native fraction plots are 
shown in Figure 31D. All probes indicated a major cooperative unfolding transition 
taking place between 2 and 4 M urea. Unfolding traces were analysed with a two-state 
transition model [Santoro, M. M.et al.1988] in order to determine thermodynamic 
parameters associated with conversion of the folded state (F) into the unfolded (U) 
state (Figure 31D and 31E). This analysis yielded values of conformational stability in 
the absence of denaturant ( ) of 4.8± 0.2, 5.2 ± 0.3  and 4.9 ± 0.2 kcal mol-1 for 
far-UV CD, near-UV CD and fluorescence, respectively and m values of 1.64 ± 0.10, 1.56 
± 0.10 and 1.63 ± 0.10 kcal mol-1 M-1 for far-UV CD, near-UV CD and fluorescence, 
respectively.  The average  and m are 5.0 ± 0.2 kcal mol-1 and 1.61 ± 0.10 kcal 
mol-1M-1, respectively. These values are in reasonable agreement with those from 
similar experiments previously carried out under slightly different conditions ( Jiang, X.,  
et al.2001, Hurshman Babbes, A. R., et al. 2008). 
Importantly, the analysis carried out with far-UV CD revealed the presence of a second 
transition located between 0 and 2.4 M urea and involving a remarkable change in CD 
signal between 195 nm and 210 nm (light grey region in Figure 31B).  
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Figure 31 Urea induced denaturation of M-TTR, followed with several spectroscopic probes. The color 
scale refers to urea concentration according to the legend displayed in panel (E). (A) Equilibrium 
unfolding followed by intrinsic (tryptophan) fluorescence. Spectra are shownas ratio between 
fluorescence at a given wavelength λand that at 335 nm. (B)Equilibrium unfolding followed by far-UV 
CD, revealing two transitions: transition 1 is visible from 195 to 205 nm (light grey), andtransition 2 at 
215-225 nm (dark grey).(C)Equilibrium unfolding followed by near-UV CD.(D) Native fraction as 
measured from best fits to a two state model of data reported in panel (A), (B) and (C).Tryptophan 
fluorescence (circles), CD at 219 nm (squares) and at 290 nm (diamonds) indicated a cooperative 
transition between 2 and 4 M urea, whereas CD at 204 nm illustrated a non-cooperative transition 
occurring between 0 and 2.4 M urea (triangles). (E) Phase diagram consisting of the plot of tryptophan 
fluorescence(F365/F335)Vs CD signal at 206 nm; this analysis suggestedtwotransitions: (i) a transition from 
a fully folded state to a molten globular (MG) state; (ii) conversion of MGinto an unfolded (U) state. (F) 
Plot of CD signal at 222 nm Vs the signal at 200 nm: this analysis is able to distinguish between folded 
(F), unfolded (U), pre-molten globular (PMG) and molten globular (MG) states. 
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Comparison between near-UV and far-UV CD spectra of M-TTR in 0 M and 2.4 M urea 
indicated that in the latter condition the protein is folded in terms of tertiary structure 
but exhibits a decrease in β-sheet structure and an increase in random coil structure. 
Such a transition involving the F state and a hidden conformation could be investigated 
by plotting the signal at 204 nm Vs [urea] (Figure 31D and 32D). The obtained plot is 
reminiscent of a cooperative transition and illustrates that the second transition is well 
separated from the first one (Figure 31D and 32D). An exhaustive analysis of the 
thermodynamic parameters showed that the concentration of middle denaturation 
(Cm) depended on wavelength, a fact reminiscent of a non-cooperative transition. 
Although this effect might reflect the low signal to noise ratio observed below 200 nm, 
which limits the possibility of getting information at urea concentrations higher than 2 
M, the present data do not allow assigning the transition as a cooperative one. 
Thus, the two transitions can be recapitulated by a phase diagram approach [ 
Kuznetsova, I. M et al. 2004]: indeed, the plot of a spectroscopic probe able to detect 
the first transition (e.g. the ratio of fluorescence at 365 and 335 nm) Vs a second probe 
able to detect the second transition (CD at 206 nm) illustrates that a hidden 
conformation forms along the unfolding pathway of M-TTR and is maximally populated 
at 2.4 M urea (Figure 31E). After the denaturation of such hidden conformation the 
unfolded state becomes populated. 
In order to characterize the conformational ensemble dominant at 2.4 M urea we 
plotted the CD signal at 222 nm Vs the signal at 200 nm (Figure 31F). It was reported 
that such an analysis is able to distinguish between folded, unfolded and molten 
globular (MG) states [Uversky, V. N et al. 2004]. In the case of M-TTR the analysis 
revealed that, as denaturant concentration increases from 0 to 2.4 M, the protein 
moves from a folded zone to a predominantly molten globular region (Figure 29F). This 
interpretation was corroborated by near-UV CD spectra, which showed a slight 
decrease in the tryptophan peak at 290 nm and in the tyrosine peak at 283 nm (Figure 
3C and S2C), a fact reminiscent of a more dynamic environment surrounding aromatic 
side chains  [Kelly, S. M.,  et al.2005] . Thus, a transition F -> MG takes place before M-
TTR undergoes a complete denaturation (MG -> U). 
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Figure 32 Urea induced denaturation followed with different spectroscopic probes, namely the ratio 
between tryptophan fluorescence at 365 and 335 nm (A), far-UV CD at 219 nm (B), near-UV CD at 290 
nm (C) and far-UV CD at 204 nm (D). Data show that there are two transitions: the first one (highlighted 
in green) occurs at low urea concentration and has a Cm value of ~ 1.79 M; the second one (highlighted 
in pink) has a Cmvalue of roughly 3.1 M. 
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Folding and unfolding kinetics revealed a transiently populated state 
 
We set out to investigate folding and unfolding kinetics of M-TTR by means of a 
stopped-flow device coupled to fluorescence or CD detection systems. Folding kinetics 
in the presence of 0.5 M urea involved a decrease in tryptophan fluorescence as M-
TTR underwent refolding (Figure 33A). Such a decrease was complete after ca. 50 ms in 
0.5 M urea. We gauged the signal of the unfolded protein under native conditions by 
linear extrapolation from measurements at high urea concentrations, where the 
protein is 100% unfolded (not shown). This analysis revealed that fluorescence of the 
unfolded state is significantly different than the signal at the beginning of the refolding 
kinetics. This suggested the occurrence of one further refolding phase within the dead-
time of our stopped-flow experiments (Figure 33A). We will refer to the fast phase 
occurring in the dead-time of our stopped-flow experiments as to λ1 and to the major 
refolding phase as to λ2 (λ2= 80 s-1 in the absence of denaturant). The occurrence of 
the fast λ1 phase was further confirmed by other spectroscopic probes, such as ANS 
binding to characterize exposure to solvent of hydrophobic clusters (Figure 33B) and 
far-UV CD to assess secondary structure content (Figure 33C).The conformational state 
populated at the beginning of the refolding kinetics exhibited a higher ANS binding 
than the unfolded state, suggesting hydrophobic clusters partially exposed to the 
solvent (Figure 4B). The CD signal did not vary during refolding, indicating that the 
conformational state at the beginning of the refolding kinetics has a secondary 
structure similar to that of the folded state  (Figure 33C). However, a dramatic change 
took place within the dead-time, as the unfolded state was found to lack any 
secondary structure (Figure 33C). Consequently, both ANS fluorescence and CD 
confirmed the occurrence of the fast λ1 phase. 
In order to get direct evidence of such a phase, we investigated M-TTR refolding by 
means of T-jump relaxation experiments using tryptophan fluorescence as a probe 
(Figure 33D). Results confirmed a rapid decrease in tryptophan fluorescence (λ1), 
complete in ca. 10 ms. As expected, the time-scale of this process was within the dead-
time of our stopped-flow experiments and was therefore masked in this latter case. 
Hence, T-jump relaxation kinetics provided direct evidence of the formation of a 
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transiently populated state. After λ1 and λ2 were complete, refolding of M-TTR 
followed by means of tryptophan fluorescence exhibited two more exponential phases 
(Figure 33E). The third and fourth phases were complete in ca. 2.5 s (λ3 = 2 s-1) and 30 
s (λ4 = 0.15 s-1), respectively. 
As far as unfolding is concerned, the process, monitored at urea concentration higher 
than 4 Mby means of tryptophan fluorescence, involved an increase in fluorescence 
(Figure 33F). Two exponential phases could be distinguished: the first phase was 
complete in ca. 50 ms in 5 M urea (inset of Figure 33F), which is on the same time-
scale of similar experiments previously reported under slightly different conditions 
[Stéphan A. et al.2001]. The second phase lasted ca. 5 s (Figure 33F). 
 
Figure 33 M-TTR refolding and unfolding kinetics, followed by means ofdifferent spectroscopic probes. 
(A-C) M-TTR refolding kinetics monitored by means ofdifferenttechniques: tryptophan fluorescence (A), 
ANS binding (B), far-UV CD (C). In each panel the spectroscopic probe was monitored in stopped-flow 
refolding experiments at 0.25 M urea. Signal for the folded (F), partially folded (PF) and unfolded states 
(U) are shown. Insets show the same kinetics up to 200 ms. (D) T-jump relaxation kinetics at 2.5 M urea 
illustrates the presence of a fast phase (λ1), complete inca. 10ms.(E) Refolding kinetics in phosphate 
buffer with 0.5 M urea show that, after λ1 and 2 are complete (grey zone in the inset) two slow phases 
can be detected, consistingin a further decrease in tryptophan fluorescence:λ3, complete in ca. 2.5 s 
(grey zone in main panel) and λ4, complete in ca. 40 s. (F) M-TTR unfolding kinetics, showing the 
occurrence of two phases, which are complete in ca. 50 ms (grey zone in the inset, λ1) and 1 s (λ2). 
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The transiently populated state is a partially folded off–pathway ensemble 
 
We built the chevron plot for M-TTR (Figure 34A). In particular, T-jump experiments 
were carried out in the urea concentration range 0.5 – 4.5 M to obtain the plot of ln 
(λ1) Vs [urea] (triangles in Figure 34A). Rate constants for the major folding/unfolding 
transition (λ2) were obtained from best fits of experimental kinetic traces to multi-
exponential equations and these values were used to build plot of ln (λ2) Vs [urea] 
(circles in Figure 34A). The Cm value obtained from the analysis of this plot -calculated 
as the urea concentration at which extrapolated refolding and unfolding rate constants 
are equal- was in good agreement with that determined for the MG -> U transition 
observed at equilibrium. Indeed, kinetic and equilibrium experiments indicated Cm 
values of 3.2 ± 0.2 and 3.1 ± 0.2 M urea, respectively. However, a downward curvature 
could be observed in the folding limb of the plot. Such a deviation from the expected 
plot for a two state folder [Jackson, S. E et al. 1991] is usually referred to as roll-over 
[Matouschek, A., et al.1990,  Ferguson, N et al.1999, Bemporad, F., et al.2004], and can 
be recapitulated in kinetic terms as follows. The extrapolated unfolding rate constant 
in the absence of denaturant was 1.82 s-1. Given the conformational stability obtained 
by equilibrium experiments the folding rate constant under the same conditions was 
expected to be ~ 6100 s-1 for a two state folder (Figure 34A). Refolding rate constant 
extrapolated by experimental data was ca. 81 s-1, two orders of magnitude lower than 
the expected value. 
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Figure 34 Characterization of the transiently populated state.(A) Natural logarithm of the observed 
folding/unfolding microscopic constants λ1 (triangles) and λ2(circles), plotted as a function of urea 
concentration (chevron plot). The refolding limb of the chevron plot deviates from linearity at urea 
concentrations lower than 2 M, where a downward curvature, generally referred to as “rollover,” is 
observed. The continuous line represents the best fit of the data to the equation for a two-state 
transition. Dashed and dotted lines represents best global fits to three-state off-pathway and on-
pathway models, respectively. (B-C)Interrupted refolding double jump experiment. The protein unfolded 
in 3M urea at pH 3.2 was first refolded by dilution into a refolding phosphate bufferat pH 7.4. After 
agiven delay time, the protein was denatured in a second jump through dilution into a solution 
containing 5 M urea at pH 7.4. (B)experimental traces obtained at different delay times (see legend); (C) 
calculated folded fraction Vsdelay time. The amount of folded protein present at the beginning of the 
refolding experiment was extrapolated from a single exponential fit. (D-E) Transient (D) and equilibrium 
(E) concentrations for the folded (F, continuous line), unfolded (U, dotted line) and partially folded (PF, 
dashed line) states according to the off-pathway model at 0 M urea (D) and plotted Vs urea 
concentration (E). Insets show magnifications to illustrate PF concentrations. 
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While roll-over in M-TTR chevron plot probably reflects the transient formation of a 
hidden conformation [ Gianni, S et al. 2007], other  interpretations were previously 
proposed for this phenomenon, including Hammond effect [ Narita M er al. 1997] and 
aggregation artefacts [Zlokovic BV 1996]. We performed refolding kinetics at different 
[M-TTR] so as to detect possible aggregation phenomena occurring during refolding 
(figure 35A and 35B). Indeed, any intermolecular process would be affected by varying 
protein concentration. However, neither kinetic constants (Figure 35C) nor phase 
amplitudes (Figure 35D) obtained from best fits of experimental data to equation 
[Johnson, S. M.,  et al. 2012] significantly changed as [M-TTR] ranged from 0.007 to 
0.07 mg ml-1 and this confirms that a conformational state different from the folded 
and unfolded states forms transiently during refolding of M-TTR. 
 
 
 
Figure 35 Folding traces obtained at different M-TTR concentrations. (A) Experimental traces; color 
ranges from red to purple as M-TTR concentration ranges from 0.5 to 5.1 μM. (B) Magnification of panel 
(A) to show the first refolding phase. (C) Natural logarithm of the three microscopic refolding rates 
plotted Vs protein concentration. (D) Relative amplitudes of refolding phases plotted Vs protein 
concentration. Panels (C) and (D) demonstrate that folding rates and relative amplitudes do not vary as 
protein concentration increases.  
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Folding slow phases arise from proline isomerism 
 
Another important question to answer was the characterization of the two folding 
slow phasesλ3 and λ4(Figure 33E). The rate constants of such phases lacked 
dependence on urea concentration and this suggested that they could arise from 
proline isomerism [Schmid, F. X. 2001]. M-TTR possesses 8 X-Pro bonds (Fig 36), all 
populating a transconfiguration in the folded state [Jiang, X.et al. 2001, Palmieri Lde, C. 
et al. 2010]. 
 
 
 
Figure 36 Front and back view of F87M/L110M TTR (M-TTR). Strands have been labelled to highlight 
topology. Mutated residues are labelled in red. Tryptophan side chains are labelled in blue. Proline 
residues are labelled in yellow. The figure was drawn using the PDB entry 1GKO(34). 
 
 
To confirm this hypothesis, we performed folding kinetics experiments in the presence 
of cyclophilin A (cypA), a peptidyl-prolylisomerase that catalyses the cis-trans 
interconversion of X-Pro peptide bonds [Schmid, F. X. 2001]. While bovine cypA did not 
have any effect on M-TTR refolding (data not shown) human cypA was able to 
accelerate the process as enzyme concentration increased from 0 to 0.6 µM (Fig 37A). 
Analysis of the traces revealed that λ2 was not affected by the presence of cypA 
whereas slow phases (λ3 and λ4) were both significantly accelerated (Figure 37B). 
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To further confirm the occurrence of proline isomerism during M-TTR refolding, 
interrupted unfolding double jump experiments were carried out. Briefly, M-TTR was 
first unfolded in 5 M urea and, after a delay time, refolded in 1 M urea. The rationale in 
this case is that by varying the delay time between the first (unfolding) and second 
(refolding) jump, one can vary the time the protein is allowed to refold. As proline 
isomerism requires several seconds to reach its equilibrium, slow phases are expected 
to decrease in amplitude and eventually disappear as delay time decreases. While the 
amplitude of the fast phase did not depend on delay time, those of the slow phases 
decreased as delay time decreased (Figure 37C). The plot of the amplitudes Vs delay 
time showed two exponential processeswhose amplitudessatisfactorily extrapolated to 
0.00 ± 0.02 (A3) and 0.04 ± 0.02 (A4) when delay time is o (Figure 37D).  
 
 
Figure 37 Characterization of M-TTR refolding slow phases (λ3 and λ4).(A) Effect of human CypA on M-
TTR folding. The folding reaction was monitored in phosphate buffer containing 0.5 M urea,in the 
presence of increasing quantities of human CypA. Color refers to cypA concentration, according to the 
table shown in the figure.(B) Microscopic refolding rate constants reported as ratios of the value 
obtained for the different phases in the presence of CypA and the corresponding value in its absence. 
(C) Double jump interrupted unfolding experiment: the protein was first denatured ina phosphate buffer 
containing 5 M urea (first jump) and then, after a given delay time, refoldedin a phosphate buffer 
containing 1 M urea (second jump). Color refers to delay time, according to the table shown in the 
figure. (D) Plot displaying phase relative amplitudes obtained from best fits of experimental data to 
equation (1) Vs delay time. These traces were analyzed with a single exponential rise function(solid 
lines). 
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Kinetic constants obtained by fitting the data of A3 and A4Vs delay time to a single 
exponential functionwere in reasonable agreement with the values obtained from 
single jump refolding experiments under the same conditions.This corroborated the 
idea that both slow phasesarise from proline isomerism. However, it should be noticed 
that while λ4 occurs on the typical time-scale for proline isomerism, λ3 appears too fast 
for such process. It is therefore possible that only λ4 should be attributed to proline 
isomerism while results for λ3originate from partial overlapping of the two slow 
phases. 
In order to assess whether the transiently populated state forming after the first fast 
phase of folding (λ1) represented a true folding intermediate or rather a kinetic trap 
which is off the refolding pathway and slows down the bulk process, we analysed our 
chevron plot with on-pathway and off-pathway models [Gianni, S. et al 2007]. Results 
of such analysis are shown in Figure 34A and summarized in table 1. In principle, the 
analysis can discriminate between the two models because only the on-pathway 
model allows λ2 to be higher than λ1 in the absence of denaturant [Gianni, S. et al 
2007, Bai, Y 1999]. If the experimental analysis shows that λ2 is higher than λ1, the off-
pathway model can be ruled out. However, in the case of M-TTR, both models 
successfully interpreted data. Consequently, while the analysis yielded all the kinetic 
parameters for the refolding of M-TTR and the transient and equilibrium 
concentrations of the species involved in the process, it was not conclusivein terms of 
folding pathway. 
In order to shed light on the on- or off-pathway nature of the transiently populated 
state, we performed an interrupted refolding double jump experiment [Haq, S. R et 
al.2010, Jemth, P. et al. 2004] In this experiment M-TTR was first unfolded in 3 M urea 
at pH 3.2 (Figure 38). It was then refolded in 1.5 M urea at pH 7.4 (first jump) and after 
a delay time unfolded back in 5 M urea at pH 7.4 (second jump). By varying the delay 
time after (Figure 34B)the first jump (refolding), one can vary the amount of protein 
undergoing unfolding in the second jump (unfolding), as described elsewhere Jemth, P. 
et al. 2004, Travaglini-Allocatelli, C. et al.2003]. Consequently,this experiment allowed 
the relative amount of native protein to be reconstructed during refolding time (Figure 
34C). The rationale behind the approach is that only in the off-pathway model the 
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amount of native protein extrapolated at the beginning of the refolding experiment 
can be higher than 0. In the case of M-TTR, the extrapolated amount of native protein 
at the beginning of the refolding experiment was 28% (Figure 34C). Consequently, the 
transiently populated state is an off-pathway kinetic trap. Only after its denaturation 
the protein can convert into the correctly folded state. 
 
 
 
Figure 38 M-TTR equilibrium unfolding experiments monitored via tryptophan fluorescence at different 
pH values. In all panels green, blue and orange refer to data at pH 3.2, 4.2 and 7.4, respectively. (A) 
Folded fraction Vs urea concentration; Cm values are indicated. (B-D) Plots showing (B) the concentration 
of middle denaturation (Cm)Vs pH, (C) free energy change upon denaturation in the absence of 
denaturant ( ) Vs pH and (D) m value VspH. 
 
The kinetic constants obtained from the off-pathway model were thus used to 
calculate transient and equilibrium concentrations of F, U and PF(Figure 34D and 34E) 
and the spectroscopic signals of PF (Figure 33A, 33B, 33C). Results revealed that the 
transiently populated state is hyperfluorescent relative to the fully folded state (Figure 
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33A), a fact reminiscent of an environment surrounding tryptophan side chains where 
quenching is lower. Furthermore, the transiently populated exhibits a higher ANS 
binding than the fully folded state (Figure 33B). However, its CD signal at 219 nm is 
comparable to that of the native state (Figure 33C). Consequently, the transiently 
populated state can be described as a partially folded (PF) conformation possessing 
secondary structure globally comparable to those of the fully folded state, some 
hydrophobic clusters exposed to solvent and some non-native contacts that must be 
dismantled before M-TTR can convert into the fully folded state. 
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Results IV: TDP-43 inclusion bodies formed in bacteria are structurally 
amorphous, non-amyloid and inherently toxic to neuroblastoma cells 
 
Accumulation of ubiquitin-positive, tau and α-synuclein-negative intracellular 
inclusions of TDP-43 in the central nervous system represents the major hallmark 
correlated to amyotrophic lateral sclerosis and frontotemporal lobar degeneration 
with ubiquitin-positive inclusions. Such inclusions have variably been described as 
amorphous aggregates or more structured deposits having an amyloid structure. 
Following the observations that bacterial inclusion bodies generally consist of 
amyloid aggregates, we have overexpressed full-length TDP-43 and C-terminal TDP-
43 in E. coli, purified the resulting full-length and C-terminal TDP-43 containing 
inclusion bodies (FL and Ct TDP-43 IBs) and subjected them to biophysical analyses to 
assess their structure/morphology. We show that both FL and Ct TDP-43 aggregates 
contained in the bacterial IBs do not bind amyloid dyes such as thioflavin T and 
Congo red, possess a disordered secondary structure, as inferred using circular 
dichroism and infrared spectroscopies, and are susceptible to proteinase K digestion, 
thus possessing none of the hallmarks for amyloid. Moreover, atomic force 
microscopy revealed an irregular structure for both types of TDP-43 IBs and 
confirmed the absence of amyloid-like species after proteinase K treatment. Cell 
biology experiments showed that FL TDP-43 IBs were able to impair the viability of 
cultured neuroblastoma cells when added to their extracellular medium and, more 
markedly, when transfected into their cytosol, where they are at least in part 
ubiquitinated and phosphorylated. These data reveal an inherently propensity of 
TDP-43 to form amorphous aggregates, which possess, however, an inherently ability 
to cause cell dysfunction. This indicates that a gain of toxic function caused by TDP-
43 deposits is effective in TDP-43 pathologies, in addition to possible loss of function 
mechanisms originating from the cellular mistrafficking of the protein. 
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Aggregation of FL TDP-43 and Ct TDP-43 in IBs of E. coli cells 
 
The cDNA encoding FL TDP-43 and Ct TDP-43 were cloned downstream of the GST 
gene in the pGEX-2T plasmid. XL1-Blue cells of E. coli were then transformed with the 
two resulting engineered plasmids.  
 
 
Figure 39. FL and Ct TDP-43 expression in E. coli cells. (A) SDS-PAGE analysis of bacterial proteins at 
different GST/FL TDP-43 (left) and GST/Ct TDP-43 (right) induction times (0 h, 2 h, 4 h and 16 h) with 1 
mM IPTG at the temperature of 37 °C. The band at ~ 69 kDa indicates GST/FL TDP-43 (left) and that at ~ 
46 kDa represents GST/Ct TDP-43 (right). (B) SDS-PAGE analysis of total bacterial proteins after GST/FL 
TDP-43 (left) and GST/Ct TDP-43 (right) inductions with 1 mM IPTG for 16 h at 37 °C and of the P and SN 
fractions of the same samples after cell lysis. (C) SDS-PAGE analysis of purified FL TDP-43 IBs, Ct TDP-43 
IBs and control IBs obtained with 1 mM IPTG expression for 16 h at 37 °C. The bands at ~ 69 kDa and ~ 
46 kDa indicates the GST/FL TDP-43 and GST/Ct TDP-43 proteins, respectively, that are absent in the 
control IBs sample. 
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To test whether bacterial cells expressed the fusion GST/FL TDP-43 protein, we 
evaluated the expression at 37 °C with 1 mM IPTG concentration and using SDS-PAGE 
(Fig. 39A).  
The GST/FL TDP-43 band corresponds to a molecular weight of ~ 69 kDa, i.e. the sum 
of the molecular weights of GST (~ 26 kDa) and FL TDP-43 (~ 43 kDa). Immediately 
before adding IPTG (0 h), a basal protein expression was present. At 2 h and 4 h from 
induction a greater quantity of expressed protein was evident. However, the major 
expression of the fusion protein was observed at 16 h. The same conditions were used 
to evaluate the bacterial expression of the fusion GST/Ct TDP-43 protein. A similar 
expression level to that of the GST/FL TDP-43 protein was observed by SDS-PAGE, with 
a band corresponding to a molecular weight of ~ 46 kDa, that is the sum of the 
molecular weights of GST (~ 26 kDa) and Ct TDP-43 (~ 20 kDa) (Fig. 39A). 
After cell growth for 8 h and protein expression for 16 h at 37 °C, the bacteria cells 
were harvested, lysed and centrifuged and the resulting supernatant (SN) and pellet (P) 
were analysed by SDS-PAGE (Fig. 39B). Both GST/FL TDP-43 and GST/Ct TDP-43 were 
found entirely in the P fraction indicating that they precipitated in IBs (Fig. 39B). 
Bacterial IBs have been shown to contain amyloid-like aggregates, as determined with 
CR and ThT binding, FTIR, X-ray diffraction, AFM and transmission electron microscopy 
(TEM) [Wang L et al 2008, Sabaté R et al 2009, García Fruitós E et al 2011, de Groot NS 
et al 2009, Wang L 2009, Gatti-Lafranconi P et al. 2011]. The presence of residual 
native-like structures and disordered chain segments has also been described, their 
content depending on the particular IB-forming protein [Oberg K, et al.1994, 
Przybycien TM et al. 1994, Fink AL 1998, Umetsu M et al 2004, Ventura S et al.2006]. 
Therefore, bacterial IBs are a physiological system consisting of several types of 
protein aggregates, both amyloid and amorphous, depending on the aggregating 
proteins. Thus, the aggregation of GST/FL TDP-43 and GST/Ct TDP-43 into IBs offered 
the possibility of investigating whether full-length TDP-43 or its C-terminal fragment 
have the propensity to form amyloid or other forms of self-assembly when aggregating 
in the highly crowded environment existing in a living organism. 
The IBs formed from cells expressing GST/FL TDP-43 (FL TDP-43 IBs), GST/Ct TDP-43 (Ct 
TDP-43 IBs) and GST (control IBs) were purified as described in 2.3. Using a 
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densitometric analysis of the SDS-PAGE bands we evaluated that the GST/FL TDP-43 
band was 29 ± 3% of all proteins present in FL TDP-43 IBs (Fig. 39C), while the GST/Ct 
TDP-43 band was 32 ± 2.9% of all proteins present in Ct TDP-43 IBs (Fig. 39C). 
Therefore, for all the biophysical data present in this work, we analysed TDP-43 IBs 
with a total protein concentration higher than that present in control IBs by ~ 30%, so 
that the three IBs samples contained the same amount of proteins distinct from TDP-
43. Using this approach, it was possible to evaluate the contribution of TDP-43 relative 
to other proteins present in IBs by difference, for example by subtracting the FTIR 
spectrum of control IBs from that of FL TDP-43 IBs or from that of Ct TDP-43 IBs. 
FL TDP-43 and Ct TDP-43 aggregates do not bind CR and ThT 
 
We used the amyloid diagnostic CR dye to assess whether FL TDP-43 and Ct TDP-43 
contained in IBs display typical amyloid properties.  
 
 
Figure 40. CR and ThT binding of FL TDP-43 IBs, Ct TDP-43 IBs and control IBs. (A) Absorbance spectra 
of FL TDP-43 IBs + CR (solid line), CR (dashed line) and FL TDP-43 IBs (dotted line). (B) Absorbance 
spectra of Ct TDP-43 IBs + CR (solid line), CR (dashed line) and Ct TDP-43 IBs (dotted line). (C) 
Absorbance spectra of control IBs + CR (solid line), CR (dashed line) and control IBs (dotted line). (D) 
Absorbance spectra of  native HypF-N + CR (solid line), CR (dashed line) and  native HypF-N (dotted line). 
(E) Difference absorbance spectra obtained for FL TDP-43 IBs (green), Ct TDP-43 IBs (red), control IBs 
(blue) and native HypF-N (purple). (F) ThT fluorescence spectra in the presence of FL TDP-43 IBs (green), 
Ct TDP-43 IBs (red), control IBs (blue) and native HypF-N (purple). 
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The CR absorbance increased in the presence of FL TDP-43 IBs and the wavelength of 
maximum absorption red-shifted to ~ 508 nm (Fig. 40A). This spectral change was very 
similar to that observed in the presence of control IBs (Fig. 40C).  
The CR absorbance increased also in the presence of Ct TDP-43 IBs, although less 
markedly than in the presence of FL TDP-43 IBs, with a maximum absorption at ~ 495 
nm (Fig. 40B). Spectral changes of CR were not observed in the presence of native 
HypF-N, used here as a soluble protein and, thus, as a negative control (Fig. 40D). For 
the three IBs samples, the difference spectrum obtained subtracting the CR spectrum 
and the IBs spectrum from the CR spectrum in the presence of IBs, showed a 
characteristic peak at ~ 550 nm, typical of CR bound to amyloid aggregates (Fig. 40E). 
By contrast, the difference spectrum obtained by subtracting the CR spectrum and the 
native HypF-N spectrum from the CR spectrum in the presence of native HypF-N was 
flat (Fig. 40E). The observation that the difference spectra obtained with FL TDP-43 IBs, 
Ct TDP-43 IBs and control IBs are superimposable at ~550 nm, indicates that TDP-43 
does not seem to contribute to the amyloid-like structures present in IBs. 
We then analyzed the capacity of the same samples to bind the ThT dye and increase 
its fluorescence. FL TDP-43 IBs increased the ThT fluorescence less markedly than 
control IBs, although this difference was not statistically significant (p>0.05); 
moreover, Ct TDP-43 increased the ThT fluorescence similarly to control IBs (Fig. 40F). 
Hence, the ThT assay confirms that the FL and Ct TDP-43 aggregates present in IBs do 
not have an amyloid-like structure (Fig. 40F). As expected, no ThT fluorescence 
increase was observed in the presence of non-aggregated native HypF-N (Fig. 40F). 
As a positive control for E. coli IBs containing amyloid-like aggregates, we purified IBs 
formed after expression of the second acylphosphatase from D. melanogaster 
(AcPDro2), a protein previously shown to form amyloid-like fibrils in vitro [Powers JM 
et al.1981]. In particular, we purified IBs formed after expression of the destabilised 
C43S mutant of the protein (C43S AcPDro2 IBs), since the wild-type protein was soluble 
after expression and the resulting IBs contained little protein (wt AcPDro2 IBs). Unlike 
the wt AcPDro2 IBs, the C43S AcPDro2 IBs were found to bind CR, with a maximum at ~ 
550 nm in the difference spectrum, and to bind ThT, with a remarkable increase of its 
fluorescence (Fig. 41). 
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Figure 41. CR and ThT binding of wt AcPDro2 IBs and C43S AcPDro2 IBs. (A) Absorbance spectra of wt 
AcPDro2 IBs + CR (solid line), CR (dashed line) and wt AcPDro2 IBs (dotted line). (B) Absorbance spectra 
of C43S AcPDro2 IBs + CR (solid line), CR (dashed line) and C43S AcPDro2 IBs (dotted line). (C) Difference 
absorbance spectra obtained for wt AcPDro2 IBs (blue) and C43S AcPDro2 IBs (red). (D) ThT fluorescence 
spectra in the presence of wt AcPDro2 IBs (blue) and C43S AcPDro2 IBs (red). The CR and ThT analyses 
show that IBs containing the destabilised and amyloidogenic C43S mutant of AcPDro2 bind CR and ThT 
more markedly than IBs formed after expression of the less stable and less amyloidogenic wt AcPDro2. 
The C43S AcPDro2 IBs, therefore, can act as a positive control showing the presence of amyloid-like 
aggregates in IBs arising from the expressed protein 
 
FL TDP-43 and Ct TDP-43 aggregates are composed of a random coil structure 
 
Amyloid fibrils are closely associated with a β-sheet content that can be typically 
detected with either far-UV CD, FTIR or X-ray fiber diffraction. The CD spectra obtained 
in the presence of FL TDP-43 IBs and control IBs display a negative peak at ca. 220-230 
nm and a positive peak at ca. 190-200 nm (Fig. 42A), which is typical of large 
aggregates containing amyloid fibrils [Nyrkova IA et al.2000, Sicorello A et al.2009]. 
The difference spectrum between them discloses the secondary structure of FL TDP-43 
aggregates wherein the presence of a random coil structure is evident, as shown by a 
negative peak at ~ 198 nm (Fig. 42A). A similar result was obtained with Ct TDP-43 IBs 
and control IBs, with the CD spectra displaying a negative peak at ~ 230 nm and a 
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positive peak below 197 nm (Fig. 42B). Similarly to the result obtained with FL TDP-43 
aggregates, a largely random coil structure emerges from the difference spectrum, 
with a negative peak at ca. 198 nm (Fig. 42B). 
 
 
 
Figure 42. Secondary structure analysis of FL TDP-43 IBs, Ct TDP-43 IBs and control IBs. CD spectra 
(A,B), amide I regions of FTIR spectra (C,D) and second derivative of FTIR spectra (E,F) of FL TDP-43 IBs 
(A,C,E) and Ct TDP-43 IBs (B,D,F). In both analyses, the spectra are those of TDP-43 IBs (green), control 
IBs (blue) and difference spectra obtained subtracting the latter from the former (red).  
 
The Amide I regions of FTIR spectra of FL TDP-43 IBs and control IBs obtained in D2O, as 
well as their second derivative spectra, display a prominent peak at ~ 1650 cm−1 
corresponding to α-helix and unordered structures, another peak at ~ 1675 cm−1 
corresponding to β-turn structure and the characteristic peak at ~ 1625 cm−1 
associated with the presence of intermolecular β-sheet structures (Fig. 42C,E). The 
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difference spectrum obtained from them shows two major bands at ~ 1667 cm−1, 
corresponding to β-turn structure, and ~ 1640 cm−1, corresponding to unordered 
structure for an FTIR spectrum obtained in D2O (Fig. 42C,E). Importantly, the difference 
spectrum shows a clear disappearance of the peak in the intermolecular β-sheet region 
(Fig. 42C,E), providing further evidence for the lack of β-sheet structure and presence 
of disordered structure in the FL TDP-43 aggregates present in IBs.  
The Amide I region of the FTIR spectrum of Ct TDP-43 IBs in D2O and its second 
derivative, along with those of control IBs obtained concomitantly, display a similar 
peak at ~ 1650 cm−1 associated with α-helix and unordered structures (Fig. 42D,F). 
Besides, Ct TDP-43 IBs spectra show a prominent peak at ~ 1680 cm−1 associated with 
β-turn structure and a secondary peak at ~ 1620 cm−1 corresponding to intermolecular 
β-sheet structures, while control IBs spectra show the major peak at ~ 1620 cm−1 
indicating the presence of intermolecular β-sheet structures and a smaller peak at ~ 
1670 cm−1 associated with β-turn structure (Fig. 42D,F). The difference spectrum 
obtained from them shows a major peak at ~ 1680 cm−1 associated with β-turn 
structure and another smaller peak at ~ 1645 cm−1 corresponding to unordered 
structure (Fig. 42D,F). Again, the difference spectrum shows no peaks in the 
intermolecular β-sheet region, indicating a largely disordered structure in the Ct TDP-
43 aggregates present in IBs. 
 
Figure 43. Amide I regions of FTIR spectra of wt AcPDro2 IBs (blue) and C43S AcPDro2 (red). The analysis 
shows that IBs containing the destabilised and amyloidogenic C43S mutant of AcPDro2 have a large 
amount of β-sheet structure with respect to IBs formed after expression of the less stable and less 
amyloidogenic wt AcPDro2. The C43S AcPDro2 IBs, therefore, can act as a positive control showing the 
presence of amyloid-like aggregates in IBs arising from the expressed protein, confirming the CR and ThT 
analyses. 
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The amide I region of the FTIR spectrum obtained with C43S AcPDro2 IBs, used here as 
a positive control for bacterial IBs containing amyloid-like aggregates, features a 
remarkable peak in the β-sheet region, unlike the wt AcPDro2 IBs, indicating the 
presence of a largly β-sheet structure in the C43S AcPDro2 aggregates (Fig. 43). 
PK digests FL TDP-43 and Ct TDP-43 aggregates contained in IBs 
 
PK is a protease usually used to map the protected core of amyloid fibrils because it is 
highly active against peptide bonds of globular and disordered proteins, but it cannot 
attack the highly packed backbones in amyloid β-sheet structures [Hughes SR et 
al.1998]. Both FL TDP-43 IBs and Ct TDP-43 IBs were treated with 20 μg/mL of PK and 
their protein content was analyzed using SDS-PAGE. At this PK concentration a fast 
cleavage of FL TDP-43 was observed, with its band disappearing after 5 min of 
incubation (Fig. 44A,B). A fast cleavage was also observed for Ct TDP-43 (Fig. 44C,D). In 
this case the Ct TDP-43 band does not seem to disappear completely after 20 min of 
incubation, but it is reasonable to assume that the apparent remaining band was 
associated with an E. coli protein present in IBs having a molecular weight 
superimposed to that of Ct TDP-43 (compare Ct TDP-43 IBs and control IBs in Fig. 39C). 
FL TDP-43 IBs were also treated with a higher PK concentration (250 μg/mL), which 
induced a rapid disappearance after only 120 s (Fig. 44E,F). Other E. coli proteins 
present in TDP-43 IBs were susceptible to the action of PK, but they were generally 
more resistant, indicating the presence of amyloid-like structures in the IBs (Fig. 44A-
F). Thus, these data confirm further the absence of an amyloid core in the FL TDP-43 
and Ct TDP-43 aggregates contained in IBs. 
The higher PK concentration (250 μg/mL) was also utilized for treating both FL TDP-43 
IBs and control IBs and follow the decrease in the turbidimetry signal at 350 nm (Fig. 
4G). At time zero the turbidimetry caused by FL TDP-43 IBs was greater than that of 
control IBs, because of the 30% protein concentration difference present in FL TDP-43 
IBs relative to control IBs. A time dependent decrease in the absorbance value was 
found to occur for both FL TDP-43 IBs and control IBs, due to digestion of non-amyloid 
aggregates. After 140 s the two curves were apparently superimposable and reached 
gradually a plateau. This implies that the FL TDP-43 aggregates were entirely digested 
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by PK within 140 s, confirming the absence of a PK-resistant cross-β organization in 
these aggregates. 
 
Figure 44. PK proteolysis of FL TDP-43 IBs, Ct TDP-43 IBs and control IBs. (A) SDS-PAGE of FL TDP-43 IBs 
after incubation with PK at the indicated times. The temperature was 37 °C, the total protein 
concentration of FL TDP-43 IBs was 14.3 mg/mL and the PK concentration was 20 μg/mL. The band at ~ 
69 kDa indicates GST/FL TDP-43. (B) Corresponding densitometric analysis graph of SDS-PAGE bands 
representing FL TDP-43 (green), proteins other than FL TDP-43 (red) and two E. coli proteins labeled P1 
and P2 (blue and purple). (C) SDS-PAGE of Ct TDP-43 IBs after incubation with PK at the indicated times. 
Conditions were as in panel A. The band at ~ 46 kDa indicates GST/Ct TDP-43. (D) Corresponding 
densitometric analysis graph of SDS-PAGE bands representing Ct TDP-43 (green), proteins other than Ct 
TDP-43 (red) and two E. coli proteins labeled P1 and P2 (blue and purple). (E) SDS-PAGE of FL TDP-43 IBs 
after incubation with PK at the indicated times. The temperature was 37 °C, the total protein 
concentration of FL TDP-43 IBs was 14.3 mg/mL and the PK concentration was 250 μg/mL. (F) 
Corresponding densitometric analysis graph of SDS-PAGE bands representing FL TDP-43 (green), 
proteins other than FL TDP-43 (red) and two E. coli proteins labeled P1 and P2 (blue and purple). (G) 
Kinetics at 37 °C of PK digestion of FL TDP-43 IBs and control IBs monitored by turbidimetry at 350 nm. 
The total protein concentration for FL TDP-43 IBs and control IBs was 14.3 mg/mL and 10 mg/mL, 
respectively, and the PK concentration was 250 μg/mL. 
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FL TDP-43 IBs, Ct TDP-43 IBs and control IBs appear morphologically irregular 
 
AFM was used to investigate the morphology of FL TDP-43 IBs, Ct TDP-43 IBs and 
control IBs. All IBs samples appeared as irregular structures with heights of 33 ± 2 nm 
for FL TDP-43 IBs (Fig. 45A), 36 ± 3 nm for Ct TDP-43 IBs (Fig. 45B) and 32 ± 2 nm for 
control IBs (Fig. 45C). Such structures were formed by a variable number of disk or 
crescent-shaped subunits having a height of 7-8 nm (Fig. 45A-C). After 1 h digestion 
with 20 μg/mL PK all IBs were proteolysed and only a large number of small structures 
having a height of ~ 3 nm remained in the samples (as exampled by FL TDP-43 IBs 
digestion reported in Fig. 45D), possibly representing small aggregates of the lipids and 
polypeptides that are known to be present in bacterial IBs [Valax P et al 1993, Jürgen B  
et al.2010, Maachupalli-Reddy J et al.1997]. Interestingly, the absence of fibrillar 
structures after PK treatment indicates that the TDP-43 aggregates present in the IBs 
are not amyloid-like. Moreover, although the ThT and CR assays, as well as CD and FTIR 
spectra, show the existence of amyloid aggregates in both FL TDP-43 IBs and Ct TDP-43 
IBs and arising from non-TDP-43 proteins, AFM imaging after PK digestion reveals that 
such structures are unstable and less packed and organized then the known amyloid 
aggregates. 
 
Figure 45. Morphology of FL TDP-43 IBs, Ct TDP-43 IBs and control IBs observed with AFM. (A-C) FL TDP-
43 IBs, Ct TDP-43 IBs and control IBs, respectively. The scan size is 2 μm. (D) FL TDP-43 IBs after 1 h 
incubation with 20 μg/mL PK. The scan size is 2 μm. The inset shows a detail of the main panel at higher 
magnification (scan size 250 nm). In all panels left and right images represent height and amplitude 
data, respectively. Z range: 130 nm (A), 100 nm (B), 90 nm (C), 10 nm (D). 
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Transfected FL TDP-43 IBs are toxic to cultured neuronal cells 
 
FL TDP-43 IBs and control IBs were also tested for their ability to cause cellular 
dysfunction in cultured neuroblastoma SH-SY5Y cells. Both forms of IBs were used to 
transfect the cells by means of the PULSin protein delivery reagent (Polyplus-
transfection, Illkirch, France), which contains a cationic amphiphilic molecule thus 
facilitating the entry of the IBs in the cellular cytoplasm. In a first experiment, carried 
out to verify directly the presence of the FL TDP-43 IBs inside the cytoplasm following 
transfection, FL TDP-43 IBs were labeled with 5-FITC and then used to transfect the 
cells. The images obtained with confocal microscopy show the presence of abundant 
exogenous TDP-43 aggregates in the cytoplasm, indicating the high yield of FL TDP-43 
IBs transfection (Fig. 46A).  
In another set of experiments, both FL TDP-43 IBs and control IBs were used to 
transfect the cells and the presence of FL TDP-43 in the transfected cells was assessed 
using anti-TDP-43 polyclonal antibodies. Untreated (non-transfected) cells showed the 
presence of abundant TDP-43 in the nuclei, as expected for cells expressing 
endogenous TDP-43 which has a nuclear localization signal (Fig. 46B). Cells transfected 
with control IBs showed a similar high abundance of endogenous TDP-43 in the nuclei, 
whereas cells transfected with FL TDP-43 IBs showed a combination of nuclear 
endogenous TDP-43 and exogenous cytoplasmic TDP-43 (Fig. 46B). Cells were also 
transfected with R-PE, a green fluorescent protein used as a positive control and 
indeed shown to be present abundantly in the cytoplasm following transfection (Fig. 
46B). 
The viability of SH-SY5Y cells treated with FL TDP-43 IBs and control IBs was assessed 
by measuring their ability to reduce MTT, their levels of intracellular ROS and their 
caspase-3 activity. All such tests are widely used to assess the toxicity of TDP-43 
expressed in eukaryotic cell cultures [Guo W et al.2011, Duan W et al.2010, Liu-
Yesucevitz L al.2010]. In all such tests, cells treated with control IBs were found to be 
less viable than untreated cells, which are cells treated with the transfection mix only 
(Fig. 46C-E). However, a significantly lower level of viability was found in cells treated 
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with FL TDP-43 IBs, showing that the presence of FL TDP-43 in the IBs increases their 
toxicity. 
 
Figure 46. Toxicity of FL TDP-43 IBs and control IBs delivered intracellularly. (A) Representative confocal 
scanning microscope images of SH-SY5Y cells transfected with FL TDP-43 IBs labeled with 5-FITC. Red 
and green fluorescences indicate cell profiles and labeled FL TDP-43 IBs, respectively; the images were 
analysed at median planes parallel to the coverslip. (B) Representative confocal scanning microscope 
images of SH-SY5Y cells transfected with FL TDP-43 IBs, control IBs and R-PE. Red fluorescence indicates 
cells profiles and green fluorescence indicates TDP-43 detected with immunofluorescence or R-PE. (C) 
MTT reduction of SH-SY5Y cells following transfection with FL TDP-43 IBs (5.7 μg/mL), control IBs (4.0 
μg/mL and 5.7 μg/mL) and R-PE (4.0 μg/mL). (D,E) Representative confocal scanning microscope images 
of SH-SY5Y cells showing intracellular ROS levels (D) and caspase-3 activation (E) after transfection with 
FL TDP-43 IBs (5.7 μg/mL) and control IBs (4.0 μg/mL and 5.7 μg/mL). The green fluorescence arises from 
the CM-H2DCFDA probe that has reacted with ROS and from FAM-FLICA™ Caspase 3&7. The histograms 
show the quantitative fluorescence values in both cases. In panels C-E untreated cell means cells treated 
with the transfection mix only without proteins. The double (**) and triple (***) asterisks refer to p 
values lower than 0.01 and 0.001, respectively.  
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Importantly, the FL TDP-43 concentration was 1.7 µg/mL in the samples used to 
transfect the cells in all such tests, indicating that the protein aggregated in the non-
amyloid form described above is highly toxic. 
For the reasons explained above, the FL TDP-43 IBs contained a total protein 
concentration higher by ca. 30% (5.7 µg/mL) than that of control IBs (4.0 µg/mL). To 
assess whether the higher toxicity observed for FL-TDP-43 IBs was due to its higher 
protein content, the cells were also treated with control IBs containing a total protein 
quantity similar to that of FL TDP-43 IBs (5.7 µg/mL), but the FL-TDP-43 IBs still 
maintained a significantly higher toxicity with all probes of cell viability (Fig. 46C-E). All 
the values of toxicity reported here refer to cells transfected with the transfection mix 
only, ruling out that the observed toxicity of internalized FL TDP-43 IBs originates from 
the transfection procedure. Moreover, R-PE was not found to decrease significantly 
the MTT reduction following transfection, ruling out that transfected protein samples 
are per se toxic (Fig. 46C). 
Transfected FL TDP-43 IBs are partially ubiquitinated and phosphorylated in cultured 
neuronal cells 
 
In order to assess whether the exogenous cytoplasmic FL TDP-43 IBs were 
ubiquitinated, we analyzed the colocalization of FL TDP-43 IBs with ubiquitin. The 
images obtained with confocal microscopy showed a weak and diffuse cytoplasmic 
ubiquitin staining in the cytoplasm of SH-SY5Y cells transfected with control IBs, 
whereas a marked staining and the presence of inclusions was evident in cells 
transfected with FL TDP-43 IBs (Fig. 47A). In particular, a partial colocalization between 
cytoplasmic TDP-43 IBs and ubiquitin was observed (Fig. 47A). To investigate whether 
the exogenous cytoplasmic FL TDP-43 IBs were phosphorylated, we employed 
antibodies that recognize phosphorylated S409/410 in TDP-43 (Fig. 47B). The confocal 
images showed a clear phosphorylation of FL TDP-43 IBs (Fig. 47B) and these 
phosphorylated sites appeared to partially colocalize with ubiquitin (Fig.47B). All these 
data suggest that FL TDP-43 IBs are partially ubiquitinated and phosphorylated, 
recapitulating major features of the endogenous cytoplasmic inclusions found in ALS 
and FTLD-U. 
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Figure 47. Ubiquitination and phosphorilation of FL TDP-43 IBs and control IBs delivered 
intracellularly. (A) Representative confocal scanning microscope images showing  partial colocalization 
of exogenous cytoplasmic TDP-43 with ubiquitin-positive aggregates in SH-SY5Y cells transfected with 
control IBs FL and TDP-43 IBs. Green and red fluorescences indicates TDP-43 and ubiquitin, respectively. 
(B) Representative confocal scanning microscope images showing  partial colocalization of 
phosphorylated S409/410 of TDP-43 and ubiquitin-positive aggregates in SH-SY5Y cells transfected with 
control IBs FL and TDP-43 IBs. Green and red fluorescences indicates pS409/410 TDP-43 and ubiquitin, 
respectively. (C) MTT reduction of SH-SY5Y cells following transfection with FL TDP-43 IBs (5.7 μg/mL), 
control IBs (4.0 μg/mL) in the absence or presence of  5 μM MG-132, 10 mM 3-MA and 40 μM 
chloroquin. The single (*) and triple (***) asterisks refer to p values lower than 0.05 and 0.001, 
respectively. 
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The toxicity of FL TDP-43 IBs and control IBs was also assessed in the presence of 
specific inhibitors of the proteasome, authophagy and lisosomes systems, such as MG-
132, 3-MA and chloroquin, respectively (Fig. 47C). Cells treated with control IBs in the 
presence of the three inhibitors were found to decrease MTT reduction to a level 
similar to control IBs alone (Fig. 47C). Interestingly, a significantly lower level of 
viability was found in cells treated with FL TDP-43 IBs in the presence of MG-132 with 
respect to cells treated with FL TDP-43 IBs alone, showing that the inhibition of the 
proteasome system increases their toxicity (Fig. 47C). The cells treated with FL TDP-43 
IBs in the presence of chloroquin also showed a significant decrease of cell viability 
with respect to cells treated with FL TDP-43 IBs alone, whereas cell treatment with FL 
TDP-43 IBs in the presence of 3-MA was not found to modify cell viability to a 
significant extent (Fig. 47C). These data indicate that the TDP-43 aggregates contained 
in FL TDP-43 IBs are toxic to the transfected cells, which react to their presence via 
mechanisms dedicated to the clearance of misfolded proteins. 
Extracellular FL TDP-43 IBs are toxic to cultured neuronal cells 
 
The toxicity of FL TDP-43 IBs and control IBs was also assessed by adding them to the 
extracellular medium of the SH-SY5Y cells in the absence of any transfection 
procedure. We first evaluated the toxic effect of both forms of IBs by measuring the 
ability of treated cells to reduce MTT (Fig. 48A). Their toxic effect was analysed at 
different protein concentrations, ranging from 7.5 μg/mL to 860 μg/mL (plus 30% for 
FL TDP-43 IBs). Aβ42 oligomers were also used as a positive control of toxicity in a range 
of concentrations varying from 7.5 μg/mL to 215 μg/mL (Fig. 48A). It was found that FL 
TDP-43 IBs, unlike control IBs, were able to decrease MTT reduction at concentrations 
of 171 μg/mL or higher (Fig. 48A). FL TDP-43 IBs were also found to cause an increase 
of intracellular ROS production and caspase-3 activation, whereas control IBs induced 
only small changes (Fig. 48B,C). 
 
 
 
Chapter 3- Results 
| 131 
 
 
Figure 48. Toxicity of FL TDP-43 IBs and control IBs added extracellularly. (A) MTT reduction of SH-SY5Y 
cells following extracellular addition of FL TDP-43 IBs, control IBs and Aβ42 oligomers. The indicated 
protein concentration refer to control IBs and correspond to values higher by 30% for FL TDP-43. The 
single (*) and triple (***) asterisks indicate a statistically significant difference between FL TDP-43 IBs 
and untreated cells (p<0.05 and p<0.001, respectively). (B,C) Representative confocal scanning 
microscope images of SH-SY5Y cells showing intracellular ROS levels (B) and caspase-3 activation (C) 
after extracellular addition of FL TDP-43 IBs, control IBs and Aβ42 oligomers. The green fluorescence 
arises from the CM-H2DCFDA probe that has reacted with ROS and from FAM-FLICA™ Caspase 3&7. 
Total protein concentrations were 280, 215 and 60 µg/mL for FL TDP-43 IBs, control IBs and Aβ42 
oligomers, respectively.  
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Chapter 4 – Discussion 
Extracellular chaperones prevent Aβ42-induced toxicity in rat brains 
 
Clusterin (Clu) and α2-macroglobulin (α2M) are markedly induced in neuropathological 
conditions such as AD, where they are found associated with Aβ plaques, suggesting a 
physiological interaction with Aβ [Kida E et al.1995, Powers JM et al.1981, Strauss S et 
al. 1992, Barral JM er al.2004, Businaro R et al.1992, Trougakos IP et al 2006]. Clu and 
α2M are also known to inhibit amyloid fibril formation in vitro [Du Y et al. 1998, 
Hughes SR et al.1998, Kumita JR et al. 2007, Yerbury JJ et al. 2007, Yerbury JJ et 
al.2009]. In particular, it has been shown that Clu binds to all types of soluble 
oligomers found to be present during the aggregation and disaggregation of Aβ40, 
preventing further growth and proliferation of aggregated species [Humphreys DT et al 
1999, Luheshi LM et al. 2010, Narayan P et al. 2012, Nielsen HM et al.2009, Wyatt AR 
et al.2011]. α2M was also found to bind small oligomers, preventing their growth 
and/or conversion into fibrils [Yerbury JJ et al. 2009]. Furthermore, Clu and α2M are 
known to mediate the clearance of extracellular protein oligomers via endocytosis [48-
50]. It is unclear, however, if extracellular chaperones have an ability to inhibit 
intrinsically the toxicity of Aβ misfolded oligomers, with evidence that has being very 
sparse and often contradictory so far. Indeed, some reports supported a toxicity-
enhancing role for extracellular chaperones [Lambert MP et al.1998, Fabrizi C et 
al.2001, Oda T et al.2005], others claimed a protective action [Du Y et al.1998, Boggs 
LN et al.1996, Mannini B et al.2012] while one study demonstrated that the ratio of 
chaperone:Aβ could determine whether the effect was protective or enhanced toxicity 
[Yerbury JJ et al.2007].  
Important suggestions have been obtained using chaperones distinct from 
extracellular ones, or protein oligomers distinct from Aβ oligomers. Indeed, it has been 
demonstrated that intracellular chaperones can prevent the toxicity of Aβ oligomers, 
sequestering and converting them into large non toxic aggregates [Ojha J et al.2011]. 
Our recent data showed that different chaperones, including Clu and α2M, can inhibit 
efficiently the toxicity of extracellularly added protein oligomers formed by three 
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different peptides and proteins in SH-SY5Y neuroblastoma cells, provided the 
chaperones are incubated with the preformed oligomers before the resulting mixtures 
are added to the extracellular medium of the cells [Mannini B et al.2012]. Such an 
inhibition is very effective as it occurs even at low chaperone concentration [Mannini B 
et al.2012]. Using HypF-N oligomers as a toxic species, the protective effect of the 
chaperones was found to result from the ability of these proteins to bind to the 
oligomers and promote their further assembly into larger species, in the absence of 
any significant reorganisation of their internal molecular structure [Mannini B et 
al.2012]. 
The present work originated from this previous study and was targeted to Aβ 
oligomers, extracellular chaperones and a context closely related to AD, such as rat 
brains and cultured neurons. We demonstrated that chaperones can inhibit in vivo the 
neurotoxicity of high concentrations of pre-formed extracellular Aβ oligomers. Such an 
ability adds to the well-established functions of extracellular chaperones in inhibiting 
protein aggregation [Du Y et al. 1998, Hughes SR et al.1998, Kumita JR et al. 2007, 
Yerbury JJ et al. 2007, Yerbury JJ et al.2009] and promoting the clearance of protein 
aggregates [Zlokovic BV et al 1996, Hammad SM et al.1997]. In all our experiments, the 
oligomers are formed before adding the chaperones, showing that the protective 
action of the latter also includes neutralisation of toxic oligomers after they have 
formed. Thus we can hypothesize that chaperones neutralize Aβ42 oligomers through a 
binding mechanism that promote the seeding of larger species, as previously 
demonstrated with HypF-N oligomers [Mannini B et al.2012]. The accumulation of Aβ 
fibrils as large plaques visible with optical microscopy and the association of such 
plaques with extracellular chaperones is indeed suggestive of this possibility. 
Multiple lines of evidence indicate that there are two locales in which Aβ oligomers 
play a role in AD pathogenesis and are implicated in a synaptic failure, namely the 
intraneuronal and extracellular compartments [Laferla FM et al.2007, Wegiel J et 
al.2007]. A dynamic equilibrium seems to exist between the pools of Aβ oligomers in 
the two locales; extracellular Aβ appears to originate from intraneuronal Aβ [Oddo S et 
al.2004]. Since Aβ is released extracellularly from a membrane precursor protein, Aβ 
plaques accumulate extracellularly and Aβ oligomers have an ability to impair cell 
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viability from the extracellular space, we have chosen to focus on extracellularly added 
oligomers rather than intracellular ones in all our experiments. 
This is the first report that molecular chaperones prevent Aβ42-induced learning and 
memory impairments in hippocampal-injected rat brains in vivo. Associated with this 
prevention is the reduction of astroglial activation, astrogliosis, lipoperoxidation, and 
caspase-3 activation in these brains. In addition, chaperones were found to be able to 
protect primary hippocampal and cortical neurons against injuries caused by misfolded 
Aβ42 oligomers, by preventing Aβ42 binding to the dendrites. In future experiments it 
will be crucial to determine whether chaperone-mediated neutralization of Aβ42 
oligomers also act in transgenic mouse models. 
Hence, these data elect extracellular chaperones as novel molecules that are 
neuroprotective against amyloid-induced injury and excellent candidates for the 
design and development of therapeutic strategies for the prophylaxis and treatment of 
AD.  
Transthyretin suppresses the toxicity of oligomers formed by misfolded 
proteins in vitro 
 
TTR was shown to inhibit aggregation and amyloid plaque formation of Aβ both in vitro 
and in vivo [Du J et al.2010,]. Analyses carried out in vitro have shown that TTR binds 
monomeric Aβ, explaining its ability to prevent aggregation of the peptide [J. Du et 
al.2010,]. However, in experiments using various forms of Aβ fixed to solid surfaces 
(e.g. nitrocellulose membranes or Biacore chips) TTR-Aβ binding was found to occur 
with higher affinity for aggregated Aβ, such as oligomers and fibrils, relative to 
monomeric Aβ, with monomeric TTR exhibiting stronger binding than tetrameric TTR 
[L. Liu et al.2006]. The high affinity between monomeric TTR and aggregated Aβ 
suggests an important role for such an interaction in vitro. Indeed, TTR was shown to 
bind to preformed Aβ oligomers and reduce their toxicity to murine primary neurons 
and human neuroblastoma SH-SY5Y cells [X. Li et al.2011]. In those studies, the 
suppression of TTR-mediated toxicity was not due to the ability of TTR to inhibit Aβ 
aggregation, but appeared to act on preformed oligomers. Subsequent studies have 
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shown that hTTR both inhibits Aβ oligomer formation and interacts with small Aβ 
oligomers to prevent the formation of nucleation competent seeds [Li et al, in 
preparation].  
Here, we found that TTR is able to suppress the toxicity of extracellularly added 
oligomers formed by two different peptides/proteins, namely Aβ42 and HypF-N, adding 
new data to the preliminary observation obtained with Aβ42 [X. Li et al.2011]. TTR was 
found to inhibit the influx of Ca
2+
 caused by the oligomers, thus eliminating the 
occurrence of later effects, manifested as oxidative stress, membrane leakage and 
apoptosis. In addition, the observed dependence of the degree of protection on the 
time of preincubation between oligomers and TTR indicates that TTR suppresses 
oligomer toxicity by interacting with the oligomers, rather than through a separate 
protective pathway mediated by direct interaction of TTR with the cells. Overall, 
therefore, these findings reveal that the deleterious effects produced by interaction of 
misfolded protein oligomers with cell membranes can be abolished by TTR. 
The three types of TTR examined here, namely hTTR, muTTR and M-TTR, were found 
to display different protective effects against oligomer-induced cytotoxicity. Indeed, 
monomeric M-TTR was able to protect SH-SY5Y neuroblastoma cells and rat primary 
neurons against oligomer-induced cytotoxicity; the highly stable tetrameric muTTR 
only showed only a small non-significant protective effect, whereas the less stable 
tetrameric hTTR had an effect intermediate between the two forms, or displayed a 
protective action more slowly or at higher concentrations than M-TTR. Hence, the 
ability of TTR to protect neuronal cells and neurons against these misfolded protein 
oligomers in vitro correlates inversely with the stability of the tetramer. 
To shed light on the molecular mechanism by which TTR prevents cytotoxicity, we 
focused on HypF-N oligomers, probing their oligomeric state and molecular structure 
after the incubation with TTRs in vitro. Using ThT fluorescence we found that TTR does 
not disaggregate the preformed oligomers. Nor does it appear to promote a structural 
re-organization of the discrete oligomers, as shown by site-directed pyrene labeling. 
Rather, TTR was found to bind to the oligomers, as determined with SDS-PAGE, 
intrinsic fluorescence and confocal scanning microscopy, and promote their further 
assembly into larger aggregates, as shown by AFM, light scattering measurements and 
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turbidimetry. The ability of TTR to bind to the oligomers and cause their clustering was 
also found for Aβ42 oligomers, using AFM and confocal scanning microscopy. Clearly, 
the ability of TTR to bind to and further assemble preformed HypF-N and Aβ42 
oligomers correlated again inversely with its stability, as the efficiency of such process 
followed the same order as that found for toxicity suppression, i.e. M-TTR > hTTR > 
mTTR. These data also suggest that the size of extracellular protein aggregates is an 
inverse correlate of their toxicity. The TTR-induced oligomer clusters are characterized 
by a reduction in their exposed hydrophobic surface and diffusional mobility, both of 
which are expected to reduce their toxicity to cells [Ojha J et al.2011].  
Recent structural analyses of the TTR/Aβ interaction have revealed a complex set of 
interactions with hTTR tetramers binding the Aβ monomer in the T4 binding pocket to 
inhibit Aβ aggregation and cytotoxicity [Li et al, in preparation]. By contrast, M-TTR 
was found to interact preferentially with Aβ oligomers [Li et al, in preparation], and 
this observation is consistent with the better binding of M-TTR to HypF-N oligomers 
shown here. Nevertheless, the M-TTR/Aβ oligomer interaction was not found to be 
associated with a size increase of the oligomers [Li et al, in preparation], whereas in 
our experimental conditions the interaction between M-TTR and HypF-N/Aβ42 
oligomers was found to involve further clustering of the oligomers. The interaction 
showed by Li et al. was obtained under different conditions compared to those used in 
the present study. M-TTR was added to the aggregation assay where Aβ was initially 
monomeric [Li et al, in preparation]. Here we added M-TTR to pre-formed HypF-
N/Aβ42oligomers. Such a difference parallels the data showed by Ojha et al. showing 
that the chaperone HspB1 converted the pre-formed oligomers of Aβ into large 
aggregates, whereas, the incubation with Aβ monomer did not produce such larger 
species [J. Ojha et al.2011]. Hence, it appears that in vitro the different experimental 
conditions, i.e. the use of monomeric aggregating protein with respect to oligomeric 
species, may determine a different mode of M-TTR/oligomer interaction and 
suppression of oligomer toxicity. Further experimental studies are necessary to clarify 
this issue. 
Overall, the molecular mechanism by which TTR protects cells against the deleterious 
effects of protein aggregation seems to involve two different levels of intervention, 
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inhibition of protein aggregation and fibril formation, as previously demonstrated [J. 
Du et al.2010], and neutralization of protein oligomer toxicity once the oligomers are 
formed, as shown here. Such dual protective behavior has also been demonstrated in 
vitro for a number of proteins that have been widely recognized as molecular 
chaperones, such as αB-crystallin, Hsp70 (both with and without ATP), clusterin, α2-
macroglobulin and haptoglobin [K. Sörgjerd et al.2006], showing that TTR can also 
behave as a molecule with ATP-independent chaperone activity and have a relevant 
functional role in vivo. 
A complex equilibrium between partially unfolded conformations in 
monomeric transthyretin 
A model for M-TTR folding 
 
In the present work we exploited a battery of biophysical methods and performed a 
number of kinetic tests to investigate the mechanisms of M-TTR refolding, with the 
final goal of proposing a model for the process.Such a model is presented in Figure 49.  
 
 
Figure 49 Model for the folding process of TTR. 4F defines the tetramer; F defines the folded monomer; 
MG1 , MG2,…MGn correspond to a set of molten globular conformations; U(t) and U(c) refer to the 
unfolded state with one or more X-Pro peptide bonds in the trans orcisconfiguration, respectively. PF(t) 
and PF(c) refer to the partially folded state with one or more X-Pro peptide bonds in the trans 
orcisconfiguration, respectively. 
 
Once a monomer of TTR(F) is released from the tetramer (4F) the protein establishes a 
complex equilibrium and can access a set of conformational ensembles. First, the 
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protein can convert from the fully folded state into an ensemble of molten globular 
(MG1 … MGn) conformations bearing increasing amounts of disorder. When compared 
to F, such MG ensemble possesses enhanced dynamics, a decrease in -sheet structure 
and an increase in random coil segments, in the presence of a substantially unaltered 
tertiary structure. Furthermore, the folded/molten globular ensemble is in equilibrium 
with the unfolded state (U). However, before the unfolded state can convert back into 
F, a kinetic trap can be transiently populated, consisting of a partially folded (PF) state. 
The PF state can be described as an ensemble of conformations exhibiting secondary 
structure content comparable to that of the folded state but a higher amount of 
hydrophobic clusters exposed to solvent compared to F. Notwithstanding that and 
given the off-pathway nature of PF, one can speculate that such ensemble possesses at 
least a few non-native contactsthat must be dismantled before M-TTR can convert into 
the correctly folded state. One further conformational ensemble can be identified 
thanks to the characterization of slow phases. Indeed, we showed that refolding of a 
subpopulation of M-TTR is decelerated due to the incorrect (cis) configuration of one 
or more X-Pro peptide bonds. Only after such bonds are converted into the right 
(trans)configuration, refolding can proceed. 
Importantly, the MG and the PF states do not refer to the same conformational state, 
as revealed by differences between these two states in terms of structure, kinetics and 
pathway: (i) the MG ensemble can be observed in equilibrium experiments and is the 
dominant species at ureaconcentrationsaround 2.4 M (Figure 31). Conversely, our 
kinetic analysis illustrates that PF is populated only transiently. Its population at the 
equilibrium is not higher than 2 % under the same conditions (Figure 34);(ii)MG is 
directly in equilibrium with F and its formation precedes denaturation, whereas the PF 
ensemble must convert into U before accessing the F state; (iii) the F -> PF transition 
appears to be cooperative, while conversionof F into MG lacks cooperativity; (iv) MG 
and F are indistinguishable in terms of tryptophan fluorescence (Figure 31A and 32A), 
while PF has a significantly higher fluorescence than F as assessed by our stopped-flow 
kinetics (Figure 33A), suggesting a different environment surrounding aromatic side 
chains; (v) CD analysis reveals that secondary structure content of PF is globally native-
like, while MG bears disordered segments. Consequently, our identification of the PF 
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and MG states illustrates two conformational ensembles that differ in terms of 
dynamics, kinetics and pathway of formation. 
It is also important to point out the abundance of the PF and MG conformations. The 
PF state is populated only transiently: calculations based on kinetic data show that 
more than 1 % of the protein populates the PF state at the equilibrium in the absence 
of denaturant (Figure 34D). As far as the MG state is concerned, the lack of 
cooperativity displayed by the F -> MG transition makes it difficult to quantify the 
amount of protein populating theMG state. However, data in Figure 31D suggest that 
the transition begins at very low urea concentrations. Consequently, the amount of 
protein experiencing a molten globular conformation may be significant even in the 
absence of denaturant, especially in the presence of destabilizing mutations. 
 
The importance of partially folded states in TTR 
 
Several decades of research on TTR have highlighted the importance of characterising 
partially folded conformations populated by this protein. First, it is now clear that 
transient conformational fluctuations induce the conversion of the fully folded state 
into an ensemble of aggregation prone conformations [ Lai, Z. et al.1996]. The 
characterization of this aggregation prone state is therefore crucial to understand the 
mechanisms underlying TTR aggregation. Several investigations by means of limited 
proteolysis and spectroscopic methods reported that the major event during the 
misfolding of monomeric TTR is the local unfolding and subsequent displacement of 
the two peripheral -strands C and D (Figure 36)and the loop connecting them [ Lai, Z. 
et al.1996]. The dislocation of this edge region unmasks amyloid prone segments 
normally buried in the TTR folded state and solvent exposure of these 
segmentsmediates the establishment of the inter-molecular interactions that initiate 
aggregation. More recently, it was proposed, by means of NMR relaxation dispersion 
experiments, that the amyloidogenic state of TTR possesses a largely native-like CBEF 
sheet while the DAGH sheet is disrupted, especially in strands D and H ( Lim, K. H et al. 
2013). This description is corroborated by molecular dynamics simulations suggesting 
that the CBEF sheet undergoes significant structural changes under conditions that 
promote aggregation( Armen, R. S.,et al.2004). Importantly, complete unfolding of TTR 
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inhibits aggregation [ Lai, Z. et al.1996]. Thus, while the characteristicsthat enable the 
TTR amyloidogenic state to self-assemble must yet be clarified, there is consensus 
about the idea that such a state(s) must possess partial and local unfolding. 
Second, evidence is accumulating that TTR may play a protective role against AD ( Li, 
X., et al.2011). Different mechanisms have been proposed for such protective activity. 
These include direct facilitation of Aβ degradation( Costa, R.,et al.2008), transport of 
Aβ from the central nervous system to serum( Schwarzman, A. L., et al.1994), 
inhibition of Aβ aggregation( Li, X.et al.2011) and suppression of Aβ oligomer toxicity (( 
Li, X.et al.2011). While the mechanisms of the TTR-mediated protection against AD 
must be yet understood, it was recently proposed that in vitrointeractions between 
TTR and Aβ can be mediated by either tetrameric or monomeric TTR, the two 
processes involving somewhat different mechanisms( Li, X et al.2011). In both cases it 
is reasonable that binding is mediated by a protein conformationable to bind peptide 
segments as hydrophobic as Aβ.  In the TTR tetramer this appears to be the highly 
hydrophobic T4 binding site.  The more hydrophobic structure of the TTR monomer 
appears to allow it to interact with relatively small oligomers, rather than the 
monomer, in essence increasing its valence with respect to Aβ monomer.  This 
conformation is likely to be different from the fully folded state and displaysome 
extent of partial unfolding. 
Therefore, the identification and characterization of partially folded states of TTR 
represents a crucial step towards understanding the peculiar properties of this protein. 
Here we showed that once a monomeris released from tetrameric TTR, a complex 
equilibrium is established between the fully folded monomer and at least two partially 
folded states. A small yet significant population of the protein populates two 
conformational states distinct from the fully folded one and possessing some degree of 
improper or incomplete folding. Future studies will clarify whether such 
conformational states correspond to the TTR amyloidogenic state and whether or not 
they may play an important role with respect to the protective effectexerted by TTR 
against AD. 
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TDP-43 inclusion bodies formed in bacteria are structurally amorphous, 
non-amyloid and inherently toxic to neuroblastoma cells 
 
In 2006 it was reported, for the first time, that ubiquitin-positive, tau- and α-synuclein-
negative intracellular inclusions found in the spinal cord motor neurons, in the 
hippocampus and neocortex of sporadic ALS and FTLD-U patients, contained the 
previously unidentified TDP-43 protein or its C-terminal fragments [Neumann M et 
al.2006]. Such inclusions appear to be phosphorylated and ubiquitinated [Neumann M 
et al.2006], but the structure adopted by TDP-43 in such deposits is currently a matter 
of debate. The IBs formed in E. coli cells following the over-expression of TDP-43 are 
informative in this regard, as bacterial IBs have been shown to consist mainly of 
amyloid-like deposits, providing an opportunity to emphasise the propensity of this 
protein to form amorphous aggregates if the amyloid form is not found in the TDP-43 
component of the IBs. Our results indicate that both FL and Ct TDP-43 aggregates 
present in E. coli IBs do not possess any of the hallmarks of amyloid fibrils, allowing 
them to be classified as amorphous. CD and FTIR both show the presence of a 
secondary random-coil and β-turn structure in the absence of any detectable β-sheet 
structure. The aggregates bind neither ThT nor CR and are highly susceptible to PK 
digestion. The AFM analysis does not allow to visualize the morphology of the TDP-43 
aggregates within the IBs. However, the IBs containing both FL and Ct TDP-43 appear 
to have an irregular morphology like that of the control IBs devoid of TDP-43. 
The question naturally arises as to whether our findings resolve the current dispute on 
the structural/morphological type of inclusions present in TDP-43 pathology or rather 
add one more contribution to the ongoing debate. In order to address this issue we 
can try to survey the current literature critically. The first reports aimed at 
characterizing the structure/morphology of TDP-43 inclusions accumulating in ALS and 
FTLD-U patients have excluded the presence of amyloid-like structures. Although the 
ultrastructure of TDP-43 inclusions analyzed with TEM have highlighted the presence 
of 10-20 nm filaments [Neumann M et al.2006], the aggregates were found to be 
unable to bind ThT, ThS or CR, ruling out the presence of an amyloid-like structure 
[Kerman A et al.2010, Cairns NJ et al.2007]. A very recent report has emphasized that 
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TDP-43 inclusions may consist of amyloid fibrils, following the observation of a few 
ThS-positive inclusions [Robinson JL et al.2013]. Nevertheless, the ThS positivity was 
found only in a small fraction of skein-like inclusions of the spinal cord; it was indeed 
absent in most spinal cord skeins and absent altogether in other types of TDP-43 
inclusions of the spinal cord [Robinson JL et al.2013]. All inclusions of the brain were 
also ThS negative [Robinson JL et al.2013]. By contrast, the most recent paper 
reporting a diffuse ThS positivity in all TDP-43 inclusions analysed in ALS spinal cords 
and FTLD-U brains raises important questions on the results obtained previously [Bigio 
EH et al.2013]. This study originated from a chemically harsh treatment of the tissue 
sections isolated from ALS and FTLD-U patients, based on the sequential use of potent 
oxidants, reductants, acids and bases, such as permanganate, metabisulfite, oxalic 
acid, sodium hydroxide and hydrogen peroxide, all known to chemically modify 
proteins and hydrolyse peptide bonds. It cannot be ruled out that the biological 
inclusions undergo a heavy structural reorganization under such circumstances. 
The difficulty of purifying TDP-43 has limited the study of TDP-43 aggregation in vitro 
and is likely to be a limiting factor in future research on TDP-43. One report exists, 
however, on the characterization of the aggregates formed in vitro from TDP-43 after 
its purification [Johnson BS et al.2009]. This study has confirmed a filamentous 
morphology of TDP-43 aggregates, in the absence of ThT and CR binding [Johnson BS 
et al.2009]. By contrast, four other reports have emphasized an amyloid-like structure 
of TDP-43 aggregates, but all of them have referred to short peptides of 13 to 50 
residues, all obtained from the sequence of TDP-43 [Saini A et al.2011, Jiang LL et 
al.2013]. It is well known that protein fragments have generally aggregation properties 
different from those of the full-length protein and it was recently reported that 
amyloid-like aggregation, as opposed to structurally undefined aggregation, is favored 
by small peptides and proteins [Ramshini H et al.2011]. 
Hence, our data and analysis suggest that FL and Ct TDP-43 form amorphous 
aggregates rather than amyloid-like. The finding that most, if not all, TDP-43 
aggregates are amorphous in the spinal cord and brain of ALS and FTLD-U patients, in 
bacterial IBs and finally in aggregates formed in vitro from purified TDP-43, suggests 
that this protein has an intrinsic propensity to form amorphous aggregates and that 
Chapter 4 - Discussion 
| 142 
 
such a propensity is not affected remarkably by specific factors present in the 
biological compartments where aggregation occurs. 
The bacterial TDP-43 IBs characterized here were found to be highly toxic to cultured 
neuronal cells, particularly following their internalization in the cytoplasm, where they 
are at least in part ubiquitinated and phosphorylated. A significant toxicity was found 
using intracellularly delivered IBs where TDP-43 was present at a concentration as low 
as 1.7 µg/mL before internalization. It is debated whether aggregation of TDP-43 in the 
cytoplasm of ALS and FTLD-U patients causes neurodegeneration due to formation of 
toxic protein aggregates (gain of function) or to the translocation of TDP-43 from the 
nucleus, which represents its physiological location, to the cytoplasm (loss of function), 
or both. Our results show that delivery of exogenous TDP-43 into the cytoplasm occurs 
in the absence of a significant loss of endogenous TDP-43 in the nucleus. Indeed, the 
images acquired after delivery show cytoplasmic TDP-43 in the absence of detectable 
clearance of nuclear TDP-43. Thus, the non-amyloid, amorphous aggregates formed 
from TDP-43 are inherently highly toxic to neuronal cells, indicating that a gain of 
function mechanism caused by TDP-43 deposits is effective in such pathology. The data 
do not exclude that a loss of function mechanism originating from the cellular 
mistrafficking of TDP-43 also contributes to pathology, but shows the inherent toxicity 
of TDP-43 aggregates. 
In conclusion we have shown, using bacterial IBs containing aggregated TDP-43 as a 
model system, that both FL and Ct TDP-43 aggregates consist of non-amyloid 
assemblies that have an intrinsically high ability to cause neuronal dysfunction when 
delivered into the cytoplasm, contributing to elucidate the pathogenesis of TDP-43 
proteinopathies such as FTLD-U and ALS. 
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